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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with a 5 year 
survival rate of less than 5 %. PDAC tumours consist of a desmoplastic stroma, which 
limits the effectiveness of chemotherapy. Pancreatic stellate cells (PSCs), which form 
a key part of this stroma, become activated in response to tumour development. 
Activated PSCs enter a cross-talk with cancer cells to induce tumour cell proliferation 
and invasion, leading to metastatic spread. Nuclear fibroblast growth factor receptor 
1 (nFGFR1) has been found in PSCs at the invasive edge of PDAC tumours. Inhibition 
of FGFR1 prevents its nuclear translocation in PSCs, which results in decreased 
invasion in 3D in vitro PDAC models. Nuclear translocation of FGFR1 in PSCs 
appears to be a vital mechanism that triggers the transcription of key proteins involved 
in PDAC invasion. 
 
We have used a powerful combination of chromatin immunoprecipitation (ChIP-seq) 
and sub-cellular mass spectrometry to determine the transcriptional targets of 
nFGFR1 and consequent sub-cellular protein flux. These techniques have allowed us 
to dissect the functional consequences of FGFR1 knockdown or inhibition in the 
PSCs. Candidate drivers of invasion are being validated in state-of-the-art 3D in vitro 
PDAC models. We have extended these functional studies to combination therapy 
with the clinical agent gemcitabine (targeting cancer cells) and all-trans retinoic acid 
(ATRA, modulating PSCs), providing translational relevance for our findings. We are 
validating this novel strategy using in vivo co-culture xenograft models with specific 
reference to FGFR1. Effectively disrupting the cross-talk between the tumour and 
stroma, either alone or in combination with other therapies, could translate to 
improved therapeutic responses in PDAC patients in the clinic. 
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1.1 The Pancreas 
1.1.1 Pancreatic development 
Embryonically the pancreas develops from two distinct buds of the endoderm: dorsal 
and ventral. As the duodenum rotates, the ventral bud with the bile duct also rotates 
such that the two buds fuse together at about 6-7 weeks gestation (Pan and Brissova, 
2014). Further differentiation of the cells within the pancreas occurs through signalling 
between mesenchymal cells and epithelial cells. Some of the main pathways involved 
in this process are Fibroblast Growth Factor (FGF), retinoic acid, Notch and Sonic 
Hedgehog (Shh) signalling (Gittes, 2009, Johannesson et al., 2009, Mfopou et al., 
2010). 
 
1.1.2 Adult Pancreas 
The adult pancreas performs two main functions. The exocrine compartment is 
involved in the secretion of many digestive enzymes, such as pancreatic lipase, 
amylase and proteases, into the duodenum. This compartment is made up of acinar 
and ductal cells, which release enzymes into ductal structures before they are further 
secreted into the digestive tract. The endocrine function of the pancreas involves 
release of hormones that can mainly control blood glucose levels amongst other 
functions. The endocrine pancreas is comprised of islets, formed of alpha (α), beta 
(β), delta (δ) and gamma (ϒ) cells. The α cells secrete glucagon, the β cells secrete 
insulin, the δ cells secrete somatostatin and the ϒ cells secrete pancreatic 
polypeptide (Figure 1.1) (Bardeesy and DePinho, 2002).  
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Figure 1.1 Structure of the pancreas 
A. Ductal structure with acini at the end of each branch. B. Acini made up of acinar cells 
producing digestive enzymes, which are then secreted into the ducts lined by the ductal cells. 
Centro-acinar cells have an indeterminate function and may represent, at least partly, the 
stem cells of the exocrine pancreas. C. The islets of Langerhans (made up of alpha, beta, 
delta and gamma cells) are interspersed between acini and carry out key endocrine functions 
to regulate blood glucose levels. Stellate cells, newly recognised interstitial pancreatic 
parenchymal cells which are of indeterminate origin, are also found surrounding the 
pancreatic acini. 
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1.2 Pancreatic Ductal Adenocarcinoma 
1.2.1 Epidemiology 
Pancreatic cancer is one of the leading causes of cancer-related death worldwide. 
The five-year survival rate for patients is below 5 % and there have been no significant 
advances in diagnosis or treatments in recent years (Bosetti et al., 2013, Siegel et al., 
2018). Pancreatic Ductal Adenocarcinoma (PDAC) arises from the exocrine 
compartment and is the most common tumour (~90 %) to occur within the pancreas 
(Hariharan et al., 2008, Rawla et al., 2019). Other rare exocrine tumours can also 
occur (~<5 %), such as acinar cell carcinoma, solid pseudopapillary neoplasm and 
pancreatoblastoma. Pancreatic neuroendocrine tumours arise from the endocrine 
compartment of the pancreas, however these are much less common (~5 %) and 
tend to have a better patient prognosis than PDAC (Brooks et al., 2019, Ilic and Ilic, 
2016). PDAC is predicted to become the third most common cause of cancer related 
death in the USA by 2030 (Rahib et al., 2014), making it a cancer of unmet clinical 
need and a focus of research. I will discuss PDAC only from now onwards. 
 
1.2.2 Risk factors 
There are a number of factors that can increase the risk of developing PDAC. The 
risk increases with the number of first degree relatives that have suffered from the 
disease (Becker et al., 2014). Furthermore, some familial conditions can be linked 
with development of PDAC; for example, Lynch syndrome (hereditary non-polyposis 
colorectal cancer), which is underpinned by mutations in DNA mismatch repair genes, 
or familial adenomatous polyposis, characterised by mutations in the APC gene 
(Elkharwily and Gottlieb, 2008, Kastrinos et al., 2009). Familial BRCA mutations can 
cause an increased risk in many cancers, including PDAC (Greer and Whitcomb, 
2007). Patients suffering from Peutz-Jeghers syndrome, caused by mutations in 
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STK11/LKB1, and familial atypical multiple mole melanoma syndrome (FAMMM), 
caused by mutations in P16INK4A/CDKN2A, have an increased risk of developing 
PDAC. Other conditions that have been linked with PDAC include cystic fibrosis, 
ataxia-telangiectasia and chronic pancreatitis (Becker et al., 2014). 
 
However, despite these links with hereditary conditions, 90 % of PDAC cases are 
sporadic. As with most tumours, the risk of developing PDAC increases with age, with 
the highest incidence occurring between the ages of 65-75 years (Lowenfels and 
Maisonneuve, 2006). Smoking, drinking alcohol and obesity can all increase the 
likelihood of developing PDAC. There is also an increased risk found in diabetic 
patients (Becker et al., 2014). This could be due to increased levels of insulin and 
insulin-like growth factors (IGFs), which can stimulate cell proliferation. Also diabetic 
patients have increased oxidative stress and inflammation within the pancreas, which 
can promote tumour development (Li, 2012). 
 
1.2.3 Clinical symptoms 
Many tumours are asymptomatic until they are advanced, meaning that most patients 
are diagnosed during the late stages of the disease. Patients may present with non-
specific abdominal pain, anorexia, weight loss and obstructive jaundice. Diagnosis is 
usually made through a Computed Tomography (CT) scan and subsequent biopsy. 
The tumour markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-
9 (CA19-9) may be elevated in PDAC, however, these alone are not specific enough 
for use in detecting the presence of PDAC. For example, CA19-9 can also be elevated 
in other gastrointestinal cancers and in non-malignant pancreatic conditions, such as 
chronic pancreatitis (Ryan  et al., 2014). 
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1.2.4 PDAC biomarkers 
Due to the lack of suitable biomarkers, biomarker discovery is currently a major area 
of research. Earlier diagnosis of patients could significantly improve treatment options 
and therefore survival rates. 
 
1.2.4.1 Serum biomarker panels 
PDAC patients have elevated levels of vascular endothelial growth factor (VEGF) and 
FGF2 in their serum, compared to healthy controls (Pistol-Tanase et al., 2008). A 
serum biomarker panel including interferon-inducible protein 10 (IP-10), interleukin 6 
(IL-6), platelet-derived growth factor (PDGF) and CA19-9 was able to distinguish 
patients with PDAC from those with benign pancreatic diseases (Shaw et al., 2014). 
The clinical utility of biomarkers can be assessed by sensitivity and specificity. 
Sensitivity measures the fraction of people with the disease that will be tested 
positive. Specificity measures the fraction of people without the disease that will be 
tested negative. A comparison of the glycan sialylated tumour-related antigen (sTRA) 
and CA19-9 levels in serum demonstrated that sTRA is more specific for detecting 
PDAC. This test was improved by combining two sTRA detection panels with CA19-
9 in a specificity optimised panel, obtaining 95 % specificity and 54 % sensitivity (Staal 
et al., 2019). A panel of biomarkers may improve the chance of reliably detecting 
PDAC compared to a single biomarker. Subsequently a panel of 25 serum biomarkers 
has been developed that can reliably differentiate patients with PDAC from healthy 
controls and patients with other pancreatic diseases, such as chronic and 
autoimmune pancreatitis (Wingren et al., 2012). 
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1.2.4.2 Metabolomics 
Metabolomics offers another promising method of identifying patients with cancer. 
For example, a panel of four metabolites (xylitol, 1,5-anhydro-D-glucitol, histidine and 
inositol) in serum from 59 patient samples compared to controls, has been shown to 
have a higher sensitivity in detecting PDAC, compared to CA19-9 and CEA (Sakai et 
al., 2016). Furthermore, palmitic acid presence in serum has been reported to 
distinguish between patients with malignant and benign lesions in 40 patient samples 
(Di Gangi et al., 2016). Other metabolite and amino acid serum panels have 
demonstrated sensitivity that can distinguish between healthy controls, pancreatitis, 
precursor lesions and PDAC (Leichtle et al., 2013, Yuan et al., 2016). These 
metabolomic approaches need to be tested in a wider cohort to confirm if any of them 
would make a suitable clinical biomarker panel for PDAC. 
 
1.2.4.3 Cell-free DNA 
Cell-free DNA (cfDNA) has been shown to be significantly increased in patients with 
cancer, making it a potential source of clinical biomarkers. Advances in sequencing 
techniques and droplet digital PCR have made it possible to isolate cfDNA and 
accurately analyse it for mutations or epigenetic changes specific to tumours. As 
KRAS mutation is an early event in PDAC development, identifying this mutation in 
cfDNA could be a useful early-stage diagnostic biomarker. In a study of 155 plasma 
samples from PDAC patients, the detection rate of circulating tumour DNA (ctDNA) 
was only 48% in localised disease, compared to over 80% in metastatic disease 
(Bettegowda et al., 2014). Another study found the same KRAS mutations in the 
primary tumour and in cfDNA in 35% of the patients analysed (Uemura et al., 2004). 
Circulating exosomes could also be used as a diagnostic tool, for example 43.6% of 
early-stage PDAC patients had detectable KRAS mutations in their exosomes 
(Allenson et al., 2017). Another study has shown increased levels of KRASG12D in 
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exosomes isolated from PDAC patients (39.6%), compared to patients with IPMN 
precursor lesions (28.6%) or healthy controls (2.6%) (Yang et al., 2017). 
 
Methylation status of cfDNA could also be used as a biomarker to predict the 
presence of PDAC. A study looking at cfDNA in 30 patient plasma samples 
discovered a panel of 17 gene promoters whose methylation could distinguish 
between chronic pancreatitis, pancreatic cancer and healthy controls (Liggett et al., 
2010). The methylation profile of the BNC1 and ADAMTS1 promotors in cfDNA has 
been described as a potential early-stage PDAC biomarker, with a sensitivity of 81% 
and a specificity of 85% (Yi et al., 2013). 
 
1.2.4.4 Non-invasive biomarkers 
The presence of cell free microRNAs (miRs) in urine can also be a potential biomarker 
test for detecting cancer. Four miRNAs (miR-143, miR-223, miR-30e and miR-204) 
have been identified as being overexpressed in PDAC, compared to healthy controls 
(Debernardi et al., 2015). Furthermore, a three-biomarker panel, Lymphatic vessel 
endothelial hyaluronan receptor 1 (LYVE-1), Regenerating islet-derived 1 alpha 
(REG1A) and Trefoil factor 1 (TFF1), discovered in urine was shown to distinguish 
early stage PDAC (stage I-II) from healthy controls (Radon et al., 2015). This could 
be very useful to detect tumours at an earlier stage when treatment is more effective. 
Further work has shown detection of volatile organic compounds (VOCs) in urine can 
reliably discriminate between healthy controls and PDAC patients with either early or 
late stage disease. A urine biomarker test would be an easy, non-invasive method to 
check for the presence of PDAC in the clinic (Arasaradnam et al., 2018). 
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A miR panel extracted from stool samples has also been shown to be a potential 
PDAC biomarker. Three miRs (miR-21, miR-155 and miR-216) were present at higher 
levels in stools from PDAC patients, compared to patients with chronic pancreatitis 
and healthy controls. Stool samples provide an equally easy and non-invasive method 
of screening for PDAC in the clinic (Yang et al., 2014). All of the discussed biomarkers 
require further wide-scale validation to assess their suitability for clinical use to detect 
PDAC (Zhang et al., 2018). 
 
1.2.5 PDAC development and progression 
The development of PDAC is considered to begin with genetic mutations and the 
appearance of precursor lesions within the pancreas. The most well-described 
precursor lesions are pancreatic intraepithelial neoplasias (PanINs), which progress 
from grade 1 to 3 before cancer develops (Figure 1.2). The early frequent oncogenic 
changes that occur during the development of PanIN lesions are K-RAS activating 
mutations (>90 %), HER2 amplification (30-40 %), the deactivation of p16 (~90 %) 
and telomere shortening (>90%). Subsequently, there may be a loss of tumour 
suppressor proteins and the inactivation of DNA repair genes, such as TP53 (~70 %) 
and BRCA1/2 (~4-14 %) (Cicenas et al., 2017, Hezel et al., 2006, Qiu et al., 2011, 
Shibata et al., 2018, van Heek et al., 2002). 
 
Other cystic precursor lesions that could lead to PDAC are intraductal papillary 
mucinous neoplasms (IPMNs) or mucinous cystic neoplasms (MCNs). IPMNs can 
develop from a main or a branch duct, depending on the location of the lesion, and 
progress from low grade to high grade dysplasia (Grützmann et al., 2011). 
Immunohistochemical staining can be used to further characterise these lesions into 
intestinal, pancreatobiliary, oncocytic and gastric subtypes (Distler et al., 2013, 
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Furukawa et al., 2005). MCNs are less common, occur mostly in women and tend to 
arise in the pancreatic body and tail (Crippa et al., 2008). These lesions can be 
classified into low, moderate and high grade dysplasia. Generally, if any precursor 
lesion is found in a scan, it will be surgically resected to prevent any risk of 
progression to invasive cancer (Distler et al., 2014).  
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Figure 1.2 Phenotypic and genetic development of PDAC 
The progression of pancreatic intraepithelial neoplasia (PanIN) lesions that can lead to the 
development of PDAC. Throughout the progression, the lesions become more irregular and 
gain increasing genetic mutations. Early events include the activation of the oncogene K-RAS 
and loss of p16. Late events involve the loss of tumour suppressor genes, such as TP53 and 
the inactivation of DNA repair proteins, such as BRCA2 (Hezel et al., 2006). 
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1.2.6 PDAC surgery 
Currently the only potentially curative treatment for PDAC is surgical resection of the 
tumour. Unfortunately, only 10-15 % of patients are eligible for surgery, due to either 
the advanced stage of the disease at diagnosis, or due to increased risk factors, such 
as age or tumour proximity to major blood vessels (Ryan  et al., 2014). The surgical 
resection procedure depends on the location of the tumour within the pancreas. 
Tumours that are located in the head are treated with pancreaticoduodenectomy (PD 
or Whipple), during which the head of the pancreas is removed, along with the 
duodenum, the gall bladder, part of the bile duct and the lower part of the stomach. 
Patients can also be treated with pylorus-preserving pancreaticduodenectomy 
(PPPD), which is the same as the PD operation except that none of the stomach is 
removed. Tumours that are present in the tail of the pancreas are treated by distal 
pancreatectomy, which removes the body and tail of the pancreas, along with the 
spleen. These surgeries are complex and can leave patients with complications such 
as diabetes or insufficient pancreatic enzyme production (Scavini et al., 2015, Strobel 
et al., 2019). Adjuvant chemotherapy and, sometimes, radiotherapy is given to these 
patients. However tumour recurrence is still common. Once the tumour has spread to 
distant organs, the patient has a poor prognosis (Hariharan et al., 2008).  
 
1.2.7 Chemotherapy 
Chemotherapy is often given to patients to extend life, however this has a limited 
effect. The poor response to drug treatment is due to the hypoxic environment within 
tumours and drug resistance of the tumour cells (Mahadevan and Von Hoff, 2007, 
Mohammed et al., 2014). 
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1.2.7.1 Gemcitabine 
The current standard chemotherapy treatment that is used to treat PDAC is the 
nucleoside analogue gemcitabine. It is incorporated into the cellular DNA in place of 
cytosine to inhibit DNA synthesis. Gemcitabine is a pro-drug, which is taken up by 
cells to be converted into the active nucleotide analogues: gemcitabine diphosphate 
(dFdCDP) and triphosphate (dFdCTP) (Marangon et al., 2008, Mini et al., 2006), 
whereby it inhibits DNA polymerase and thymidylate synthase, causing increased 
cellular toxicity. Gemcitabine metabolites can be incorporated into RNA as well as 
DNA, causing chain termination (Plunkett et al., 1995a, Plunkett and Gandhi, 1996). 
This method of action allows drug damage to avoid detection by DNA repair enzymes 
and increases the level of drug induced apoptosis (Heinemann et al., 1988). 
 
Gemcitabine also decreases the level of competing deoxyribonucleotides by inhibiting 
the enzyme ribonucleotide reductase. Other affected enzymes include the drug 
metabolising enzyme deoxycytidine monophosphate deaminase (dCMPDA), leading 
to increased levels of active metabolites within the cells (Mini et al., 2006, Plunkett et 
al., 1995b). This drug can cause toxic side effects, as it targets all cells; however 
tumour cells divide more frequently than other cells, making them vulnerable to the 
treatment, therefore increasing the therapeutic index in patients. 
 
1.2.7.2 Nab-paclitaxel 
Despite gemcitabine treatment, the median overall survival of patients is 6 months 
(Sun et al., 2014). There have been many clinical trials to develop more effective 
chemotherapy regimens in these patients. One drug that has been approved for use 
is nanoparticle albumin-bound paclitaxel (nab-paclitaxel). This is a formulation of the 
taxane: paclitaxel, which binds to microtubules preventing depolymerisation and, 
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therefore, prevents effective cell mitosis. Nab-paclitaxel contains the hydrophobic 
drug bound to albumin to form soluble nanoparticles, which reduces the side-effects 
of paclitaxel drug formulation. It has also been shown that nab-paclitaxel can reach 
higher concentrations in xenograft tumours compared to traditional formulations of 
paclitaxel (Desai et al., 2006). Another factor which could be responsible for increased 
drug response in tumours is that nab-paclitaxel could destroy the stroma surrounding 
the tumour. In a tumour xenograft study (Von Hoff et al., 2011), mice injected with 
nab-paclitaxel had decreased levels of collagen fibres and an increase in the 
presence of endothelial cells within the tumour mass. Furthermore, in the genetically 
engineered KPC (LSL-Kras(G12D) (/+);LSL-Trp53(R172H) (/+);Pdx-1-Cre) mouse 
model, it was reported that nab-paclitaxel caused a reduction in the levels of the 
gemcitabine metabolising enzyme cytidine deaminase, through the production of 
reactive oxygen species (ROS). This could lead to higher levels of gemcitabine 
triphosphate within the tumour cells, thereby increasing the cytotoxic effect of the 
combination treatment (Frese et al., 2012, Olive and Tuveson, 2006).  Combination 
chemotherapy of gemcitabine and nab-paclitaxel has been shown, in clinical trials, to 
increase patient survival by nearly 2 months over gemcitabine treatment alone (Von 
Hoff  et al., 2013). 
 
1.2.7.3 Combination chemotherapy 
Other chemotherapy regimens can be used in the clinic, usually combining a number 
of different drugs to give increased patient response. The combination chemotherapy 
regimen FOLFIRINOX has been shown to increase patient survival within groups of 
PDAC patients with a good performance status (Conroy et al., 2011). FOLFIRINOX 
comprises folinic acid (a vitamin B derivative that increases the effects of 5-FU by 
further inhibiting the activity of the thymidylate synthase enzyme), fluorouracil (5-FU, 
a pyrimidine analogue which is incorporated into the DNA and binds to thymidylate 
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synthase, preventing DNA replication and causing cell apoptosis), irinotecan (a 
topoisomerase 1 inhibitor which prevents effective DNA unwinding and replication) 
and oxaliplatin (a platinum based drug that intercalates in the DNA causing inter- and 
intra-strand cross-links, causing ineffective DNA replication and transcription) 
(Longley et al., 2003, Raymond et al., 2002, Robert and Rivory, 1998). There is also 
a nanoparticle formulation of irinotecan that has been approved by the Food and Drug 
Administration (FDA) to be used in combination with 5-FU and folinic acid as a 
second-line therapy in patients, after gemcitabine resistance (Hsueh et al., 2016). 
Capecitabine is an oral pro-drug of 5-FU which is also given to patients along with 
gemcitabine, decreasing side effects (Cunningham et al., 2009). Another oral pro-
drug of 5-FU that has been approved for use as adjuvant chemotherapy following 
surgery in PDAC patients in Japan is S-1. This formulation improves the activity of 5-
FU by inhibiting dihydropyrimidine dehydrogenase, which is the key enzyme of 5-FU 
catabolism (Sudo et al., 2014, Uesaka et al., 2016). 
 
Despite all these therapeutic options, PDAC patients consistently show a poor 
response to chemotherapy. This could be due to the desmoplastic stroma and 
hypoxic environment within the tumour, the advanced stage of the tumour at 
diagnosis, the performance status of the patients or due to intrinsic drug resistance in 
the tumour cells. Consequently there is an urgent need for new therapeutic strategies 
for these patients. 
 
1.2.8 PDAC sub-groups 
Attempts have been made to categorise PDAC patients into sub-groups (Figure 1.3), 
allowing treatment options to become more tailored and hopefully improve patient 
response. Gene expression microarray data from PDAC tumours could divide 
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patients into three main sub-groups (Collisson et al., 2011). The quasi-mesenchymal 
(QM) group showed high levels of mesenchymal gene expression and was 
associated with worse prognosis. The exocrine sub-group showed a high expression 
of tumour cell derived digestive genes and the classical sub-group had higher 
expression of epithelial and adhesion genes (Collisson et al., 2011). 
 
The sub-groups identified in 2011 were refined further by RNA expression profiling of 
PDAC patients to determine four sub-groups (Bailey et al., 2016). The features in 
these groups were matched with histopathological and genetic mutation data to 
further characterise these populations of patients. The four groups determined from 
this analysis were squamous, pancreatic progenitor, immunogenic and aberrantly 
differentiated endocrine exocrine (ADEX). The squamous, pancreatic progenitor and 
ADEX groups overlapped with the QM, classical and exocrine-like groups 
respectively. The immunogenic group was a newly classified sub-group within this 
analysis. The squamous sub-group had notably poor survival compared to the other 
three groups and was characterised by gene networks involved in inflammation, 
hypoxia response, metabolic reprogramming, autophagy and TGF-β signalling. 
Additionally, this sub-group was characterised by TP53 mutations and increased 
expression of TP63, which has been shown to cause a more metastatic phenotype in 
genetically engineered mice (KrasG12D/+; Trp53fl/+; TAp63fl/fl KPC mice) (Miller et al., 
2015). Indeed, there was an increase in expression of genes related to metastasis 
within this group, such as lysyl oxidase (LOX), which could indicate tumours with a 
higher metastatic potential and therefore a worse prognosis for these patients. 
Whereas, the pancreatic progenitor subtype had increased expression of pancreatic 
endoderm cell-fate determination transcription factors, such as pancreatic and 
duodenal homeobox 1 (PDX1), as well as fatty acid oxidation, drug metabolism and 
hormone biosynthesis pathways. The immunogenic sub-group had expression of 
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similar pathways to pancreatic progenitor, with an enriched immune infiltrate 
signature. The ADEX sub-group had enriched expression of pathways related to 
exocrine and endocrine pancreatic lineage differentiation.  
 
An alternative approach combined a genetic signature for the tumour cells with either 
activated or non-activated stroma to form four sub-groups of patients (Moffitt et al., 
2015). In this study, virtual microdissection was used to separate the gene expression 
signatures from the tumour cells and the stromal cells. Two sub-groups of tumour 
cells emerged from this analysis, named basal-like and classical, alongside the two 
sub-groups of stroma, activated or normal. It was found that the basal-like tumour 
with activated stroma signature gave the worst prognosis, whereas classical tumour 
with normal stroma had the best overall survival. The basal-like tumour sub-group 
most strongly associated with the squamous sub-group from the Bailey analysis, with 
half of the samples falling into this category and the rest divided between the other 
three categories. 
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Figure 1.3 Comparison of transcriptomic sub-grouping of PDAC 
This summary figure shows how the four sub-groups identified in the Bailey analysis 
overlapped with previously published transcriptomic sub-groups. In all three sets of 
data, there is one tumour sub-group that isolates out and is associated with poor 
survival. The gene expression data were also matched with histopathological and 
genetic mutation data, however no clear correlation was identified (Bailey et al., 2016) 
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A further classification of PDAC based on genetic mutations within the tumour has 
identified sub-groups linked to response to specific therapies (Waddell et al., 2015). 
The four sub-groups that arose from the whole genome sequencing and copy number 
variation analysis were named stable, locally rearranged, scattered and unstable. The 
unstable chromosomal phenotype frequently had mutations within the BRCA genes 
and showed more sensitivity to DNA damaging drugs, such as platinum-based 
compounds. These patients may also be responsive to poly (ADP-ribose) polymerase 
(PARP) inhibitor therapies, which can be used as a targeted synthetic lethality 
approach to tumour treatment (Fogelman et al., 2011). 
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1.3 PDAC stroma 
1.3.1 Stromal composition 
PDAC is characterised by a desmoplastic stroma that surrounds the tumour cells 
(Merika et al., 2012). There are many different cells that can be found within the 
stroma of PDAC tumours, including fibroblasts, immune cells, endothelial cells and 
stellate cells, embedded within an abundance of extracellular matrix proteins and 
polysaccharides, such as collagen, laminin, hyaluronic acid (HA) and fibronectin 
(Figure 1.4). This stroma creates a hypoxic environment that protects the cancer cells 
from chemotherapy treatment (Olive et al., 2009). It also means that angiogenesis 
inhibitors have little effect against pancreatic tumours. The stroma surrounding the 
tumour is often very stiff and has been shown to help promote tumour development 
(Nielsen et al., 2016). The most abundant protein found within the desmoplastic 
stroma is collagen, in particular collagen 1 (Linder et al., 2001). Cross-linking of 
collagen fibres by the amine oxidase LOX or tissue transglutaminase 2 (TG2) 
increases the stiffness of PDAC tumours. Expression of LOX is increased under 
hypoxic conditions and is a mediator of metastasis (Cox et al., 2013). TG2 is induced 
by TGF-β and can stimulate cancer-associated fibroblasts (CAFs) to produce more 
collagen (Lee et al., 2015). Additionally, HA is an important glycosaminoglycan 
present within PDAC stroma. This can bind non-covalently to proteoglycans and 
retain water to increase the stiffness of the stroma. The stiff stroma disrupts adherens 
junctions and can trigger cells to lose polarity, leading to increased cell proliferation 
and tumour progression. Additionally, the desmoplastic stroma has been shown to 
increase MMP secretion and therefore allow cells to remodel the ECM and 
metastasise (Haage and Schneider, 2014, Weniger et al., 2018). 
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Figure 1.4 Desmoplastic stroma in PDAC 
The stroma makes up a large volume of PDAC tumours. Many cells found within the 
stroma can contribute to tumour progression and invasion, such as activated 
pancreatic stellate cells, inflammatory immune cells and cancer associated fibroblasts. 
The stroma is very stiff due to the high levels of ECM proteins and polysaccharides 
that are laid down by activated stellate cells and fibroblasts. PDAC tumours are 
hypoxic and do not contain many blood vessels (Chu et al., 2007). 
52 
 
1.3.2 Pancreatic stellate cells 
Within the stroma of PDAC, one of the key supporting elements is the stellate cell.  
The origin of stellate cells is proposed to be local mesenchymal cells in developing 
organs. They were first described in the liver by Karl van Kuppfer in 1876 and were 
distinguished by their storage of vitamin A in droplets within the cytoplasm (Geerts, 
2001). Since this discovery, stellate cells have been identified in other organs, such 
as the kidney, intestine and lung (Omary et al., 2007). The first description of vitamin 
A storing cells within the pancreas was in 1982 in vitamin A loaded mice (Watari et 
al., 1982). The role of stellate cells has been most widely studied in the liver and 
pancreas. 
 
Pancreatic stellate cells (PSCs) make up less than 5 % of cells in a healthy pancreas 
and exist in a quiescent state, with a round cell body and long cytoplasmic processes. 
However, during pancreatic injury, PSCs become activated, begin proliferating and 
lose their vitamin A stores (McCarroll et al., 2006). These cells are characterised by 
the expression of glial fibrillary acidic protein (GFAP), desmin, vimentin and alpha-
smooth muscle actin (α-SMA) when activated. The storage of vitamins in lipid droplets 
in quiescent stellate cells can also be observed using lipid dyes, such as Oil Red O 
or BODIPY (Bynigeri et al., 2017). 
 
It has been shown that activated stellate cells are critical for the development of 
PDAC. These cells are involved in cross-talk with the tumour cells via growth factors 
and cytokines to promote inflammation, extra-cellular matrix (ECM) degradation and 
tumour metastasis (Apte et al., 2013). Stellate cells promote tumour cell proliferation 
and invasion, whilst the tumour cells also increase stellate cell activation (Figure 1.5) 
(Apte and Wilson, 2012). Activated stellate cells release matrix metalloproteinases, 
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which can digest the surrounding ECM. They may also induce epithelial to 
mesenchymal transition (EMT) in tumour cells, rendering them with a metastatic 
potential (Kikuta et al., 2010). This suggests a key role of stellate cells in PDAC 
tumour invasion and metastasis. 
 
Due to their importance in fibrosis and tumour development, PSCs have been isolated 
and maintained in cell culture. This process was first described in 1998 using density 
gradient centrifugation of cells from a rat pancreas and has been replicated with 
human PSCs (Apte et al., 1998, Bachem et al., 1998). Immortalisation of PSCs using 
SV40 large T antigen or human telomerase allows them to be studied extensively in 
the laboratory. PSCs become activated when grown in plastic tissue culture flasks 
and studies have shown that immortalised PSC lines have a similar phenotype and 
gene expression profile to  activated PSCs (Jaster et al., 2005, Jesnowski et al., 2005, 
Masamune et al., 2003, Sparmann et al., 2004). This makes immortalised stellate cell 
lines an invaluable tool for PDAC research (Feig et al., 2012). 
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Figure 1.5 Interaction of stellate cells and cancer cells 
Pancreatic stellate cells become activated in response to tissue injury and 
inflammation. This activation causes the cells to lose their vitamin-filled lipid droplets 
and express myofibroblast markers. Activated stellate cells in tumours can promote 
tumour cell proliferation through growth factor secretions, such as FGF2. Tumour 
cells can also promote stellate cell activation through growth factors, such as TGF-
β. Activated stellate cells can be returned to their quiescent state through treatment 
with ATRA or vitamin D derivatives (Habisch et al., 2010). There is increasing 
evidence for heterogeneity within activated PSCs which may interact with cancer 
cells in different ways (Neuzillet et al., 2019). 
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1.3.3 Pancreatic stellate cell heterogeneity 
Most attempts to determine subtypes of PDAC have based analysis on properties of 
the cancer cells (Section 1.2.4). However, a large component of these tumours is the 
desmoplastic stroma and therefore it may be necessary to consider heterogeneity in 
this compartment. Recently, there has been a growing interest in the classification of 
different subtypes of cancer-associated fibroblasts (CAFs), which are considered to 
be mostly activated PSCs in PDAC tumours. Two spatially distinct types of CAFs 
have been reported to be present within tumours: αSMA-positive myofibroblastic 
CAFs and αSMA-negative/IL-6-positive inflammatory CAFs (Ohlund et al., 2017). 
Another proposed classification is based on the expression of fibroblast activation 
protein (FAP) (pro-tumour) and αSMA (anti-tumour), determined by ablating either 
the FAP- or αSMA-positive CAF population (Kalluri, 2016). 
 
A different study has classified CAFs into four subtypes (A-D) using transcriptomic 
analysis of cells isolated from patient tumour samples. CAF heterogeneity was 
observed both within the same tumour and between different patients. Subtype A was 
distinguished by expression of periostin at the invasive front: high expression 
correlated with aggressive tumours and therefore worse patient prognosis in this 
group. Myosin-11 was identified as a marker of subtype B and podoplanin expression 
was a feature of subtype C. There was no clear marker for subtype D CAFs; however 
platelet-derived growth factor receptor α (PDGFRα) was reported as a pan-CAF 
marker. In this study, αSMA expression did not associate with any specific CAF 
subtype. In patient samples, it appeared that periostin expression was at the invasive 
edge and the centre of PDAC tumours, whereas expression of myosin-11 and 
podoplanin was found only in the centre of the tumours. CAFs in subtype C have an 
immunogenic profile, which correlated with a better prognosis than other subtypes. 
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Moreover, CAF subtypes D and A were associated with worse overall patient survival 
in the ICGC and Beaujon patient cohorts respectively (Neuzillet et al., 2019).  
 
1.4 Targeting the stroma 
1.4.1 Overview 
Since the desmoplastic stroma plays a vital role in PDAC development, targeting both 
the stromal and tumour cells may provide a therapeutic advantage to patients. 
Stromal modulating agents have been explored within the setting of PDAC alongside 
immune targeted therapies.  
 
1.4.2 Hyaluronic acid 
One key component of the ECM is hyaluronic acid (HA), a glycosaminoglycan that 
has been associated with tumour development and progression (Provenzano et al., 
2012, Toole, 2004). HA is synthesised as a large polysaccharide by hyaluronan 
synthases (HAS1, 2 and 3) at the plasma membrane, where it is secreted directly into 
the ECM. HA can be cleaved by hyaluronidases, mainly HYAL1 and 2 (Toole, 2004). 
In normal tissues HA levels are closely regulated, however in tumours this balance is 
disrupted and there is a build-up of HA in the ECM. It has been shown that the 
presence of low-molecular-weight HA (25-75 kDa), rather than high-molecular-weight 
HA (400-600 kDa) within the PDAC stroma is linked to tumour progression (Cheng et 
al., 2016, Karbownik and Nowak, 2013, Schmaus et al., 2014). Due to the large 
accumulation of HA within PDAC stroma and the resulting increase in tumorigenesis 
(Kultti et al., 2014), HA has gathered interest as a potential therapeutic target. There 
are three strategies for targeting HA in tumours: blocking the synthesis, interrupting 
the signalling or depleting from within the stroma. An example of a drug that can block 
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the synthesis of HA is 4-methylumbelliferone (4-MU). 4-MU competitively binds to 
UDP-glucuronosyltransferase (UGT) and downregulates HAS2 and 3. UDP-
glucuronic acid is used in many different pathways, not just HA biosynthesis. It is 
synthesised in the cytosol to be used in the production of glycosaminoglycans, and 
can be translocated into the Golgi apparatus for the biosynthesis of heparan sulphate 
and chondroitin. UGT is also responsible for adding glucuronic acid to xenobiotics to 
eliminate them, meaning that it is responsible for the inactivation of many drugs (Kultti 
et al., 2009). 4-MU has been shown in pre-clinical studies to increase the effects of 
gemcitabine in combination therapy (Nakazawa et al., 2006). To effect HA signalling, 
potential therapies could target binding partners, such as CD44 and receptor for 
hyaluronan-mediated motility (RHAMM) (Sato et al., 2016). The most advanced 
method of targeting HA within PDAC tumours is through depletion within the stromal 
compartment. PEGPH20 is an enzyme that has been shown to deplete HA within the 
stroma and increase the effectiveness of gemcitabine in the KPC mouse model 
(Jacobetz et al., 2013). The success of this therapy in pre-clinical models has 
translated into clinical trials in metastatic PDAC patients, in combination with 
gemcitabine and nab-paclitaxel. Phase I and II trials demonstrated a significant 
increase in progression-free survival in patients with high HA expression within their 
tumours (8.6 months compared to 4.5 months in the control arm) (Hingorani et al., 
2013, Hingorani et al., 2015, Hingorani et al., 2016). Due to the success in phase II 
trials, a phase III trial has been launched in PDAC patients (NCT02715804). 
 
1.4.3 Wnt signalling 
The Wnt pathway is strongly associated with tumour growth and invasion in PDAC, 
making it an attractive drug target. Restoration of PSC quiescence leads to increased 
secretion of frizzled-related protein 4 and, therefore, a decrease in Wnt-β-catenin 
signalling in cancer cells (Froeling et al., 2011). An antibody against the frizzled 
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receptor, OMP-18R5 (vantictumab) has shown anti-tumour effects against PDAC 
cancer in pre-clinical models and is now in clinical trials in combination with 
gemcitabine and nab-paclitaxel (NCT02005315) (Zhang et al., 2013)(Zhang et al., 
2013)(Zhang et al., 2013)(Zhang et al., 2013)(Zhang et al., 2013). Furthermore, a 
recombinant protein that competes with the frizzled receptor for ligand binding (OMP-
54 F28) is in clinical trials in combination with gemcitabine and nab-paclitaxel in PDAC 
patients (NCT02050178). 
 
1.4.4 Hedgehog signalling 
Hedgehog signalling has been strongly associated with PDAC progression. KrasG12D 
mutations and NF-κB expression have been linked with increased expression of sonic 
hedgehog in pancreatic tumours (Bailey et al., 2008, Ling et al., 2012). These pre-
clinical data suggest that overexpression of sonic hedgehog in cancer cells causes 
an activation of the hedgehog signalling pathway in stromal cells, creating a pro-
tumour microenvironment. However, studies where Shh was knocked out in PDAC 
cells, or signalling activity was depleted in the stroma, showed a more aggressive 
phenotype (Bailey et al., 2009, Feldmann et al., 2008). The classical understanding 
of the role of stroma within PDAC is that it is protective for the tumour cells and 
supports a pro-tumoural response. However, in recent studies in the KPC mouse 
model, the stromal compartment of PDAC tumours was decreased following depletion 
of Shh. Surprisingly, the tumours with Shh deleted in the stroma displayed a more 
aggressive tumour phenotype, suggesting that the stroma may also have a tumour 
suppressive role (Rhim et al., 2014). In fact, in a phase I/II clinical trial of the Shh 
inhibitor (IPI-926) and gemcitabine versus gemcitabine treatment alone in metastatic 
PDAC, patients receiving the combination treatment had worse outcomes, triggering 
early termination of the trial (NCT01130142). This indicates that many aspects 
59 
 
relating to the role of the stroma and the contribution of hedgehog signalling to PDAC 
development and progression are still not understood.  
 
1.4.5 Immune therapies 
Immune cells are present within pancreatic tumours, providing new hope for patients 
with the development of immunotherapy treatments. However, these treatments have 
not translated to improved outcomes in the clinic (Inman et al., 2014). This could be 
due to an inflammatory immune cell phenotype and, therefore, a tumour supportive, 
rather than tumour suppressive, role of immune cells. One of the main risk factors for 
the development of PDAC is pancreatitis and chronic inflammation within the 
pancreas. This could recruit inflammatory immune cells and trigger a wound-healing 
response, activating stellate cells (Bazhin et al., 2014). Another explanation for the 
disappointing results of immune therapy in PDAC treatment could be that the immune 
cells are physically separated from the tumour cells by other stromal cells and a stiff 
ECM. This could prevent an effective immune response from being triggered, 
particularly in advanced disease (Inman et al., 2014, Kotteas et al., 2016). 
 
1.4.6 Targeting stellate cells 
In PDAC patients, there is a reduction in pancreatic and bile acid secretions, causing 
a deficiency of fat soluble vitamins, such as vitamin A and D. The tumour-activated 
PSCs cannot be de-activated as their vitamin A stores cannot be replenished. 
Treatment with All-Trans Retinoic Acid (ATRA) has been found to return activated 
stellate cells to their quiescent state and induce storage of vitamin A within lipid 
droplets (McCarroll et al., 2006). Retinoic acid treatment of mice with chronic 
pancreatitis (induced by repetitive cerulein injection) and cultured PSCs in vitro 
caused down-regulation of Wnt 2 and β-catenin. The treated mice also showed 
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reduced fibrosis following treatment (Xiao et al., 2015). ATRA treatment in 3D 
organotypic models and KPC mice also reduced paracrine Wnt signalling, causing 
decreased cancer cell proliferation and invasion (Froeling et al., 2011). Another study 
using calcipotriol (a vitamin D receptor ligand) induced a quiescent state within 
pancreatic stellate cells through transcriptional reprogramming. The reversion of 
stellate cells to a quiescent state increased the level of gemcitabine within the tumour 
and increased survival in the KPC mouse model (Sherman et al., 2014). Returning 
stellate cells to this inactivated state may decrease the fibrotic reaction surrounding 
the cancer cells and may allow more chemotherapy treatment to reach the tumour, 
potentially increasing patient response. A combination therapy of gemcitabine and 
ATRA can decrease tumour cell proliferation and tumour invasion in 3D organotypic 
models and decrease tumour volume in KPC mice (Carapuça et al., 2016). 
 
These studies suggest a combination therapy approach targeting the stroma 
alongside cancer cells could be beneficial to patients. Moreover, understanding the 
critical cross-talk mechanisms within PDAC tumours may present new therapeutic 
targets that can be interrogated in the clinic. 
 
During PDAC progression, many developmental pathways become activated, which 
could provide key insights into stromal-cancer cross-talk (Rhim and Stanger, 2010). 
One of the critical pathways in pancreas development that has also been associated 
with PDAC is the FGF signalling pathway, which I have examined in this project 
(Gittes, 2009, Kang et al., 2019b). FGF signalling and its role in cancer development 
will now be discussed in detail. 
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1.5 Fibroblast Growth Factor Signalling 
1.5.1 FGF signalling overview 
The Fibroblast Growth Factor signalling pathway is a key regulator of cell growth, 
development, cell to cell contact and differentiation. It is made up of a family of 18 
secreted growth factors and four signalling receptor tyrosine kinases (FGFR1-4). 
There is also a fifth FGF receptor (FGFR5), which can bind to FGF ligands but has 
no tyrosine kinase activity. This may dimerise with the other receptors to negatively 
control FGF signalling (Regeenes et al., 2018, Trueb, 2011, Wiedemann and Trueb, 
2000). The FGF pathway is tightly governed to control cell differentiation and ensure 
tissue homeostasis. Disruption to FGF signalling has been associated with many 
different diseases, including cancer, (Carter et al., 2015, Clayton et al., 2017, Tanner 
and Grose, 2016, Turner and Grose, 2010). 
 
The FGF family can be separated into seven sub-groups relating to their function. 
There are five canonical secreted FGF subfamilies that all act by binding to the 
FGFRs with the co-factor heparan sulphate (HSPG) to trigger paracrine signalling: 
The FGF1 subfamily (FGF1 and 2), the FGF4 subfamily (FGF4, 5 and 6), the FGF7 
subfamily (FGF3, 7, 10 and 22), the FGF8 subfamily (FGF8, 17 and 18) and the FGF9 
subfamily (FGF9, 16 and 20) (Ornitz and Itoh, 2015). Another subfamily are the 
endocrine FGFs (FGF15/19 subfamily made up of FGF15/19, 21 and 23). These 
require Klotho as a co-factor for binding and have been reported to regulate 
hepatocyte and adipocyte metabolism, as well as bile acid synthesis (Potthoff et al., 
2012, Smith et al., 2014). The final group are the intracellular FGFs (FGF11 subfamily 
made up of FGF11, 12, 13 and 14). These are not secreted and do no interact with 
FGFRs but instead bind to the carboxy tail of voltage gated sodium channels to 
regulate neuronal and myocardial excitation (Goldfarb, 2005). 
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HSPG can contribute to FGF signalling pathway activation and cells lacking HSPG 
can only stimulate a transient activation of the MAPK pathway and therefore cannot 
stimulate DNA synthesis (Delehedde et al., 2000, Delehedde et al., 2002). HSPGs 
are made up of a carbohydrate chain of sulphated disaccharides and glucuronic acid 
linked to N-acteylglucosamine, which is covalently bound to a core protein (Matsuo 
and Kimura-Yoshida, 2013). The average HS chain is between 50-200 disaccharides 
units in length and can be modified by sulphotransferase enzymes (Esko and Selleck, 
2002, Kim et al., 2011). HSPGs can interact with both FGF ligands and FGFRs to 
regulate the activation of FGF signalling. The length and sulphation of the HS chain, 
as well as cleavage of the core protein can affect binding and therefore activation. 
The presence of different HSPG saccharides can dictate specificity of ligand-receptor 
interactions (Guimond and Turnbull, 1999). Longer chains and increased sulphation 
can increase FGF signalling (Escobar Galvis et al., 2007, Ornitz et al., 1992, Patel et 
al., 2008).  
 
1.5.2 FGF Receptors  
FGFR1-4 are made up of three immunoglobulin-like (Ig) domains, a single 
transmembrane region and an intracellular tyrosine kinase domain. Ligands bind at 
the second and third Ig loops, alongside heparan sulphate proteoglycans (HSPG), 
which stabilise the interaction between the ligand and receptor. The receptors can 
have tissue- or cell-specific expression and differences in ligand binding specificity 
arise due to alternative splicing of the third Ig domain. Three common variants of 
these receptors are IIIa, IIIb and IIIc (Figure 1.6). Fibroblast growth factor receptor 
IIIa is a secreted, truncated form of the receptor, which has no transmembrane region 
or signalling capacity. It is involved in mesoderm induction and expressed in 
embryogenesis and in the brain (Gong, 2014). FGFR IIIb isoforms use exon 8, are 
generally expressed in epithelial cells and bind ligands in the FGF7 subfamily, 
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whereas FGFR IIIc isoforms use exon 9, are expressed by mesenchymal cells and 
bind ligands in the FGF4 and 8 subfamilies (Kelleher et al., 2013). This helps to 
regulate reciprocal signalling between cell types within tissues. 
 
Receptor N-glycosylation can lead to ligand- and HSPG-binding specificity. Removal 
of N-glycans from FGFR1-IIIc derived from Chinese Hamster Ovary cells caused an 
increase in binding to FGF2 and HSPG. Mass spectrometry analysis has 
demonstrated that the majority of N-glycans on FGFR1 are bi- and tri-antennary core-
fucosylated complex structures with one, two or three sialic acids. In silico modelling 
suggests that these N-glycans can be positioned to block FGF/HSPG binding to the 
receptor and therefore control activation of FGF signalling (Duchesne et al., 2006). In 
fact, mutations in N-glycosylated sites of FGFRs can result in impaired protein folding, 
changing the affinity for FGF ligand binding and causing developmental skeletal 
disorders and craniosynostosis syndromes (Raivio et al., 2009). Studies in 
Caenorhabditis elegans (C. elegans) demonstrated that removal of N-glycosylation 
sites caused phenotypes associated with FGFR over-activation, indicating the 
importance of glycosylation in the regulation of FGF signalling (Polanska et al., 2009). 
 
In cancer cells, changes in the expression of FGFR isoforms have been linked to 
tumorigenesis (Liu et al., 2007). Both the b and c isoforms of the receptor can either 
have three Ig-like domains (FGFR b/c alpha) or only two Ig-like domains (FGFR b/c 
beta). In the beta form of the receptor, the first Ig domain is deleted by splicing, giving 
a higher affinity for ligand binding with FGF1 and FGF2. Splicing of the first Ig domain 
has been found in PDAC, as well as breast cancer and glioblastoma (Bruno et al., 
2004). 
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Figure 1.6 Alternative splicing of FGFR isoforms 
Alternative splicing of the IgIII domain in FGF receptors can lead to the expression 
of different isoforms. HSPG co-factor will bind below the acid box (orange box) to 
stabilise ligand binding. The invariant exon (IIIa) is spliced to either the IIIb or IIIc 
exon, both of which then splice to the transmembrane (TM) exon (blue filled in area). 
This alternative splicing leads to ligand binding specificity due to the tertiary 
structure of the receptor. The b isoform is usually expressed by epithelial cells whilst 
the c isoform is expressed by mesenchymal cells. Both b and c isoforms can have 
either two or three Ig-like domains. Isoform expression can change during tumour 
development (Section 1.5.2) (Turner and Grose, 2010). 
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1.5.3 FGF signalling pathway 
Upon ligand binding, FGFRs dimerise, causing a conformational shift and activating 
the intracellular tyrosine kinase domain (Goetz and Mohammadi, 2013). This triggers 
transphosphorylation of key tyrosine residues, activating the receptor and providing 
docking sites for adaptor proteins inside the cell. Adaptor proteins bind to the 
phosphotyrosine residues by Src homology 2 (SH2) or phosphotyrosine-binding 
(PTB) domains (Eswarakumar et al., 2005). The main FGFR adaptor protein is FGFR 
substrate 2 (FRS2), which is bound to the plasma membrane of the cell and binds to 
the juxtamembrane region of FGFRs via a PTB domain. The activated FGFR 
phosphorylates FRS2, which consequently recruits Son of Sevenless (SOS), SH2-
containing protein tyrosine phosphatase (SHP2) and growth factor receptor-bound 2 
(GRB2), triggering activation of RAS, RAF and the MAPK signalling pathway (Gotoh, 
2008). Another protein that can be recruited to GRB2 is GRB2-associated binding 
protein 1 (GAB1). This can then activate the phosphoinositide 3-kinase (PI3K)-Akt 
pathway (Altomare and Testa, 2005). 
 
Independently of FRS2 binding and activation, other adaptor proteins can be recruited 
to activated FGFRs through SH2 domains, such as phospholipase Cγ (PLCγ). 
Activated PLCγ can then hydrolyse phosphatidylinositol-4,5-bisphosphate (PIP2) to 
inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG), subsequently activating 
protein kinase C (PKC) (Peters et al., 1992). Another pathway activated through FGF 
signalling is the Janus kinase/signal transducer and activator of transcription 
(JAK/STAT) pathway (Hart et al., 2000). This is particularly activated upon mutations 
within FGF receptors, such as FGFR3 (Hart et al., 2000). A predominance of 
JAK/STAT signalling has been shown downstream of chondrocytes overexpressing 
FGFR3 (Krejci et al., 2008, Li et al., 2010). It has also been suggested that this could 
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be due to intracellular activation of mutant FGFR3 and JAK/STAT signalling from the 
endoplasmic reticulum (Lievens et al., 2004). 
 
Ligand binding specificity of FGFRs can be controlled by the concentration of ligand 
available to FGFRs, as well as the relative availability of HSPG co-receptors. 
Gradients of FGFs are important for regulating the development of the ventral foregut 
into the liver and lung, as well as limb outgrowth (Cohn et al., 1995, Serls et al., 2005). 
Cells exposed to high levels of FGF2 (100 ng/ml) have little effect on stimulating 
FGFR1 signalling, with only a transient early peak of MAPK activation and inefficient 
phosphorylation of FRS2. Whereas, cells stimulated with an optimal dose of FGF2 
(300 pg/ml) exhibit a sustained activation of FRS2 and downstream signalling 
pathways (Zhu et al., 2010). This mimics results seen in frs2 null mice, where FGF1 
can only activate GRB2, triggering transient activation of the MAPK pathway and no 
cell proliferation. This phenotype can be rescued by re-expressing FRS2 in these 
cells, restoring their ability to respond to FGF1 and fully activate downstream 
signalling pathways (Hadari et al., 2001). 
 
Negative feedback mechanisms can regulate FGF signalling. Receptors will be 
internalised into the cell and then either degraded or recycled back to the membrane. 
The Casitas B-lineage lymphoma (CBL) protein can trigger ubiquitination of FGFR 
and FRS2, causing degradation (Thien and Langdon, 2001). Additionally, 
downstream signalling can be inhibited by negative regulators, such as sprouty 
(SPRY), similar expression to FGF (SEF), Shp2 and Dual-specificity phosphatase 6 
(DUSP6) (Ekerot et al., 2008, Fürthauer et al., 2002, Hacohen et al., 1998). These 
negative regulators either de-phosphorylate the activated proteins or prevent further 
binding and activation of downstream signals (Figure 1.7) (Katoh and Nakagama, 
2014, Ornitz and Itoh, 2015, Turner and Grose, 2010). 
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Figure 1.7 FGF signalling pathway 
FGF receptors bind to relevant FGF ligands and heparan sulphate (HSPG) to become 
activated. This triggers receptor dimerization and transphosphorylation of kinase 
domains. Downstream signalling is initiated by FRS2 binding to the juxtamembrane 
region, activating the MAPK and PI3K-Akt pathways. FGF receptor tyrosine kinase 
phosphorylation also activates the PLCγ-PKC and JAK/STAT pathways. These 
signalling pathways lead to cell proliferation, survival and migration (Section 1.5.3) 
(Turner and Grose, 2010). 
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In addition to canonical pathways, FGF signalling can promote cell adhesion and 
proliferation through interaction with integrins. FGF1 has been reported to bind to αvβ3 
integrin at a different site to the FGFR binding domain, suggesting formation of an 
FGFR-FGF-integrin complex (Mori et al., 2008b). Mutations in the integrin binding site 
of FGF1 interrupt its ability to stimulate DNA synthesis, cell proliferation and 
migration, suggesting that integrin interactions are critical for activation of FGF1-
driven signalling (Mori et al., 2008a, Mori and Takada, 2013, Yamaji et al., 2010). 
Substrate-bound FGF2 can promote endothelial cell adhesion through interaction 
with αvβ3 integrin and mutations in the integrin binding site of FGF2 causes decreased 
activation of signalling and DNA synthesis (Mori et al., 2017, Rusnati et al., 1997). 
Activation of FGFR1 at these FGF2-αvβ3 cell adhesion contacts can trigger endothelial 
cell proliferation and migration, highlighting cross-talk between FGFR1 and αvβ3 
integrin (Tanghetti et al., 2002). 
 
Tissue cohesion and cell migration can be mediated through the action of cadherins. 
In particular neuronal cadherin (N-cadherin) is responsible cell migration and neurite 
outgrowth (Bixby and Zhang, 1990, Derycke and Bracke, 2004). Two main pathways 
have been associated with this: direct binding of cadherins to the actomyosin 
cytoskeleton to drive movement and activation of FGFR signalling (Bard et al., 2008, 
Williams et al., 1994). FGF signalling has been linked to N-cadherin expression in 
many different cell types, including stem cells, osteogenic cells and ovarian cells to 
promote survival and differentiation (Debiais et al., 2001, Takehara et al., 2015, 
Trolice et al., 1997). In breast cancer, prostate cancer and melanoma cells, N-
cadherin can stabilise FGFR at the plasma membrane, leading to sustained activation 
of signalling and promoting cell proliferation (Suyama et al., 2002). It has also been 
shown that FGFR1 can stabilise N-cadherin at the cell membrane by decreasing its 
internalisation (Nguyen et al., 2019). Furthermore, in pancreatic cancer xenografts, 
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inhibition of FGFR signalling causes a decrease in N-cadherin expression and 
invasion (Taeger et al., 2011). It has been shown that N-cadherin and FGFR1 can 
interact directly through their extracellular domains, forming stable cadherin junctions 
and anchoring N-cadherin to actin. This indicates that cell migration may depend on 
a balance between FGFR1 mediated N-cadherin adhesion and actin interaction 
(Nguyen et al., 2019). 
 
1.5.4 FGF signalling in cancer 
FGF signalling is dysregulated in many different cancers, usually causing 
uncontrolled activation of the pathway. Recent reports suggest that FGF signalling is 
disrupted in more than 7 % of cancers (Figure 1.8) (Helsten et al., 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 FGF signalling pathway alterations in cancer 
The FGF signalling pathway can become altered in many ways in cancer to cause 
sustained cell proliferation and survival: A. Overexpression of FGF receptors cause 
ligand independent activation, e.g. FGFR2 in gastric cancer. B. Receptor 
translocations can occur also leading to ligand independent activation of signalling, 
e.g. FGFR fusion with TACC in bladder cancer. C. Activating mutations within the 
FGF receptors cause constitutive activation even in absence of the ligand, e.g. 
FGFR2 in endometrial cancer. D. Paracrine or autocrine overexpression of FGF 
ligands can lead to increased FGF signalling, e.g. FGF1 in ovarian cancer. E. Sub-
cellular translocation of either the full length or a cleaved version of the receptor 
can occur, for example to the nucleus where it could act as a transcription factor, 
e.g. FGFR1 in pancreatic or breast cancer (Turner and Grose, 2010). 
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1.5.4.1 FGFR amplification 
FGF receptor amplification can lead to ligand-independent signalling, increased 
response to ligands or reduced receptor recycling, which in turn increases the activity 
of the pathway. FGFR2 is amplified in about 10 % of gastric cancers and is associated 
with a poor prognosis (Kunii et al., 2008, Matsumoto et al., 2012). Overexpression of 
FGFR2 has also been reported in about 4 % of triple-negative breast cancers (Turner 
et al., 2010). Amplification of FGFR1 occurs in approximately 10-15 % of breast 
cancers, 75-80 % of head and neck squamous cell carcinomas, 5 % of small cell lung 
carcinomas and 20 % of non-small cell lung carcinomas, as well as in some cases of 
prostate, bladder and ovarian cancers, and osteo- and rhabdomyo-sarcomas 
(Elbauomy Elsheikh et al., 2007, Guagnano et al., 2012, Hamaguchi et al., 1995, Jang 
et al., 2012, Koole et al., 2016a, Lee et al., 2014, Missiaglia et al., 2009, Peifer et al., 
2012, Reis-Filho et al., 2006, Tomlinson et al., 2009, Weiss et al., 2010). 
Overexpression of FGFR3 has been reported in about 50 % of oral squamous cell 
carcinomas, as well as some cases of non-small cell lung cancer and bladder cancer 
(Baldia et al., 2016, Koole et al., 2016b, Theelen et al., 2016). FGFR4 overexpression 
has been detected in 50 % of hepatocellular carcinomas and is linked to increased 
tumour invasion (Guagnano et al., 2012, Ho et al., 2009). Melanoma cell lines have 
increased levels of FGFR2 and 4 (Metzner et al., 2011). 
 
1.5.4.2 FGFR mutation 
Another common method of FGF signalling disruption is through activating mutations. 
This either causes constitutive receptor activation or increased affinity for ligand 
binding. For example, around 50 % of bladder cancers have a mutation in the FGFR3 
gene (Cappellen et al., 1999). This is associated with non-muscle invasive disease in 
these patients. The majority of these mutations cause constitutive dimerization and 
activation of the receptor by formation of a disulphide bridge. However, mutations can 
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also occur in the transmembrane domain and the kinase domains in these tumours 
(Pouessel et al., 2016, van Rhijn et al., 2001). Mutations in FGFR3 also occur in other 
tumour types, such as spermatocytic seminomas, prostate cancer, cervical cancer, 
melanoma and multiple myeloma (Goriely et al., 2009, Hafner et al., 2006, Hernandez 
et al., 2009, Wu et al., 2000). FGFR2 mutations are present in around 12 % of 
endometrial carcinomas, which cause increased affinity for ligand binding and 
autocrine signalling (Dutt et al., 2008, Pollock et al., 2007). An amino acid substitution 
in FGFR4 in breast cancer cells allows the receptor to form ligand-independent 
dimers, which triggers constitutive activation of signalling in the tumour cells (Roidl et 
al., 2010). 
 
1.5.4.3 Paracrine/autocrine signalling 
Paracrine or autocrine action of FGF ligands can also cause uncontrolled FGF 
signalling in cancer. Increased levels of FGFs in plasma of cancer patients suggests 
that high levels are produced by cells present in the tumour, or that ligands are 
released from the ECM during cancer progression (Poon et al., 2001). High levels of 
FGF2-FGFR1 signalling occur in melanoma and a similar FGF2 autocrine loop has 
been reported in non-small cell lung cancer (Marek et al., 2009, Wang and Becker, 
1997). Moreover, amplification of FGF1 in ovarian cancer is associated with poor 
survival and increased angiogenesis in tumours (Birrer et al., 2007).  Additionally, in 
prostate cancer, there are increased levels of FGF2 and FGF6, which could indicate 
a paracrine signalling loop (Giri et al., 1999, Ropiquet et al., 2000). Increased ligand 
levels from cells or ECM within the tumour could cause over-activation of the FGF 
pathway. 
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1.5.4.4 Fusion proteins 
Chromosomal translocations can also lead to the expression of FGFR fusion proteins 
in cancer. FGFR fusion with transforming acidic coiled-coil (TACC) proteins can occur 
in bladder cancer and glioblastoma, as well as FGFR1 fusion with FGFR1 oncogene 
partner 1 and 2 (FOP1/2) in lung cancer and leukaemia (Gu et al., 2006, Mano et al., 
2007, Singh et al., 2012, Williams et al., 2013). An FGFR2-PPHLN1 fusion has been 
reported in 16 % of intrahepatic cholangiocarcinoma cases with a poor patient 
prognosis (Sia et al., 2015). Other FGFR fusion proteins have been discovered in 
cases of breast, lung and prostate cancer (Wu et al., 2013). These translocations can 
alter downstream signalling of the FGF pathway in tumours due to loss of specific 
tyrosine residues or the FRS2 binding site (Jackson et al., 2010, Williams et al., 2013). 
Moreover, translocations can lead to altered subcellular localisation due to the loss of 
the transmembrane region in the fusion proteins (Mano et al., 2007, Olsen et al., 
2006, Sohal et al., 2001). 
 
1.5.4.5 Sub-cellular localisation 
Another method of deregulation of FGF signalling is sub-cellular translocation of the 
receptors. In lung cancer, full length FGFR1 has been reported to localise to the outer 
membrane of the mitochondria. Moreover, a FOP2-FGFR1 fusion protein has been 
found in the intermembrane space of mitochondria in lung cancer cells. Translocation 
of FGFR1 to the mitochondria can modify metabolism within the cancer cells. FGFR1 
can phosphorylate and therefore activate pyruvate dehydrogenase kinase 1 
(PDHK1), leading to a decrease in pyruvate dehydrogenase complex (PDC) activity 
and therefore promoting generation of energy by glycolysis (the Warburg effect) 
(Hitosugi et al., 2011). 
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Both FGF ligands and receptors can localise to the nucleus, where they are thought 
to control gene expression either through direct DNA binding or through interactions 
with other DNA binding molecules (Chen and Hung, 2015). Nuclear translocation of 
FGF1 has been associated with DNA synthesis, whilst nuclear FGF2 has been linked 
with glioma cell proliferation (Lin et al., 1996, Wang et al., 2015). Nuclear FGFR1 is 
important in neuronal differentiation and appears to be linked with invasion in breast 
cancer and PDAC (Chioni and Grose, 2012, Coleman et al., 2014b, Stachowiak et 
al., 2007, Stachowiak and Stachowiak, 2016). 
 
1.5.4.6 FGFR1-mediated invasion 
FGFR1 expression has been linked with invasion in many cancers. In breast cancer 
cells, the upregulation of FGF2 expression has been shown in response to GPER. 
This leads to an FGF2/FGFR1 paracrine signalling cross-talk between cancer cells 
and CAFs, triggering expression of CTGF and invasion (Santolla et al., 2019). 
Additionally, TGF-β mediated EMT in breast cancer cells has been shown to increase 
expression of the FOXC1 transcription factor, which in turn promotes isoform 
switching to FGFR1 IIIc, resulting in increased invasion (Hopkins et al., 2017). FGFR1 
expression has been negatively correlated with the tumour suppressor miR-133b in 
osteosarcoma and was related to advanced clinical tumour stage and increased 
invasion (Gao et al., 2018). Moreover, in colorectal cancer, expression of Crumbs3 
has been correlated with increased cell migration and invasion, which has been 
attributed to its intracellular interaction with FGFR1 (Iioka et al., 2019). Furthermore, 
in high grade gliomas FGFR1 inhibition demonstrated significant anti-migratory 
effects in 3D in vitro models (Egbivwie et al., 2019). This indicates the importance of 
FGFR1 in cell migration and invasion, providing a potential novel therapeutic target 
in the clinic for many cancers. 
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1.5.5 FGF signalling in PDAC 
During PDAC progression, many developmental pathways are activated, including 
FGF signalling (Rhim and Stanger, 2010). The FGF signalling pathway is deregulated 
in cancer, either by mutations, overexpression, activation or translocation of 
receptors, as well as increased ligand expression (Turner and Grose, 2010). Cancers 
driven by FGF signalling can be treated with targeted therapies, such as tyrosine 
kinase inhibitors (Table 6.1). This highlights the notion that targeting FGF signalling 
is a viable clinical option, with therapies already being used in patients. 
 
1.5.5.1 FGF ligands 
In PDAC, FGF signalling is increasingly recognised as one of the critical pathways 
involved in cross-talk between cancer and stellate cells within the tumour (Kang et 
al., 2019b). FGF1 and FGF2 can be overexpressed by cancer cells and have been 
correlated with advanced tumour stage (Yamanaka et al., 1993). High levels of FGF2, 
VEGF and FGF13 have also been correlated with shorter patient survival and 
increased liver metastasis (Kuwahara et al., 2003, Missiaglia et al., 2010). It was 
shown that FGF2 overexpression led to increased cell proliferation and invasion in 
cancer cells (Yamazaki et al., 1997). Antibodies against either FGF2 or FGF receptors 
caused a 50% reduction in cell proliferation or reduced cell invasion in PDAC cancer 
cells in rudimentary single cell type 2D cultures, respectively, suggesting FGF 
signalling could be a good therapeutic target (Hasegawa et al., 1994, Leung et al., 
1994). Interestingly, it has also been demonstrated that secretion of FGF2 can lead 
to increased cancer cell adhesion and inhibition of invasion of cancer cells (El-Hariry 
et al., 2001a, El-Hariry et al., 2001b, Escaffit et al., 2000). 
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Other FGF ligands, including FGF5, FGF7 and FGF10, have been reported to be 
overexpressed in PDAC leading to increased cell proliferation and invasion 
(Kornmann et al., 1997, Kornmann et al., 2001, Niu et al., 2007, Nomura et al., 2008). 
In particular, FGF7 and FGF10 are reported to signal from the stroma to the cancer 
cells. FGF7 can activate nuclear factor kappa B (NF-κB) and induce the expression 
of VEGF, MMP-9 and urokinase-type plasminogen activator (Niu et al., 2007). A study 
looking at the pre- and post-chemotherapy serum profiles of PDAC patients 
demonstrated that FGF10 was differentially expressed in response to gemcitabine 
and erlotinib, indicating that changes in FGF10 levels could be used as a predictive 
biomarker of chemotherapy response in patients (Torres et al., 2014). Furthermore, 
stimulation of PDAC cancer cells with FGF ligands, such as FGF1, 2, 7 and 10, 
triggered changes in expression of key pancreatic development genes, such as SRY-
related HMG-box gene 9 (SOX9), hepatocyte nuclear factor 3-beta (HNF3b), hairy 
and enhancer of split-1 (HES1), GATA-4 and GATA-6 (Gnatenko et al., 2018).  
 
Moreover, FGF signalling has been associated with increased expression of inducible 
nitric oxide synthase (iNOS), indicating that oxidative stress may play a role in FGF-
mediated PDAC progression (Vickers et al., 1999). To support this, there is evidence 
that FGF signalling can regulate response to oxidative stress as in keratinocytes 
(Marchese et al., 1995, Pentland, 1994). In particular, expression of glutathione 
peroxidase 1 (GPX1) has been shown to be a downstream target of activated FGF 
signalling in wound healing (Frank et al., 1997, Munz et al., 1997). As well as 
overexpression of FGF ligands, it has been reported that the levels of FGF-binding 
proteins (FGF-BP) are increased in PDAC patients (Tassi et al., 2006). This could be 
an indicator of early initiation of PDAC lesions. 
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1.5.5.2 FGF receptors 
FGF receptors, such as FGFR1, are also overexpressed within PDAC and can be 
associated with patient survival (Kobrin et al., 1993, Ohta et al., 1995). 
Overexpression of FGFR4 has been linked with cancer cell adhesion to ECM 
proteins, such as laminin and fibronectin, decreasing cell migration and increasing 
patient survival (Motoda et al., 2011). Inhibition of FGFR4 prevented matrix adhesion 
through neural cell-adhesion molecule (N-CAM), suggesting that this could be a key 
pathway regulating pancreatic cell migration and invasion (Cavallaro et al., 2001). In 
contrast, FGFR2 overexpression has been linked with shorter patient survival in 
PDAC (Nomura et al., 2008). Downregulation or inhibition of FGFR2 can reduce 
tumour cell survival and migration, as well as tumour development in vivo (Matsuda 
et al., 2014). 
 
Alternative splicing and isoform expression can alter the role of FGF receptors in 
PDAC. For example, FGFR1α has been linked with decreased cancer cell 
proliferation and increased anti-tumour responses, whereas expression of FGFR1β 
increased resistance to chemotherapy treatment in xenograft models, consistent with 
an inhibitory role for the first Ig-loop, which is absent in FGFR1β (Vickers et al., 2002). 
The third membrane proximal Ig-loop is also important: expression of the IIIc isoform 
of FGFR2 has been associated with increased cell proliferation and liver metastasis 
(Ishiwata et al., 2012). Contrastingly, expression of the FGFR1 IIIb isoform has been 
shown to decrease tumour growth in mouse models (Liu et al., 2007). Additionally, it 
has been reported that the overexpression of FGFR1 IIIb in PDAC cells induces the 
expression of secreted protein acidic and rich in cysteine (SPARC), which regulates 
cell-cell interactions and decreases tumour progression (Chen et al., 2010). FGFR 
IIIb isoforms are usually expressed on epithelial cells, whilst FGFR IIIc isoforms are 
expressed by mesenchymal cells (Turner and Grose, 2010). Changes in isoform 
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expression in cancer cells have been linked with tumorigenesis (Liu et al., 2007). The 
expression of FGFR1 isoforms on PDAC cells can be modulated by the stroma, with 
PSCs inducing cancer cells to switch to the mesenchymal FGFR1-IIIc isoform 
(Kornmann et al., 2001, Tian et al., 2012). 
 
1.5.6 Targeting FGF signalling 
Due to the frequency of FGF signalling disruption in cancer, it is a popular therapeutic 
target. Many of the strategies to disrupt this pathway are designed to prevent ligand-
dependent activation of signalling, such as small-molecule tyrosine kinase inhibitors 
(TKIs), antibodies to prevent ligand binding, antagonistic peptide mimics or ligand 
traps. TKIs have been the main focus of FGF therapies, with some clinical success; 
however, drug resistance often develops (Babina and Turner, 2017, Camidge et al., 
2014, Katoh, 2019). 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Phase I and II clinical trials of FGFR inhibitors, such as dovitinib, lucitanib, ponatinib, 
nintedanib and pazopanib are ongoing in a variety of solid tumours. For example, a 
phase Ib trial determined that dovitinib is safe to give to PDAC patients, alongside 
gemcitabine and capecitabine. Dovitinib is a multi-kinase inhibitor and FGF23 
changes in the plasma can be used as an indicator of FGFR modulation. The major 
toxicities caused by adding dovitinib to standard chemotherapy were neutropenia and 
thrombocytopenia (Ma et al., 2019). Addition of FGFR inhibitors to chemotherapy 
treatment of PDAC could lead to enhanced overall survival and improved patient 
prognosis. Using FGF23 as a serum biomarker to assess the effectiveness of 
treatment is also an important aspect for future studies. FGFR1 is upregulated in 
about 5 % of pancreatic tumours and this has been related to an increase in overall 
survival and improved patient prognosis (Haq et al., 2018). This reveals a clear clinical 
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sub-group of PDAC patients that may respond to FGFR inhibitors in the clinic, 
however this analysis did not provide information on isoform switching, which will be 
critical for determining patient outcomes. Sensitivity to FGFR inhibition has also been 
demonstrated in a subset of cell lines and primary explant cultures in vitro, supporting 
that this is a viable clinical option in some patients (Zhang et al., 2014a).  Despite an 
increase in overall survival, the prognosis of all PDAC patients is poor; therefore any 
options to effectively target sub-groups of patients, such as FGFR inhibitors, should 
be explored. 
 
The nuclear role of FGFRs has been shown to be very important in cancer. Therefore 
another approach to targeting the FGF pathway could be to prevent nuclear 
translocation. For example, targeting granzyme B could prevent FGFR1 cleavage and 
translocation to the nucleus in breast cancer (Chioni and Grose, 2012). Furthermore, 
inhibiting importin-β reduces the nuclear translocation of FGFR1 and therefore 
decreases cell proliferation (Mahipal and Malafa, 2016, Reilly and Maher, 2001). 
Therapies that focus on preventing the nuclear translocation of the receptor rather 
than traditional TKIs may help to avoid the development of resistance in patients 
(Porębska et al., 2018). 
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1.6 Nuclear receptor signalling 
1.6.1 Nuclear receptor tyrosine kinase signalling 
Nuclear signalling by several transmembrane receptors has been reported, such as 
insulin (Sun et al., 2003), vascular endothelial growth factor (Carpenter and Liao, 
2013), epidermal growth factor (EGF) (Carpenter and Liao, 2013), nerve growth factor 
(Bryant and Stow, 2005), FGF (Stachowiak et al., 1996, Maher, 1996) and interleukin 
receptors (de Oca B et al., 2010). These receptors are usually considered to be 
located within the plasma membrane. Upon binding to their target ligand, intracellular 
activation occurs, for example through tyrosine kinase transphosphorylation. This 
activates an intracellular signalling cascade, which can cause cell effects such as 
proliferation, growth and invasion. However, discovery of these receptors within the 
nucleus suggests that there is a less well-understood non-canonical mechanism of 
action within these pathways. Membrane-bound receptors are known to be taken into 
endosomes upon activation and then either degraded or recycled back to the plasma 
membrane. However, it is now understood that some of these receptors can 
translocate into the nucleus instead. Other methods of nuclear translocation of these 
proteins could be alternative splicing to create nuclear receptor tyrosine kinase (RTK) 
fragments, binding to nuclear chaperones or by retro-translocation from the 
endoplasmic reticulum (Bryant and Stow, 2005, Wiley and Burke, 2001). Once in the 
nucleus, RTKs can act as kinases or as transcriptional regulators and are related with 
a poor prognosis in cancers. 
 
One of the most well documented receptor translocations is for the epidermal growth 
factor receptor family. Nuclear full-length ErbB1-4 have all been reported, whilst ErbB-
4 can also be cleaved to produce an intracellular domain, which can translocate to 
the nucleus (Wang and Hung, 2009). Nuclear ErbB1 (EGFR) correlates with highly 
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proliferating cells (Lin et al., 2001, Marti et al., 1991). Moreover, nuclear ErbB2-4 have 
been detected in the frontal cortex of monkeys, suggesting they play a role in brain 
development (Thompson et al., 2007). This nuclear localisation of ErbB proteins was 
also found in primary human umbilical venous endothelial cells (HUVEC) and arterial 
endothelial cells (HUAEC) (Bueter et al., 2006). EGFR is associated with chromatin 
at specific DNA sequences, alongside other transcription factors, suggesting it plays 
a role in transcriptional regulation. Cyclin D1, iNOS, Aurora A and B-MYB have 
emerged as potential targets for EGFR within the nucleus (Hanada et al., 2006, Hung 
et al., 2008, Lin et al., 2001, Lo et al., 2005). COX-2 has been reported as a target for 
nuclear ErbB2 (Wang et al., 2004), and ErbB4 has been reported to increase 
expression of β-casein and decrease expression of the tumour suppressor gene 
ETO-2 (Linggi and Carpenter, 2006, Williams et al., 2004). Nuclear ErbB4 can 
activate oestrogen receptor α (ER-α) and render breast cancer cells sensitive to 
tamoxifen treatment (Naresh et al., 2008). 
 
It has also been reported that ErbB1, -2 and -4 can continue to act as tyrosine kinases 
within the nucleus. For example, p34Cdc2 can be phosphorylated by nuclear ErbB2, 
delaying M-phase entry and causing drug resistance in breast cancer (Tan et al., 
2002). Moreover, ErbB4 can inhibit mouse double minute 2 (MDM2), increasing p53 
and p21 expression (Arasada and Carpenter, 2005). It has also been reported that 
EGFR can phosphorylate proliferating cell nuclear antigen (PCNA), which led to 
increased DNA synthesis and repair (Wang et al., 2006). 
 
Nuclear expression of EGFR in oropharyngeal squamous cell carcinoma was 
associated with recurrence and a decrease in progression-free survival (Psyrri et al., 
2008). Moreover, a high level of phosphorylated-EGFR in the nucleus, but not 
elsewhere in the cell, correlated with a more aggressive disease stage and poorer 
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patient prognosis in oesophageal cancer (Hoshino et al., 2007). A constitutively active 
form of EGFR (EGFRvIII) has also been described in the nucleus of prostate, breast 
and brain tumour cells (de la Iglesia et al., 2008, Edwards et al., 2006, Ge et al., 
2002). In hormone-refractory prostate cancer this nuclear translocation was 
associated with a decreased overall survival, whilst in glioblastoma it is reported to 
induce glial transformation by binding to STAT3 and upregulating iNOS (de la Iglesia 
et al., 2008, Edwards et al., 2006). Blocking nuclear translocation of EGFR by 
inhibiting receptor activation or treatment with vitamin D has been shown to decrease 
tumour growth and re-sensitise cells to other therapeutic agents, highlighting the 
clinical significance of the nuclear role of this receptor (Cordero et al., 2002, Kim et 
al., 2009, Wang and Hung, 2009). 
 
1.6.2 FGF signalling within the nucleus 
Nuclear translocation of FGFRs can occur through a number of mechanisms. One 
example is retrotranslocation of full length FGFRs from the ER/Golgi into the nucleus 
(Stachowiak and Stachowiak, 2016). FGFRs may be released into the cytosol by the 
sec61 channel in a similar manner to ER-associated protein degradation (ERAD) 
(Stachowiak et al., 2007). The cytosolic FGFRs may then bind with other proteins, 
such as FGF2 or ribosomal S6-kinase 1 (RSK1), which can target localisation to the 
nucleus (Coleman et al., 2014a, Dunham-Ems et al., 2006, Hu et al., 2004). Importin 
β has also been shown to be involved in nuclear translocation of FGFRs in fibroblasts. 
This caused increased expression of c-Jun, resulting in cell proliferation (Reilly and 
Maher, 2001). Another method of nuclear translocation of full length FGFRs is through 
internalisation from the plasma membrane. Instead of being degraded or recycled, 
the endosomal FGFRs are targeted to the nucleus using retrograde vesicular 
transport (Bryant et al., 2005, Maher, 1996, Spooner and Lord, 2015). 
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Another purported mechanism of nuclear FGFR signalling is through proteolytic 
cleavage creating intracellular fragments, which can then be transported into the 
nucleus. For example after FGFR3 binding to FGF1, it has been reported that the 
extracellular and intramembrane domains of the receptor can be cleaved off by γ-
secretase and other proteases, releasing a soluble intracellular fragment. This can 
then be transported into the nucleus (Degnin et al., 2011). Moreover, nuclear FGFR 
signalling has been described in breast cancer through Granzyme B mediated 
cleavage of the intracellular portion of the receptor. It was found that this truncated 
form of FGFR1 was binding to the DNA and controlling the expression of target genes. 
Three target genes had increased expression, keratin associated protein 5-6 
(KRTAP5-6), stratifin (SFN) and serine protease 27 (PRSS27), whilst the expression 
of glutamate ionotropic receptor NMDA type subunit associated protein 1 
(GRINA) and epstein barr virus induced 3 (EBI3) was decreased. The respective 
changes in expression of these target genes all caused an increase in cell migration 
and invasion in breast cancer cells (Chioni and Grose, 2012). 
 
In head and neck squamous cell carcinoma (HNSCC) samples, nuclear FGFR1 
correlates with poorly differentiated cells, invasion and poor survival. Treatment with 
the FGFR inhibitor, PD173074, decreased growth and invasion in HNSCC cell lines, 
associated with a decrease in the expression of matrix metalloproteinases (MMPs) 
and Snail1 and 2. Therefore nuclear FGFR1 has been associated with the induction 
of EMT in HNSCC, which can be reversed using the inhibitor PD173074 though the 
transcription factor AP-1 (Nguyen et al., 2013). 
 
Nuclear localisation of FGFR1 regulates gene expression to determine cell 
proliferation and differentiation. In neural progenitor cells, FGFR1 is translocated into 
the nucleus by importin β due to signals from neurotransmitters, hormonal or growth 
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factor receptors. Once in the nucleus, FGFR1 works with cyclic AMP responsive 
element-binding protein (CBP) to activate transcription and regulation of a multitude 
of developmental and differentiation genes. This has been termed integrative nuclear 
fibroblast growth factor receptor 1 signalling (INFS) (Peng et al., 2002, Stachowiak et 
al., 2007). Nuclear FGFR1 has been shown to be necessary for neuronal 
differentiation through binding to cAMP-response elements (CREs) and activator 
protein-1 (AP-1) sites, affecting expression of many active neuronal genes (Bharali et 
al., 2005, Fang et al., 2005, Stachowiak et al., 2009). Three different states of nuclear 
FGFR1 have been described: fast mobile, slower mobile (chromatin-bound) or 
immobile (associated with the nuclear matrix). When transcription is activated, 
FGFR1 is released from the immobile nuclear-matrix bound and fast mobile 
populations to increase the levels bound to chromatin (Dunham-Ems et al., 2009). 
Furthermore, within embryonic stem cells there is an accumulation of nuclear FGFR1 
in response to retinoic acid. Nuclear FGFR1 forms complexes with retinoic acid 
receptors (RARs), retinoid acid receptors (RXRs) and Nurs to activate response 
elements and induce neuronal differentiation in these cells (Baron et al., 2012, Lee et 
al., 2012, Lee et al., 2013, Terranova et al., 2015). This suggests that nuclear FGFR1 
could be a global regulator of neuronal cell differentiation during development 
(Terranova et al., 2015).  
 
1.6.3 Nuclear FGFR1 signalling in PDAC 
It has been shown previously that nuclear translocation of full length FGFR1 occurs 
within stellate cells situated at the invasive front of tumours in patients. This was also 
confirmed using 3D models within the laboratory. Invading stellate cells showed 
FGFR1 and FGF2 within nuclear speckles and co-localised with SC35, indicating that 
these proteins may be involved in gene transcription (Figure 1.9). Furthermore, 
treatment with an FGFR selective inhibitor (PD173074) can decrease the nuclear 
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translocation of FGFR1 in stellate cells and prevent invasion into 3D organotypic gels 
(Figure 1.9) (Coleman et al., 2014b), suggesting that FGFR1 could be a good 
therapeutic target in PDAC patients. To determine the role and importance of nuclear 
FGF signalling within pancreatic stellate cells, it is necessary to validate target genes 
that are under transcriptional control of FGFR1. This may lead to the discovery of new 
therapeutic targets that can provide improved treatment for PDAC patients.  
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Figure 1.9 Nuclear FGFR1 within PSCs 
Organotypic gels showing PS1 cells highlighted by positive vimentin staining (red) and 
stained for FGFR1 (green). The organotypics were treated with either the FGFR 
inhibitor PD173074 or DMSO vehicle control on alternate days until the gels were 
harvested on day 14. Scale bar = 100 µm. A. PS1 cells have started invading into the 
gel at 14 days. The highlighted area shows positive nuclear FGFR1 staining within the 
invading PSCs. B. Following treatment with PD173074, there is a decrease in nuclear 
FGFR1 localisation within the stellate cells, as well as a decrease in invasion. C. 
Immunofluorescence staining shows the co-localisation of nuclear FGFR1 with SC35 
in stellate cells. This suggests that FGFR1 may have a transcriptional role in the 
nucleus of stellate cells. Scale bar = 20 µm (Coleman et al., 2014b). 
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1.7 Aims and Objectives 
PDAC is a disease that has a poor patient prognosis and requires the development 
of new therapeutic targets. The stroma has a significant role in the development of 
PDAC tumours and can modulate the response to standard chemotherapy, with 
pancreatic stellate cells playing a key role in tumour progression and invasion. 
However, targeting the stroma in patients is complicated and so far has yielded limited 
success in the clinic (Section 1.4). This highlights the importance in developing our 
understanding of stromal-cancer cross-talk and translating this into effective 
treatment options for patients. 
 
Invasion and metastasis are responsible for the poor survival of PDAC patients, 
meaning that understanding this process is critical. Nuclear translocation of FGFR1 
(nFGFR1) occurs in stellate cells that are present at the invasive edge of these 
desmoplastic tumours. Inhibition of FGFR1 can prevent receptor translocation and 
decrease stellate cell invasion. Furthermore, nFGFR1 localises in speckles with 
SC35, indicating it may contribute to transcriptional control (Section 1.6). Therefore, 
as nFGFR1 appears to be a major regulator of cellular cross-talk mediated invasion 
in PDAC, it is pertinent to develop further understanding of its activity. 
 
The overall aim of this project is to understand the novel role of nFGFR1 and use this 
to develop therapeutic strategies to decrease stellate cell invasion and tumour 
metastasis.  
 
 
 
88 
 
The main objectives of my PhD project are: 
 To investigate the specificity of targeting FGFR1 in PSCs to disrupt stromal-
cancer cross-talk and its consequent effects 
 To identify mechanisms of FGFR1-mediated changes in PSCs 
 To build on existing and developing PDAC therapies by including FGFR1 
targeting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Materials and Methods 
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2.1 Cell Lines and culture reagents 
2.1.1 Cell Lines 
The PDAC cell lines, AsPC-1, MIA PaCa-2, PANC-1 and COLO 357, and the stellate 
cell line, PS1, have been used in this project (Chen et al., 1982, Lieber et al., 1975, 
Morgan et al., 1980, Wu et al., 1977, Yunis et al., 1977). All cell lines have been 
submitted for short tandem repeat (STR) profiling (Appendix 1) and tested for 
mycoplasma every six months. The PS1 cell line was isolated and immortalised 
previously by expression of ectopic human telomerase reverse transcriptase (hTERT) 
(Li et al., 2009). HEK293T (Human embryonic kidney) cells were used to generate 
lentiviral particles. The primary cancer-associated stellate cell lines M1245 and 
M1090T (sub-type A) were used to confirm the validity of PSC FGFR1 expression in 
PDAC. These cell lines were isolated using the outgrowth method and confirmed to 
be of stellate cell origin by expression of key PSC markers and reversion to 
quiescence with ATRA treatment and Oil Red O staining (Section 2.3.2) (Neuzillet et 
al., 2019). PS1 cells with inducible expression of an FGFR1-HaloTag construct have 
been generated (referred to as PS1-HT). Three PS1 cell lines with inducible shRNA-
mediated knockdown of FGFR1 have also been generated in this project (referred to 
as shRNA1, shRNA2 and shRNA3). Stable cell lines expressing fluorescently labelled 
histone subunits were also generated using lentiviral constructs. Stellate cell lines 
were labelled with H2B-GFP and PDAC cancer cell lines were labelled with H2B-RFP. 
 
2.1.2 Cell Culture 
AsPC-1 and COLO 357 cancer cells were cultured in RPMI-1640 medium (R8758, 
Sigma-Aldrich) supplemented with 10 % (v/v) foetal bovine serum (FBS) (F9665, 
Sigma). PS1, PS1-HT, shRNA1, shRNA2 and shRNA3 cells were cultured in 45 % 
(v/v) Dulbecco’s modified Eagle’s medium (DMEM) (D6429, Sigma), 45 % (v/v) Ham’s 
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F-12 (N 6658, Sigma-Aldrich), 10 % (v/v) FBS and occasionally supplemented with 1 
µg/ml puromycin as a selection agent (P9620, Sigma-Aldrich). M1090T, M1245, 
HEK293T, MIA PaCa-2 and PANC-1 cells were cultured in DMEM plus 10% FBS. All 
cell lines were incubated at 37oC and 5 % humidified CO2. 
 
To passage the cells, the growth medium was removed from the flasks without 
disturbing the cell layer. Trypsin-EDTA 10X (59418C, Sigma-Aldrich) was added to 
the flask and incubated at 37oC until all the cells detached. The trypsin-EDTA action 
was inhibited by adding appropriate medium (with FBS). The cell suspension was 
centrifuged at 240 x g for 3 minutes to form a pellet of cells and then the cells were 
re-suspended in fresh medium. The cells were counted using a haemocytometer and 
seeded as necessary into new flasks. 
 
For storage, cell pellets were resuspended in FBS plus 10 % (v/v) dimethyl sulfoxide 
(DMSO) (D/4120/PB08, Fisher Scientific) and 1 ml aliquots were placed into cyrovials. 
These were frozen slowly to -80oC and then transferred to liquid nitrogen for long-
term storage. Upon cell recovery, cyrovials were thawed at 37oC in a water bath and 
transferred into a falcon tube containing standard medium. The cell suspension was 
then centrifuged at 240 x g for 3 minutes to remove DMSO in the supernatant and 
cells were re-suspended in standard medium ready for culture. 
 
2.1.3 Stimulation assay 
Cells were seeded in standard medium at a relevant density and incubated at 37oC. 
After 24 hours, medium was removed and cells were serum-starved in FBS-free 
medium overnight. Following this, cells were stimulated for 15 minutes with 100 ng/ml 
recombinant FGF2 (100-18C, Peprotech) plus 300 ng/ml heparin sodium salt (H3393, 
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Sigma-Aldrich), compared to relevant unstimulated controls, then harvested as 
appropriate. 
 
2.2 Cell survival assays 
2.2.1 MTS Assays 
Cells were seeded into the middle 60 wells of a 96 well plate (Figure 2.1) at an optimal 
density of 2 x 103 and 1.5 x 103 cells per well for cancer and stellate cell lines, 
respectively. 200 µl of phosphate buffered saline (PBS) was added to the outside 
wells to prevent dehydration within the plate during incubation. The cells were seeded 
in relevant medium at a volume of 90 µl per well and incubated at 37oC and 5 % CO2 
for 24 hours. 
 
Serial dilutions of AZD4547 (S2801, Selleckchem) were prepared to treat the cell 
cultures after 24 hours. In total, 17 drug solutions were added to the 96 well plates 
(10 µl per well) to give a final drug concentration ranging from 0.122 nM to 100 µM. 
Background absorbance was removed from the analysis using a positive control 
(Staurosporine 1 μM) (S5921, Sigma-Aldrich) and the results were normalised to 
negative vehicle control samples. There were three repeats of each drug 
concentration on each 96 well plate. The plates were then incubated at 37oC for 72 
hours. 
 
To analyse the level of cell survival at each dilution, 20 µl of MTS reagent (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
(G3581, Promega) was added. This was left at 37oC for two hours for AsPC-1 cells 
or four hours for PS1 cells. MTS is a tetrazolium dye that is metabolised by the 
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mitochondria in viable cells into a brown formazan product. After incubation, the 
intensity of the colour in each well was measured by the absorbance at 492 nm, using 
a 96-well microplate reader (Infinite® F50, Magellan software). These values were 
adjusted to allow for the background absorbance and normalised to the control wells, 
providing a Cell Viability Index. Non-linear regression was used to draw dose 
response curves and determine the GI50 value on GraphPad Prism® (GraphPad). 
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Figure 2.1 MTS assay plate layout 
MTS cell viability assays were performed in 96 well plates. PBS was placed in the outer 
wells (shown by red arrows) to reduce edge effect and prevent dehydration within the 
plate during the experiment. All drug treatments were given to cells seeded within the 
middle 60 wells (shown by the blue box). 
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2.2.2 Flow Cytometry 
Cell proliferation assays of PS1 and AsPC-1 proliferation in response to increasing 
concentrations of AZD4547 in mono- and co-culture conditions were carried out using 
CellTracker dyes and Flow Cytometry analysis. Cells were labelled with 5 µM green 
CellTracker dye (AsPC-1) (C2925, Life Technologies) or red CellTracker dye (PS1) 
(C34553, Life Technologies) for 45 minutes in serum free medium. The cells were 
then seeded in 60 mm dishes in either monoculture or co-culture conditions at an 
optimal density of 1.5 x 105 and 2 x 105 cells for PS1 and AsPC-1 monoculture, 
respectively. In co-culture conditions, 2 x 105 cells were plated in total in a 2:1 ratio of 
PS1 cells to AsPC-1 cells (Kadaba et al., 2013). After 24 hours, the cells were treated 
with either vehicle control or increasing concentrations of AZD4547, in the range of 
0.5-50 μM. These plates were then incubated at 37oC for 48 hours. 
 
To analyse the effect of increasing drug concentration on proliferation, the cells were 
detached from the dishes with trypsin-EDTA 10X. After neutralising the trypsin and 
centrifuging, the cell pellet was re-suspended in PBS plus 2 % (v/v) FBS and 
transferred into a polystyrene round bottom tube for flow cytometry analysis. The cell 
solutions were then analysed on a BD LSRFortessa™ machine (Becton Dickinson). 
After gating to exclude debris and doublets, the AsPC-1 and PS1 fluorescent 
populations were recorded. When cells divide, the CellTracker dye will be passed to 
both daughter cells, decreasing the staining intensity in each cell by half and therefore 
demonstrating the level of proliferation in a sample. Geometric mean (average 
fluorescence intensity per cell) was calculated for each cell line and normalised to 
vehicle controls. This was used to determine changes in cell proliferation with 
increasing drug concentrations. The differences in proliferation between mono- and 
co-culture were analysed in GraphPad Prism®. 
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2.3 Immunostaining 
2.3.1 Immunocytochemistry 
Cells were seeded onto coverslips and grown until confluent. They were then fixed in 
10 % (v/v) formalin (4 % formaldehyde) (BAF-0010-01A, CellPath) for 10 minutes and 
blocked in 0.1 % (w/v) saponin (S4521, Sigma-Aldrich), 6 % (w/v) bovine serum 
albumin (BSA) (A8022, Sigma-Aldrich) in PBS for 15 minutes. The relevant antibodies 
were then added according to the dilutions and incubation times in Table 2.3 in 6 % 
(w/v) BSA in PBS. Between primary and secondary antibodies, the coverslips were 
washed three times in PBS-0.05 % (v/v) Tween-20 (A1389, Pancreac Applichem) 
(PBST). After the final antibody incubation, the samples were washed three times in 
PBST and once in distilled water. The nuclei were counterstained and samples were 
mounted with Pro-Long® Gold Antifade mountant with DAPI (4,6-diamidino-2-
phenylindole) (P36931, Life Technologies). The samples were viewed using the 
Confocal 710 or Confocal 510 microscope (Carl Zeiss MicroImaging LLC). 
 
2.3.2 Oil Red O staining 
Cells were seeded onto coverslips and treated daily with either ATRA (1 µM) (R2625, 
Sigma-Aldrich) or 0.1 % (v/v) ethanol (E/0650DF/17, Fisher Scientific) vehicle control. 
The coverslips were fixed in formalin for 10 minutes and then stained with Oil Red O 
(O-0625, 5 mg/ml, Sigma-Aldrich) for one hour. The Oil Red O stain was freshly 
diluted in water (3:2) and filtered on the day of use. The cells were then counterstained 
with Mayer’s haematoxylin (MHS16, Sigma) and mounted. Images were taken using 
the Axiophot microscope and Axiovision Rel 4.8 software (Carl Zeiss MicroImaging 
LLC). 
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2.3.3 Immunofluorescence 
Formalin fixed, paraffin embedded sections were dewaxed using xylene (X/0250/17, 
Fisher Scientific) and rehydrated by passing through graded alcohols (100 %, 80 %, 
70 %, 50 % (all v/v) and distilled water), finally ending in PBS/Tween. Heat induced 
epitope retrieval (HIER), to unmask antigens, was performed by boiling sections in 10 
mM citrate buffer pH 6.0 (S/3280/60, Fisher Scientific) for 11 minutes (20 minutes for 
Ki67 staining). Samples were blocked with 0.05 % goat serum (v/v) (R2283, Sigma) 
in ABC buffer, 2 % (w/v) BSA, 0.02 % (w/v) fish gelatin (G-7765, Sigma) and 10 % 
(v/v) FBS in PBS, for 1 hour at room temperature. Primary antibodies were diluted in 
ABC buffer and incubation was performed according to Table 2.3. After washing the 
primary antibodies, the slides were incubated with relevant secondary antibodies 
(Table 2.3) diluted in PBS for 1 hour at room temperature in the dark. The samples 
were viewed using the Confocal 510, 710 or 880 microscopes (Carl Zeiss 
MicroImaging LLC). 
 
2.3.4 Immunohistochemistry 
Formalin fixed, paraffin embedded sections were dewaxed and rehydrated as 
described above, including an extra incubation in methanol plus 3 % (v/v) hydrogen 
peroxide (231-765-0, Fisher Scientific) to block endogenous peroxidases. IHC was 
carried out using the Vectastain kit (PK-6101, Vector) and samples were blocked 
according to manufacturer’s instructions, briefly samples were incubated with 1.5 % 
(v/v) goat serum in PBS for 15 minutes. Antigen retrieval, primary antibody dilution 
and incubation were performed according to Table 2.3. After washing off the primary 
antibodies, the slides were incubated with relevant secondary biotinylated antibodies 
(50 µl in 1.5 % (v/v) goat serum in PBS) and an avidin-biotin layer (100 µl avidin and 
100 µl biotinylated HRP in 1.5 % (v/v) goat serum in PBS) to amplify the staining 
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signal, according to manufacturer’s instructions. After washing, the samples were 
incubated with 3,3’-diaminobenzidine (DAB) (SK-4100, Vector) to view the positive 
staining. After washing off excess DAB, the slides were counter-stained with Mayer’s 
haematoxylin, dehydrated through graded alcohols and mounted with a coverslip 
using DPX, which is a mix of distyrene, plasticiser and xylene (360294H, VWR). H&E 
staining was performed by the BCI Pathology Core Services and all slides were 
viewed using the Pannoramic scanner (3DHISTECH). 
 
2.3.5 IN Cell analysis 
PS1 cells were seeded into a 96 well plate at a density of 6,000 cells per well. After 
24 hours, the cells were treated with increasing concentrations of AZD4547 (0.25-1 
µM) or vehicle control and then after another 24 hours the plates were processed for 
imaging. Cells were fixed in formalin for 10 minutes, before being stained for FGFR1 
using the same conditions as Section 2.3.1. The cells were counterstained with DAPI 
(D9542, Sigma-Aldrich) for ten minutes at room temperature in the dark. Nuclear 
staining was analysed using the IN Cell 2200 high-throughput microscope (GE 
Healthcare Life Sciences) and the number of nuclear foci in each well was quantified 
using the IN Cell Investigator Software (GE Healthcare Life Sciences). 
 
2.4 Western Blotting 
2.4.1 Protein isolation 
Cells were lysed using lysis buffer (50 mM Tris-HCl pH 7.5 (T3253, Sigma), 150 mM 
sodium chloride (NaCl, 7647-14-5, Sigma-Aldrich), 1 mM EDTA (D/0450/50, Fisher 
Scientific), 1 % (v/v) Triton-X-100 (A16046, Alfa Aesar)) with protease and 
phosphatase inhibitors (539131 and 524625, Millipore) and scraping with a cell 
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scraper. The lysate was centrifuged for 10 minutes at 20,000 x g at 4oC to pellet cell 
debris (some membrane proteins may be sequestered in the pellet). The protein in 
the supernatant was quantified using Bio-Rad DC Protein Assay (solution A 500-
0113, solution B 500-0114 and solution S 500-0115), according to manufacturer’s 
instructions. Briefly add 20 µl reagent S to 1 ml reagent A to make the working 
solution. Place 25 µl of this solution into each well then add 5 µl of the relevant protein 
standard or sample. Finally add 200 µl of reagent B and incubate the plate for 5 
minutes at room temperature. After incubation, the intensity of the colour in each well 
was measured by the absorbance at 620 nm, using a 96-well microplate reader 
(Infinite® F50, Magellan software). Equal amounts of protein were prepared with 
sample buffer (60 mM Tris-HCl pH 6.8, 2 % (v/v) sodium dodecyl sulphate (SDS, 
BP1311, Fisher Scientific), 10 % (v/v) glycerol (49782, Sigma-Aldrich), 0.5 M 
dithiothreitol (DTT) (D0632, Sigma-Aldrich), 0.01 % (v/v) bromophenol blue (B5525, 
Sigma-Aldrich) final concentration). 
 
2.4.2 Western blotting 
The prepared lysate samples were boiled for 5 minutes to denature the proteins and 
separated on either 7.5 % (v/v) or 10 % (v/v) sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) gels. The gels were run at 140V for 1.5 hours and 
then transferred onto a nitrocellulose membrane (1060000, GE Healthcare) in a Bio-
Rad semi-dry transfer tank at 20V for 1 hour, or using a BioRad wet transfer tank at 
120V for 1 hour. Ponceau S solution (P7170, Sigma) was used to confirm efficient 
protein transfer and then the membranes were blocked in 5 % (v/v) milk (70166, 
Sigma) in Tris-buffered saline (20-6400-10, Severn Biotech Ltd)-0.1 % (v/v) Tween-
20 (TBST) for at least 30 minutes. 
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2.4.3 Detection and analysis 
The membranes were incubated with primary antibodies (Table 2.3) diluted in 3 % 
(v/v) BSA-TBST at 4oC overnight, to detect the levels of specific proteins in the 
samples. After unbound primary antibody was removed from the membrane with 
TBST, HRP-conjugated secondary antibodies (Table 2.3) were incubated with the 
membranes for at least one hour at room temperature. Excess secondary antibody 
was also removed from the membrane using TBST and detection was carried out 
using Luminata Forte Western HRP substrate (WBLUF0100, Millipore) and the 
Amersham Imager 600 (GE Healthcare). 
 
2.5 Generation of inducible cell lines 
2.5.1 Transient transfection of FGFR1-HaloTag 
Cells were seeded into dishes to achieve 50 % confluency after 24 hours. An FGFR1-
HaloTag construct (FHC10532, Kazusa DNA Research Institute) was then transiently 
transfected into these cells using 1 µg of plasmid DNA in 50 µl of OptiMEM 
(31985062, ThermoFisher Scientific) and 3 µl of FuGENE HD transfection reagent 
(E2311, Promega). This solution was incubated at room temperature for ten minutes 
and then added to the cells in 1 ml of fresh medium (plus FBS). Confirmation of 
transfection was carried out by tetramethyl rhodamine (TMR) (G825A, Promega) 
labelling 48 hours later. Successful transfection was also confirmed using Western 
Blot analysis (as described in 2.4). 
 
2.5.2 Gateway cloning of FGFR1-HaloTag 
The gateway cloning system (12535-027, Invitrogen) was used to generate an 
inducible FGFR1-HT construct (Figure 2.2) (Reece-Hoyes and Walhout, 2018). 
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Primers were designed to amplify FGFR1-HT from the pFC14K HaloTag vector 
(9PIG966, Promega) with attB sites (see Table 2.1 and Figure 2.3), using Phusion 
polymerase (F530S, ThermoFisher). Confirmation of successful PCR was 
determined by a positive band at ~3,200 bases on an agarose gel and direct 
sequencing (SourceBioScience). After effective PCR of the FGFR1-HT construct, this 
was put into a pDONR/zeo plasmid (12535-035, Invitrogen) using the BP clonase 
recombination reaction (11789-013, Invitrogen). Heat shock transformation of TOP10 
cells (C4040-03, Invitrogen) was then carried out using the product of the BP clonase 
reaction. The TOP10 cells were grown on zeocin (46-0509, Invitrogen) agar plates 
overnight to produce colonies. 
 
After antibiotic selection, clones were selected and amplified in overnight cultures. 
Plasmid DNA was removed from these cells using the peqGOLD plasmid miniprep kit 
(732-2780, VWR), according to manufacturer’s instructions. Briefly, the culture was 
pelleted by centrifuging at 5,000 x g for 10 minutes and the supernatant was 
discarded. The pellet was lysed by vortexing in 250 µl of solution I, then adding 250 
µl of solution II and mixing gently. Neutralisation of the solution with 350 µl of solution 
III was performed and then this was loaded onto a PerfectBind DNA column. The 
column was centrifuged at 10,000 x g for 1 minute to allow the DNA to bind and the 
flow-through was discarded. Three washes were performed by adding wash buffer to 
the column and centrifuging at 10,000 x g for 1 minute, discarding the flow-through. 
The column was dried to remove all the ethanol by centrifuging at 10,000 x g for 2 
minutes. The DNA was eluted by adding 50 µl of elution buffer and centrifuging at 
5,000 x g for 1 minute. 
 
Following miniprep extraction and restriction digest with BsrG1 (R0575S, New 
England Biolabs), clone 4 (which expressed the FGFR1-HT construct) was selected 
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to move forwards into the LR clonase reaction (11791-019, Invitrogen). This reaction 
transferred the construct into the pInducer21 plasmid (46948, Addgene). 
Transformation of this product into one shot Stbl3 Escherichia coli (C737303, 
ThermoFisher) was carried out and the cells were grown on agar plates containing 
ampicillin (11593027, ThermoFisher) overnight. Again clones were selected and 
amplified in overnight cultures. After miniprep of plasmid DNA and restriction digest 
with BsrG1 to isolate the construct, one clone was selected to be sequenced using 
the sequencing primers in Table 2.1 and Figure 2.4 by Source Bioscience. Following 
confirmation of successful cloning, this construct was used to generate lentiviral 
particles (pInducer21-FGFR1-HT).  
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Figure 2.2 Gateway cloning process 
Summary of the process to produce a pinducer21 plasmid expressing the FGFR1-HT 
construct to use for lentiviral production. Primers were designed to amplify the construct 
with attB sites on either end. This allowed homologous recombination reactions to transfer 
the construct into the donor vector and finally into the destination vector. At each point 
with the red star, confirmation of the presence of the construct was carried out by running 
the product on an agarose gel. The final pinducer21 construct has GFP expression as a 
selection marker and doxycycline inducible expression of FGFR1-HT (Reece-Hoyes and 
Walhout, 2018). 
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Figure 2.3 pFC14K HaloTag CMV Flexi Vector plasmid map 
FGFR1-HaloTag construct was isolated from a purchased pFC14K HaloTag plasmid 
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2.5.3 FGFR1 shRNA generation 
Three validated shRNA constructs were created with Age1 (R0552S, New England 
BioLabs) and EcoR1 (R0101, New England BioLabs) restriction sites on the 5’ end of 
the sequence (TRCN0000312516, TRCN0000312574 and TRCN0000312572, 
Sigma-Aldrich). The oligonucleotides were annealed by diluting in annealing buffer 
(0.1 M NaCl and 10 mM Tris-HCl pH 7.4 final concentration) and placing the solution 
in a boiling water bath, which was allowed to cool to 30oC over 2-3 hours. The 
oligonucleotide mixture was then diluted 1:400 in 0.5X annealing buffer. 
 
The tet-pLKO-neo plasmid (21916, Addgene) (Figure 2.4) was used as the lentiviral 
vector for shRNA expression. Firstly, the plasmid was digested with Age1 and EcoR1 
in a sequential restriction digest (Age1 plus NEB buffer 1 (B7001S, New England 
BioLabs) at 37oC for 1 hour then EcoR1 plus NEB buffer 3 (B7003S, New England 
BioLabs) at 37oC for 1 hour). The product of this digest was run on a gel to separate 
the backbone and the stuffer fragments. The backbone was cut from the gel and 
purified using Monarch® DNA Gel Extraction Kit (T1020S, New England BioLabs) 
according to manufacturer’s instructions. Briefly, the gel was dissolved by adding 4 
volumes of gel dissolving buffer and incubating at 50oC for 10 minutes with vortexing. 
The solution was then added to the DNA column and centrifuged at 10,000 x g for 1 
minute to allow the DNA to bind, the flow-through was discarded. Two washes were 
performed by adding DNA wash buffer to the column and centrifuging at 10,000 x g 
for 1 minute, discarding the flow-through. The DNA was retrieved in a fresh 1.5 ml 
collection tube by adding DNA elution buffer to the column and centrifuging at 10,000 
x g for 1 minute.  
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Ligation of the oligonucleotides and pLKO backbone was carried out in ligase buffer 
(B0202S, New England BioLabs) using T4 DNA ligase (M0202S, New England 
BioLabs) overnight at 4oC. One shot Stbl3 cells (C737303, ThermoFisher) were 
transformed using this plasmid and grown overnight on agar plates containing 
ampicillin (11593027, ThermoFisher). Clones were isolated, amplified in overnight 
cultures and screened to check for successful uptake of the tet-pLKO-neo plasmid by 
digest with Xho1 (R0146S, New England BioLabs). One clone of each shRNA was 
selected to generate lentiviral particles. 
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Figure 2.4 Tet-pLKO-neo plasmid map 
The tet-pLKO-neo plasmid was used as a lentiviral vector for creating the PS1 
FGFR1 shRNA cell lines in this project. The red lines indicate where sequential 
digest was used to linearise the plasmid, remove the stuffer and insert the relevant 
shRNA construct. 
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2.5.4 Lentiviral production and infection 
HEK293T cells were seeded into a 60 mm dish to reach 90 % confluency after 24 
hours. The following day 5 µg of pinducer21-FGFR1-HT plasmid (46948, Addgene), 
H2B-RFP (26001, Addgene), H2B-GFP (25999, Addgene) or tet-pLKO-neo (FGFR1 
shRNA containing) plasmid, 1.75 µg pMD2.G (1259, Addgene) and 3.25 µg 
CMVR8.74 (12263, Addgene) was prepared in 470 µl optiMEM with 30 µl FuGENE 
transfection reagent. This mixture was incubated at room temperature for 10 minutes 
and then added to the HEK293T cells in 5 ml of fresh medium (plus FBS). After 24 
hours, the medium was replaced with fresh DMEM. The viral supernatant was 
collected 24 hours later, pelleted for cell debris and stored at -80oC. 
 
To infect PS1 cells, the cells were seeded into a six well plate to reach 30 % 
confluency the next day. Viral supernatant was then added to the PS1 cells and 
incubated for 24 hours. After this, fresh medium was placed on the cells and infection 
efficiency was confirmed. Cells were selected for successful transduction by sorting 
on the expression of GFP or RFP (PS1-HT and H2B labelling) using the BD FACS 
Aria II or Aria Fusion cell sorters (BD Biosciences) or treatment with 600 µg/ml 
neomycin (shRNA). 
 
2.5.5 RNA extraction and qPCR analysis 
RNA was extracted using the RNeasy Mini Kit (74104, QIAGEN), according to 
manufacturer’s instructions. Briefly, cells were lysed by adding 350 µl of RLT buffer 
and vortexing. Next, 350 µl of 70 % (v/v) ethanol was added to the lysate and this 
was loaded into an RNeasy spin column, centrifuged at 8,000 x g for 15 seconds and 
the flow-through was discarded. The RNA was washed three times by adding wash 
buffer into the column and centrifuging at 8,000 x g for 15 seconds. The column was 
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dried to remove all the ethanol by centrifuging at 10,000 x g for 1 minute. RNA was 
eluted into a 1.5 ml collection tube by adding 30 µl of RNase-free water to the column 
and centrifuging at 8,000 x g for 1 minute. The RNA was quantified following 
extraction using a nanodrop ND-1000 spectrophotometer. Reverse transcription was 
carried out to convert 1 µg of RNA into cDNA using Superscript II reverse 
transcriptase kit (18064014, Invitrogen) with deoxynucleotide triphosphates (dNTPs) 
(BIO-39036 – 39039, Bioline) and random hexamer primer mix (RHP-108G, Bioline) 
according to manufacturer’s instructions. Briefly, sample RNA, random hexamer 
primer mix and 10 mM dNTP mix were heated to 65oC for 5 minutes before being 
chilled on ice. Next, first strand buffer and 0.1 M DTT were added and the solution 
was incubated at room temperature for 2 minutes. Following this incubation, the 
Superscript II RT enzyme was added to the mix and this was incubated at 25oC for 
10 minutes, 42oC for 50 minutes and then 70oC for 15 minutes. The cDNA was 
subjected to quantitative polymerase chain reaction (qPCR) analysis using 
SensiFAST SYBR® HI-ROX kit (BIO-92005, Bioline), according to manufacturer’s 
instructions, using relevant primers (Table 2.1) and the StepOnePlus Real Time PCR 
system (ThermoFisher Scientific). Briefly, each well had 9 µl of mastermix (0.3 µM 
relevant forward and reverse primers and 5 µl SYBR-green diluted in RNase-free 
water) plus 1 µl of cDNA or water control. The plate was then heated to 95oC for 10 
minutes, before entering 40 cycles of 95oC for 30 seconds (denaturation), 60oC for 30 
seconds (annealing) and 72oC for 30 seconds (extension). The plate was then 
incubated at 95oC for 15 seconds, 60oC for 1 minute and 95oC for a further 15 seconds 
to end the reaction. 
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Table 2.1 Primer and oligonucleotide sequences 
Target Sequence – Forward Sequence – Reverse 
FGFR1b 
TTA-ATA-GCT-CGG-ATG-
CGG-AG 
ACG-CAG-ACT-GGT-TAG-
CTT-CA 
FGFR1c 
TGC-TGG-AGT-TAA-TAC-
CAC-CG 
CCA-GAA-CGG-TCA-ACC-
ATG-CA 
HPRT-1 
GAC-CAG-TCA-ACA-GGG-
GAC-AT 
CCT-GAC-CAA-GGA-AAG-
CAA-AG 
B2M 
AGT-TAA-GTG-GGA-TCG-
AGA-C 
GCA-AGC-AAG-CAG-AAT-
TTG-G 
FGFR1-HT 
GGG-GAC-AAG-TTT-GTA-
CAA-AAA-AGC-AGG-CTT-
CAT-GTG-GAG-CTG-GAA-
GTG-CC 
GGG-GAC-CAC-TTT-GTA-
CAA-GAA-AGC-TGG-GTC-
TTA-ACC-GGA-AAT-CTC-
CAG-AGT 
FGFR1-HT 
sequencing 1 
CCA-TCC-TGC-AAG-C  
FGFR1-HT 
sequencing 2 
GCA-GAC-AGG-TAA-C  
FGFR1-HT 
sequencing 3 
GGA-GCA-GCT-CTC  
FGFR1-HT 
sequencing 4 
GTA-CCT-GGA-CC  
FGFR1-HT 
sequencing 5 
GGA-GTT-CAT-CC  
FGFR1 
shRNA1 
CCG-GGA-TGG-CAC-CCG-
AGG-CAT-TAT-TCT-CGA-
GAA-TAA-TGC-CTC-GGG-
TGC-CAT-CTT-TTT 
AAT-TAA-AAA-GAT-GGC-
ACC-CGA-GGC-ATT-ATT-
CTC-GAG-AAT-AAT-GCC-
TCG-GGT-GCC-ATC 
FGFR1 
shRNA2 
CCG-GTG-CCA-CCT-GGA-
GCA-TCA-TAA-TCT-CGA-
GAT-TAT-GAT-GCT-CCA-
GGT-GGC-ATT-TTT 
AAT-TAA-AAA-TGC-CAC-
CTG-GAG-CAT-CAT-AAT-
CTC-GAG-ATT-ATG-ATG-
CTC-CAG-GTG-GCA 
FGFR1 
shRNA3 
CCG-GCC-ACA-GAA-TTG-
GAG-GCT-ACA-ACT-CGA-
GTT-GTA-GCC-TCC-AAT-
TCT-GTG-GTT-TTT 
AAT-TAA-AAA-CCA-CAG-
AAT-TGG-AGG-CTA-CAA-
CTC-GAG-TTG-TAG-CCT-
CCA-ATT-CTG-TGG 
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2.6 3D assays 
2.6.1 Mini-organotypic 
Cells were grown in the 3D mini-organotypic model to assess effects on invasion. For 
this assay, Transwell™ inserts (3413, Costar) were coated with collagen I (354249, 
BD Biosciences) diluted in PBS (1:100) for 1 hour at 37oC. The collagen coat was 
carefully removed by pipetting and replaced with organotypic gel mix (2.25 volumes 
collagen I (2 mg/ml final concentration), 1.75 volumes matrigel (354234, BD 
Biosciences), 1 volume 10X DMEM (E15-843, PAA Laboratories), 1 volume relevant 
cell culture medium and 1 volume FBS). The pH of the gel was adjusted with 1 M 
sodium hydroxide (124260010, Acros Organics) to neutralise the acidic collagen, 
allowing cells to grow. The gels were left at 37oC for 2 hours to set, then 350 µl of 
relevant medium was placed underneath the Transwell insert, creating an air-liquid 
interface. 
 
Cells were then seeded on top of the gel in either mono or co-culture with 100,000 
cells per gel. In co-culture conditions, a 2:1 ratio of stellate cells to cancer cells was 
used (Coetzee et al., 2019, Kadaba et al., 2013). The cells were left for 24 hours to 
attach to the gel before treatments were added into the medium below the Transwell 
insert. For this study, organotypic gels were treated with either 1 μM AZD4547 daily 
or on alternate days, 2 μM PD173074 (P2499, Sigma-Aldrich) on alternate days, 1 
μM ATRA daily (R2625, Sigma), 100 nM gemcitabine (Fresenius Kabi Oncology PLC 
38 mg/ml) weekly or 1 μg/ml doxycycline on alternate days (Figure 2.5). 
 
After 7 days, the gels were incubated with 1 mM BrDU (550891, BD Biosciences) 
(plus or minus drug) for 2 hours at 37oC. The Transwells were then gently washed 
once in PBS and fixed in 10 % (v/v) formalin for 24 hours. The formalin was replaced 
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by 70 % (v/v) ethanol and the gels were cut in half and embedded in paraffin wax. 
H&E, immunofluorescence and immunohistochemistry were carried out on sections 
prepared from these gels as described previously (Section 2.3). Embedding and 
sectioning of these gels was performed by the Pathology department at Barts Cancer 
Institute. Invasion and total cell layer area on top of the gels was quantified from H&E 
sections using the Pannoramic Viewer software (3DHISTECH). Cells invading into 
the gels were counted individually using the manual cell counter tool and the cell layer 
thickness was calculated from 4-6 distance measurements made per gel. Proliferation 
was measured by immunofluorescence staining for Ki67 and counting the number of 
positive nuclei as a percentage of the total cell nuclei in at least five fields of view from 
each gel (the whole gel layer was imaged). Apoptosis was measured by staining for 
cleaved caspase 3 and counting the number of positive nuclei as a percentage of the 
total cell nuclei for each gel. Median and Interquartile range was used to summarise 
the data and the Kruskal-Wallis statistical test with Dunn’s multiple comparison was 
performed. 
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Figure 2.5 Experimental timelines for organotypic cultures 
Organotypic gels were made and cells seeded on top on day 0. The gels were then 
maintained in culture for 7 days before fixing in formalin and harvesting. On the day of 
harvesting, some gels were treated with BrDU for 2 hours before fixing to assess 
proliferation. Gels were treated with AZD4547 or doxycycline every other day (A) by 
refreshing the medium beneath the gels. For the combination therapy protocol, AZD4547 
and ATRA treatment were given daily, whilst gemcitabine treatment was only given once, 
to match patient protocols in the clinic (B). 
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2.6.2 Spheroid 
A second 3D PDAC model was used in this project. In the spheroid model, cells were 
seeded into a 2.5 % (v/v) methylcellulose (M0512, Sigma) droplet. This droplet was 
suspended from the lid of a 150 mm dish, allowing cells to form a sphere inside. 1,000 
cells were seeded per droplet in either mono- or co-culture, with the same 2:1 co-
culture ratio as previously described (Kadaba et al., 2013). 
 
Twenty-four hours later, a 96 well plate was pre-coated with organotypic gel mixture 
(10.5 volumes high concentration collagen (354249, Corning®, 2 mg/ml final 
concentration), 7 volumes matrigel, 1 volume HEPES (H7006, Sigma) and 21.5 
volumes relevant cell culture medium plus sodium hydroxide to neutralise the pH). 
The coating prevented spheres from touching the plastic at the base of the well. Once 
the pre-coating had set, the spheres were gently collected using a cut pipette tip, 
washed and suspended in organotypic mixture. These were seeded into the 96 well 
plate (50 µl of gel with an average of 6 spheres per well) and the gels were left to set. 
Medium containing any relevant drug treatments was placed on top of the gels and 
the cultures were incubated for 2-5 days. 
 
At the end of the assay the gels were imaged using an Axiovert 135 (Carl Zeiss 
MicroImaging LLC) and quantified using ImageJ (National Institutes of Health). 
Quantification was performed by drawing around the whole spheroid to obtain the 
total area, as well as around the central sphere to get the sphere area. The central 
sphere area was then subtracted from the total area to obtain the invasive area, 
including the protrusions leaving the central spheroid. Median and Interquartile range 
was used to summarise the data and the Mann-Whitney U statistical test was 
performed. Stellate cell lines labelled with H2B-GFP and PDAC cancer cell lines 
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labelled with H2B-RFP were used to determine which cells were leading the invasion 
out of the sphere. Z-stack images were taken of the whole spheroid using the 
Confocal 710 microscope.  
 
2.7 Chromatin Immunoprecipitation 
2.7.1 Chromatin Isolation 
To perform chromatin immunoprecipitation (ChIP), chromatin must be isolated from 
the cell of interest, fragmented to an optimal length, immunoprecipitation performed 
with a suitable antibody and then the immunoprecipitated DNA extracted. To give an 
unbiased analysis of genome binding by FGFR1, cross-linked ChIP (XChIP) with 
random sonication induced chromatin shearing was used. 
 
2.7.2 Active Motif optimisation 
ChIP assays were initially optimised using the ChIP-IT High Sensitivity kit (53040, 
Active Motif), according to manufacturer’s instructions. Briefly, Complete Cell Fixation 
Solution was prepared by adding 180 µl of Fixation Buffer, 1.57 ml of sterile water 
and 750 µl of 37 % (v/v) formaldehyde. This was then added to the plates (1/10 of the 
growth medium volume) and incubated at room temperature for required fixation time, 
gently shaking. The fixation reaction was stopped by adding 1/20 medium volume of 
Stop Solution and incubating at room temperature for 5 minutes. The cells were then 
removed from the plate by scraping and collected into a tube on ice. The cells were 
pelleted by centrifugation at 1,250 x g at 4oC for 3 minutes. The supernatant was then 
discarded and the pellet was washed twice in ice-cold PBS wash buffer (21.25 ml 
sterile water, 2.5 ml 10X PBS and 1.25 ml Detergent). Following the final wash, the 
pellet was re-suspended in 5 ml Chromatin Prep Buffer (supplemented with 5 µl PIC 
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and 5 µl 100 mM PMSF) and incubated on ice for 10 minutes. The cells were then 
lysed using a needle and syringe. The chromatin was pelleted by centrifugation at 
1,250 x g at 4oC for 3 minutes. The pellet was then re-suspended in 500 µl ChIP 
Buffer (supplemented with 5 µl PIC and 5 µl 100 mM PMSF), incubated on ice for 10 
minutes and sonicated. The first step was testing different fixation times (either 5 or 
10 minutes) and number of sonication cycles (10, 15 or 20). A Bioruptor sonicator 
(Diagenode) was used for the sonication of samples throughout ChIP optimisation 
using an optimal 30 seconds ON 30 seconds OFF sonication cycle setting. 
 
2.7.3 Millipore optimisation 
A further ChIP kit was used for optimisation, the EZ-ChIP kit (17-295, Merck Millipore), 
according to manufacturer’s instructions. Briefly, to prepare the cells, 14 confluent T-
175 flasks were used to collect chromatin, with 1 confluent T-175 flask of MFE-296 
cells as a positive control. The samples were fixed in 1 % (v/v) formaldehyde at 37oC 
for 10 minutes, then 1 M glycine (1/10) was added to stop the fixation reaction at 4oC. 
The samples were then washed twice with ice cold PBS and harvested by scraping 
in PBS (plus PIC). The cells were pelleted by centrifuging at 8,000 x g at 4oC for 3 
minutes and the supernatant was discarded. The cells were lysed by incubation with 
SDS Lysis Buffer on ice for 10 minutes and sonicated for 10 cycles (30 seconds ON, 
30 seconds OFF). The input DNA was then extracted (Section 2.7.4.4) and run on a 
1 % (w/v) agarose (16500, Invitrogen) gel to confirm chromatin fragmentation.  
 
2.7.4 ChIP-seq 
2.7.4.1 Culture conditions 
Cells were seeded into 10 x 150 mm dishes per condition to achieve confluency at 
time of harvest (~20 million cells). After 24 hours, cells were treated with AZD4547, 
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doxycycline to induce FGFR1 knockdown, or relevant vehicle controls. Cells treated 
with FGFR inhibitors were harvested 24 hours after treatment and shRNA cells were 
harvested after 48 hours of knockdown. 
 
2.7.4.2 Chromatin harvesting and fragmentation 
At the time of harvesting, medium was removed and the cells were incubated at room 
temperature on a rocker for 5 minutes with fixing solution: 1 % (v/v) formaldehyde 
(28908, Thermofisher) in relevant cell culture medium plus protease inhibitor cocktail 
(05 056 489 001, Roche). This reaction was then quenched by 5 minutes incubation 
with 1.25 M glycine solution pH 6.0 (G/0800/60, Fisher Scientific) at a final 
concentration of 125mM, at room temperature on a rocker. The cells were then 
washed twice in ice cold PBS and collected by scraping with PBS plus protease 
inhibitor cocktail. Once all the dishes had been harvested, the cells were pelleted, the 
supernatant was discarded and the pellet was snap frozen and stored at -80oC.  
 
Chromatin was harvested by thawing cell pellets on ice for 30 minutes. Lysis buffer 
(1 % (v/v) SDS, 50 mM Tris-HCl pH 8.0, 10 mM EDTA plus protease inhibitor cocktail) 
was then added to the pellet and it was broken up using a syringe and 27 gauge 
needle – whilst being careful not to introduce bubbles. Cells were lysed on ice for 30 
minutes. The chromatin was then sonicated using a Bioruptor pico sonicator 
(Diagenode) in 15 ml TPX tubes with beads (C01020031, diagenode) to enhance the 
fragmentation. The samples were originally sonicated for 10 cycles (30 seconds ON 
and 30 seconds OFF), the fragmentation was then examined by taking a small 
sample, extracting the DNA and running on 1 % (w/v) agarose gel. If further 
fragmentation was required, five more sonication cycles were performed. 
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2.7.4.3 Immunoprecipitation 
Once the fragmentation of the samples was satisfactory, as judged by a diffuse band 
of 100-300 bp following agarose gel electrophoresis, the samples were subjected to 
immunoprecipitation with an FGFR1 antibody (ab10646, Abcam). Briefly, chromatin 
samples were diluted in 1:4 ratio with dilution buffer plus protease inhibitor cocktail 
(Table 2.2), giving a final concentration of 0.2 % (v/v) SDS. The diluted chromatin was 
then incubated with dynabeads (10003D, Life Sciences, resuspended in working 
buffer, Table 2.2) rotating at 4oC for 2 hours to pre-clear any non-specific binding. 
 
Following pre-clearing with dynabeads, 10 % of each sample was taken to be used 
as an input. The rest of the sample was incubated with 4 µg of FGFR1 antibody at 
4oC rotating overnight. To prevent non-specific binding 0.5 % (w/v) BSA and 0.1 µg/µl 
tRNA (10 109 541 001, Roche Diagnostics) were added. Meanwhile, dynabeads were 
blocked overnight at 4oC with 0.5 % (w/v) BSA. 
 
The next day, the blocked dynabeads were incubated with the chromatin-antibody 
solution at 4oC, rotating for 2 hours. After this incubation, the bound dynabeads were 
subjected to a series of washes (low salt immune complex, high salt immune complex, 
LiCl immune complex and TE buffer, Table 2.2) before eluting in elution buffer (Table 
2.2) at room temperature. 
 
2.7.4.4 DNA extraction 
The enriched chromatin samples were then incubated with RNase A (EN0531, 
Thermo Scientific) and proteinase K (P8107S, New England BioLabs) overnight to 
remove protein-DNA cross-links. The DNA was then extracted from the sample using 
phenol-chloroform (77617, Sigma) and ethanol precipitation, following a standard 
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protocol. Qubit and Tapestation™ analysis confirmed DNA quality and fragmentation 
before the samples were submitted for sequencing at Oxford Genomics Centre.  
 
2.7.4.5 ChIP-seq analysis 
Sequencing hits were analysed by aligning to the reference genome (hs37d5). Reads 
were mapped using MACS2 and peaks were called using diffBind. Initial analysis of 
FGFR1 binding was performed by examining the enriched peaks in control samples 
compared to the relevant input background control. Known blacklist regions, such as 
satellite regions, were removed from the analysis. The enriched peaks could then be 
compared between samples to highlight the most reliable hits. Search Tool for the 
Retrieval of Interacting Genes/Proteins (STRING) was used to analyse interactions 
between common enriched peaks across the samples. 
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Table 2.2 Chromatin Immunoprecipitation buffers 
Buffer Recipe 
Immunoprecipitation 
Lysis Buffer 
2 % (v/v) Triton 
1 % (v/v) SDS 
100 mM NaCl 
10 mM Tris-HCl pH 8.0 
1 mM EDTA 
Protease Inhibitor Cocktail 
Dilution Buffer 
50 mM HEPES pH 8.0 
140 mM NaCl 
1 mM EDTA 
0.75 % (v/v) Triton 
0.1 % (v/v) sodium deoxycholate (D5670, 
Sigma) 
Protease Inhibitor Cocktail 
Working Buffer 
1 x Immunoprecipitation Lysis Buffer 
4 x Dilution Buffer 
Protease Inhibitor Cocktail 
Low Salt Immune 
Complex Wash 
Buffer 
1 % (v/v) Triton 
150 mM NaCl 
20 mM Tris-HCl pH 8.0 
0.1 % (v/v) SDS 
2 mM EDTA 
High Salt Immune 
Complex Wash 
Buffer 
1 % (v/v) Triton 
500 mM NaCl 
20 mM Tris-HCl pH 8.0 
0.1 % (v/v) SDS 
2 mM EDTA 
LiCl Immune 
Complex Wash 
Buffer 
0.25 M LiCl 
1 % (v/v) sodium deoxycholate 
10 mM Tris-HCl pH 8.0 
1 % (v/v) NP40 
1 mM EDTA 
TE buffer 
10 mM Tris-HCl pH 8.0 
1 mM EDTA 
Elution Buffer 
0.1 M Sodium bicarbonate (NaHCO3, 25080094, 
ThermoFisher Scientific) 
1 % (v/v) SDS 
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2.8 Sub-cellular Mass Spectrometry 
2.8.1 Culture conditions and fractionation 
Cells were seeded into 30 x 150 mm dishes to achieve confluence at time of harvest 
(~60 million cells). After 24 hours, the plates were either placed in serum free medium 
overnight or treated with 1 μM AZD4547, doxycycline to induce FGFR1 knockdown 
or relevant vehicle control. The cells were harvested 24 hours after AZD4547 
treatment and 48 hours after FGFR1 knockdown by washing with ice-cold PBS and 
then scraping off the dishes in PBS plus protease inhibitors. In the serum starved 
condition, cells were stimulated according to Section 2.1.3 and harvested as 
described above. 
 
Once the cells had been collected, sub-cellular fractionation was carried out using the 
Minute™ Plasma Membrane Protein Isolation and Fraction kit (SM-005, Invent 
Biotechnologies) according to manufacturer’s protocol. Briefly, cells were collected by 
centrifuging at 500 x g for 5 minutes, the pellet was washed once with cold PBS and 
re-suspended in 500 µl of buffer A. The cell suspension was incubated on ice for 10 
minutes and then the tube was vortexed vigorously for 30 seconds. The cell 
suspension was transferred to the filter cartridge and centrifuged at 16,000 x g for 30 
seconds. The cell suspension in the collection tube was then transferred back onto 
the same filter and centrifuged again to increase the yield. Then the filter was 
discarded and the pellet was re-suspended in the collection tube by vortexing for 10 
seconds. This was centrifuged at 700 x g for 1 minute to collect the intact nuclei. The 
supernatant was then transferred into a fresh 1.5 ml tube and centrifuged at 16,000 x 
g for 30 minutes at 4oC. The supernatant was removed and kept as the cytosol 
fraction. Then the pellet was re-suspended in 200 µl of buffer B by vortexing. This 
was centrifuged at 7,800 x g for 1 hour at 4oC, the pellet contained the intracellular 
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membrane-bound organelles. The supernatant was then transferred into a fresh 2 ml 
tube and 1.6 ml cold PBS was added. This was mixed by inverting the tube a few 
times and then centrifuged at 16,000 x g for 1 hour at 4oC. The supernatant was 
discarded and the pellet was kept as the plasma membrane fraction. The efficiency 
of sub-fractionation was confirmed by looking for the enrichment of relevant peptides 
in each fraction (Figure 5.17). Each fraction was re-suspended in SDS lysis buffer (2 
% (v/v) SDS, 100 mM Tris-HCl pH 7.5). 
 
2.8.2 Peptide isolation and preparation 
The protein concentration in each fraction was quantified using Bio-Rad DC Protein 
Assay, according to manufacturer’s instructions (Section 2.4.1), and 25 µg was taken 
forward to carry out Mass Spectrometry analysis. DTT was added to each sample at 
a final concentration of 100 mM and the tubes were incubated at 95oC for 10 mins. 
Following this, 7 x volumes of urea buffer (UA, 8 M urea plus 100 mM Tris HCl pH 
8.5) was added to all the samples and this was mixed gently. The samples were then 
transferred into vivacon 500 filters (VN01H21, Sartorius) and centrifuged at 14,000 x 
g for 20 minutes. Following this another 400 µl of UA buffer was added to the samples 
and they were centrifuged again (14,000 x g for 20 mins). Flow through was 
discarded. 
 
Following this, 0.05 M iodoacetamide (IAA, 786-228, G Biosciences) dissolved in UA 
buffer was added to each sample. These were incubated in the dark for 30 mins. The 
sample was concentrated by centrifuging at 14,000 x g for 10 minutes. Next, three 
washes with UA buffer were carried out with centrifuging at 14,000 x g for 20 minutes 
and the flow-through was discarded. After this, three washes with 100 mM 
triethylammonium bicarbonate (TEAB, 90114, Thermo Scientific) were performed on 
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each filter, centrifuging the samples at 14,000 x g for 10 minutes and the flow-through 
was discarded. The filters were then placed into collection tubes and 100 µl of 100 
mM TEAB buffer was added. Next, 2.5 µg (2.5 µl) of trypsin (T6567, Sigma) was 
added to the filters and they were incubated overnight at 37oC, shaking. 
 
The following day, acetonitrile (271004, Sigma-Aldrich) was added to each tube and 
incubated with vortexing for 5 minutes. The relevant TMT label (90061, ThermoFisher 
Scientific) was incubated with each fraction for 1 hour at 25oC, shaking. The peptides 
were eluted by centrifuging at 14,000 x g for 10 minutes. A further two washes and 
centrifugations with TEAB buffer were carried out to ensure all the peptides were 
eluted fully. In the final elution, 30 % (v/v) acetonitrile was added to the filters before 
centrifuging at 14,000 x g for 10 minutes. All the eluates from each fraction were 
combined and vacuum dried overnight. 
 
2.8.3 Mass Spectrometry analysis 
The number of peptides detected was increased by fractionating the samples using 
Pierce™ high pH Reverse-Phase Peptide Fractionation Kit (84868, Thermo 
Scientific), according to the manufacturer’s protocol. Briefly, the spin column was 
centrifuged at 5,000 x g for 2 minutes to remove the solution and pack the resin 
material, the flow-through was discarded. Next, the column was conditioned by 
centrifuging at 5,000 x g for 2 minutes with acetonitrile twice and 0.1 % (v/v) 
trimethylamine (TEA) twice. The peptide solution dissolved in 0.1 % (v/v) TEA was 
then added to the column and centrifuged at 3,000 x g for 2 minutes. The eluate was 
kept as the flow-through fraction. The column was then placed into a new collection 
tube and the sample was centrifuged again with water, the eluate was kept as the 
wash fraction. The TMT-labelled samples were then subjected to a further wash step 
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to remove unbound TMT reagent by centrifuging with 5 % acetonitrile in 0.1 % (v/v) 
TEA. The 8 peptide fractions were then collected in new collection tubes by 
centrifugation with increasing percentages of acetonitrile (10 %, 12.5 %, 15 %, 17.5 
%, 20 %, 22.5 %, 25 % and 50 %) (all v/v) in 0.1 % (v/v) TEA. Samples were vacuum 
dried overnight and then analysed by Liquid Chromatography Mass Spectrometry (Dr 
Faraz Mardakheh). Quantitative peptide identification was performed using 
MaxQuant software. The log2fold change was then used to highlight the most up- or 
down-regulated peptides upon AZD4547 treatment in the whole cell lysate samples. 
For the sub-cellular analysis, the percentage change of each peptide within the 
nuclear compartment between the two conditions was calculated to demonstrate the 
most increased or decreased nuclear peptides. STRING was used to analyse 
potential interactions between the significantly changed peptides upon AZD4547 
treatment in both the whole cell lysate and nuclear compartment. This was a pilot 
experiment and will be repeated in future (Section 5.4). 
 
2.9 Murine experiments 
2.9.1 Cell preparation 
MIA PaCa-2 cancer and PS1 stellate cells were amplified in tissue culture ahead of 
in vivo pilot experiments. MIA PaCa-2 cells were prepared for injection in either mono- 
or co-culture with PS1 cells in a ratio of 1:2 respectively. On the day of injection 
various cell numbers were prepared in both mono- and co-culture in either PBS or 
PBS plus 50 % (v/v) matrigel: 1 x 106 MIA PaCa-2 + 2 x 106 PS1; 2 x 106 MIA PaCa-
2 + 4 x 106 PS1; 4 x 106 MIA PaCa-2 + 8 x 106 PS1 or 5 x 106 MIA PaCa-2 + 10 x 106 
PS1. Cells were kept on ice before being transferred to the animal house for injection. 
PS1 cells in mono-culture were injected into mice as a control to demonstrate that 
these cells cannot induce tumour formation alone. 
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2.9.2 In vivo injections and tumour monitoring 
Female nude mice were purchased from Charles River and maintained within the 
BSU at Charterhouse Square. Mice were left for at least one week to acclimatise 
before any procedures were carried out. Cell preparations were injected 
subcutaneously into each flank of the mice (two tumours per mouse). Each mouse 
either had two tumours consisting of cancer cells in either monoculture or co-culture 
with stellate cells. Mice were weighed twice a week and tumour size was measured 
using callipers three times a week, starting from 7 days post injection. AZD4547 
treatment (12.5 mg/kg AZD4547 in a 2.5 % (v/v) solution of Tween-80/PEG300) was 
given to mice by oral gavage daily, following a five days on, two days off protocol. All 
procedures were completed according to Home Office guidelines under the project 
license of Professor Kairbaan Hodivala-Dilke (PF220CE02). No tumours were 
allowed to breach the limit of 1.44 cm3. Any animals showing signs of pain, ill health 
or with a weight loss of 20 % body weight were euthanised. 
 
2.9.3 Tumour harvesting 
At the end of each pilot experiment, mice were euthanised by cervical dislocation and 
any tumours were removed. These were either fixed in formalin for 24 hours, washed 
in ethanol and paraffin embedded or snap frozen in liquid nitrogen. The pancreata of 
3 mice from the co-culture cohort of each experiment were also harvested. Half of 
each pancreas was formalin fixed and paraffin embedded, whilst the other half was 
snap frozen. The lungs and kidney of these mice were also snap frozen in liquid 
nitrogen. 
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Table 2.3 Antibodies used in the project 
Antibody Species 
Incubation 
conditions 
Dilution for 
IF/IHC 
Dilution for 
WB 
α-SMA 
(F3777, Sigma) 
Mouse 
1h RT 
(dark) 
1:500  
Vimentin 
(HPA001762, Sigma) 
Rabbit 1h RT 1:100  
Vimentin 
(M0725, DAKO) 
Mouse O/N 4oC 1:200  
Desmin 
(D1033, Sigma) 
Mouse 1h RT 1:100  
GFAP 
(G3893, Sigma) 
Mouse 1h RT 1:500  
FGFR1 
(ab10646, Abcam) 
Rabbit 1h RT 1:100  
HaloTag 
(G9211, Promega) 
Mouse O/N 4oC  1:2000 
FGFR1 
(9740, Cell Signalling) 
Rabbit O/N 4oC  1:500 
Fibronectin 
(sc-73601, Santa Cruz) 
Mouse O/N 4oC  1:1000 
GAPDH 
(MAB374, Millipore) 
Mouse O/N 4oC  1:2000 
HSC70 
(SC-7298, Santa Cruz) 
Mouse O/N 4oC  1:1000 
PHLDA1 
(HPA019000-100UL, 
Sigma-Aldrich) 
Rabbit O/N 4oC  1:1000 
Ki67 
(DAKO M7240) 
Mouse O/N 4oC 1:100  
Cytokeratin 8/18 
(ab194130, Abcam) 
Guinea-
pig 
O/N 4oC 1:100  
E-Cadherin 
(ab1416, Abcam) 
Mouse O/N 4oC 1:100  
Cleaved caspase 3 
(D175, Cell Signaling) 
Rabbit 1h RT 1:400  
Pan-cytokeratin 
(Z0662, DAKO) 
Rabbit 1h RT 1:200  
Anti-Mouse-HRP 
(P0447, DAKO) 
Goat 1h RT  1:5000 
Anti-Rabbit-HRP 
(P0448, DAKO) 
Goat 1h RT  1:5000 
Anti-Mouse 488/546 
(A11017, A11003, 
Invitrogen) 
Goat 
1h RT 
(dark) 
1:500  
Anti-Rabbit 488/546 
(A11034, A11035, 
Invitrogen) 
Goat 
1h RT 
(dark) 
1:500  
Mouse IgG 
(X0931, DAKO) 
Mouse 1h RT 1:10  
Rabbit IgG 
(ab172730, Abcam) 
Rabbit 1h RT 1:100  
RT = room temperature 
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Chapter 3 Results I: Targeting FGF 
signalling in pancreatic stellate cells 
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3.1 Introduction 
FGF signalling is an important developmental pathway that can become activated in 
cancer to drive tumour progression (Helsten et al., 2016, Turner and Grose, 2010). 
One of the ways that FGF signalling can drive tumour progression is by nuclear 
translocation of the FGF receptors or ligands. Nuclear translocation of the FGF2 
ligand has been associated with glioma progression (Wang et al., 2015). On the other 
hand nuclear translocation of the receptor, FGFR1, in either cancer or stromal cells 
is related to tumour progression and invasion in breast and pancreatic neoplasms 
(Chioni and Grose, 2012, Coleman et al., 2014b). It has also been shown that nuclear 
translocation of FGFR1 plays a role in transcriptional regulation of neurons in 
physiology (Lee et al., 2013, Terranova et al., 2015).  
 
FGF signalling has been linked with PDAC development and progression for some 
time, though the exact mechanism has remained elusive. For example, increased 
expression of FGF1 and FGF2 has been correlated with a more advanced PDAC 
stage in patient tumours (Yamanaka et al., 1993). FGF2 expression was also linked 
with shorter overall survival and increased hyperplasia (Kuniyasu et al., 2001). In 
contrast to this, there is evidence that overexpression of FGFR1 in PDAC tumours is 
correlated with lower grade tumours and therefore better patient prognosis (Haq et 
al., 2018). The conflicting effects of FGF signalling on PDAC development could be 
due to different isoform expression. It has been reported that PDAC tumours and 
cancer cell lines switch to expression of the FGFR1 and 2 IIIc isoforms, promoting 
autocrine signalling through the MAPK pathway and driving cell proliferation and 
migration (Ishiwata et al., 2012, Kornmann et al., 2002). This makes FGF signalling 
an interesting though complex target to explore in PDAC tumours. 
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We have shown that nuclear FGFR1 can be found in myofibroblast cells at the 
invasive edge of PDAC tumours (Coleman et al., 2014b).  By blocking nuclear FGFR1 
signalling in 3D models, the invasion of cancer and stellate cells can be reduced. This 
indicates that FGF signalling may mediate a critical cross-talk mechanism between 
different cellular compartments of PDAC tumours. To assess the role of FGF 
signalling in PDAC progression, I first investigated the importance of nuclear FGFR1 
in pancreatic stellate cells and possible therapeutic strategies to target receptor 
translocation. 
 
3.2 FGF expression in PDAC cancer cell lines 
To investigate the effect of disrupting FGF signalling cross-talk, I needed to assess 
the importance of this pathway in PDAC. The pancreatic expression database (PED) 
(Marzec et al., 2018) is a repository of published data relating to pancreatic cancer. 
One of the key features of this database is that it allows interrogation of gene 
expression in PDAC cell lines. I searched the database for the relative expression of 
all the FGF receptors and some relevant FGF ligands (Table 3.1, Figure 3.1 and 3.2). 
 
The data from all the cancer cell lines included in the PED analysis showed a variable 
expression of the FGFs and FGFRs, with no clear link between expression and site 
of cell line isolation, for example from a primary tumour or a metastatic site. FGFR1 
was the receptor with maximal expression in the highest number of PDAC cell lines. 
These data support the concept that expression of FGF signalling components may 
not be enough to explain the complex role this pathway plays in PDAC development 
and progression. Additionally PED does not provide information on the specific 
receptor isoforms expressed, which could be critical for the effect of FGF signalling 
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within these cells. I used a range of PDAC cell lines in this project, isolated from either 
primary tumours or metastatic sites, with variable expression of FGFs and FGFRs. 
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 Table 3.1 FGF/FGFR expression in PDAC cell lines 
 
 
 
 
 
 
 
 
Cell Line Source FGFR1 FGF2 
MIA PaCa-2 Primary   
PANC-1 Primary   
AsPC-1 Ascites   
COLO 357 
Metastasis 
(lymph node) 
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Figure 3.1 FGFR expression in PDAC cell lines 
The relative expression of FGFR1-4 in a range of PDAC cell lines is shown compared to 
the average, taken from PED. The colour of the bars relates to the site that the cell line 
was generated from, either a primary or metastatic (ascites, spleen, liver or lymph node) 
tumour. There is variable expression of all four FGFRs across the cell lines. 
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Figure 3.2 FGF expression in PDAC cell lines 
The relative expression of FGF1 and FGF2 in a range of PDAC cell lines is shown 
compared to the average, taken from PED. The colour of the bars relates to the site 
that the cell line was generated from, either a primary or metastatic (ascites, spleen, 
liver or lymph node) tumour. There is variable expression of both FGFs across the 
cell lines. 
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3.3 Stellate cell line characterisation 
3.3.1 Immunostaining 
The PS1 stellate cell line was used in this project. These cells were isolated from a 
healthy donated pancreas and immortalised by expression of ectopic hTERT (Li et 
al., 2009). To confirm that these cells retained their phenotype in culture, 
immunofluorescence for stellate cell markers was carried out. PS1 cells were 
confirmed to stain positive for four different stellate cell markers (Apte et al., 1998): 
GFAP, α-SMA vimentin and desmin (Figure 3.3). 
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Figure 3.3 Immunocytochemistry staining for PS1 characterisation 
PS1 cells grown on coverslips were fixed and stained for four different stellate cell 
markers: vimentin, GFAP, α-SMA and desmin (Section 2.3.1). The images are 
representative of three biological replicates and show positive staining for all the 
markers, with an unstained negative control. Scale bar = 20 µm. 
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3.3.2 Oil Red O 
A feature of stellate cells is that upon treatment with vitamin A, the cells will become 
quiescent, stop proliferating and store the vitamin in lipid droplets within the cell. PS1 
cells were treated daily with either ATRA or ethanol vehicle control. After fixing, Oil 
Red O staining was carried out to identify the induction of storage of vitamin A in lipid 
droplets following treatment with ATRA (Bachem et al., 1998, Froeling et al., 2011). 
Nuclei were counterstained with haematoxylin (Figure 3.4). 
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Figure 3.4 Oil Red O staining of lipid droplets in PS1 cells 
PS1 cells grown on coverslips and treated daily with either ethanol vehicle control 
(A) or ATRA (B). The cells were fixed and stained for lipid droplets using Oil Red 
O (Section 2.3.2). The ATRA treated cells showed a greater number of lipid droplets 
than the untreated controls (shown by the arrows). These slides were counter 
stained with haematoxylin and are representative of three biological replicates. 
Scale bar = 10 µm. 
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3.4 Drug response assays 
To assess the effect of interrupting FGF signalling cross-talk in PDAC, I used FGFR 
tyrosine kinase inhibitors. Several ATP-mimetic FGFR inhibitors are available and 
previous work in the laboratory had been carried out using PD173074 (Coleman et 
al., 2014b). PD173074 can only be used as a laboratory tool compound due to its 
toxicity. Therefore I decided to use an ATP-mimetic FGFR inhibitor that is currently in 
clinical trials: AZD4547 (Gavine et al., 2012) (Figure 3.5). AZD4547 is active against 
FGFR1-4 and VEGFR2 (Table 6.2). 
 
3.4.1 AZD4547 
Initial phase 1 trials of AZD4547 were carried out in advanced solid malignancies to 
determine tolerability and safety (NCT01213160, NCT00979134). Following this a 
number of phase 2/3 trials were initiated to target tumours with FGFR mutations, gene 
amplifications and fusions. Specifically, AZD4547 has been used in clinical trials to 
target recurrent gliomas expressing FGFR-TACC gene fusion (NCT02824133) and 
FGFR1/2 amplified gastric, oesophageal, breast or squamous lung cancers 
(NCT01795768, NCT02965378). It has also been tested in combination with 
docetaxel in NSCLC (NCT01824901). In oestrogen receptor positive breast cancer, 
AZD4547 has been trialled in combination with anastrozole/letrozole in patients that 
have progressed (RADICAL, NCT01791985) and in combination with fulvestrant in 
patients with FGFR1 polysomy or gene amplification (GLOW, NCT01202591). In 
gastric and gastro-oesophageal cancer, AZD4547 treatment has been compared with 
paclitaxel in patients with FGFR2 polysomy or gene amplification (SHINE, 
NCT01457846). This drug has now been included in many trials with multiple targeted 
therapies using a biomarker driven approach to recruit patients to relevant treatment 
arms. For example, the BISCAY (NCT02546661) phase 1b trial in patients with 
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muscle invasive bladder cancer, the Lung-MAP second line therapy trial in patients 
with recurrent stage IV squamous cell lung cancer (NCT02154490), the MATCH 
(NCT02465060) screening trial in patients with advanced refractory solid tumours, 
lymphomas or multiple myeloma and the national lung matrix trial in patients with 
NSCLC (NCT02664935). There are also two trials using genetic analysis as a 
decision tool in patients with metastatic disease to decide on treatment with relevant 
therapies including AZD4547, SAFIR02_Breast (NCT02299999) and SAFIR02_Lung 
(NCT02117167). 
 
Following all these clinical trials using AZD4547 to target FGFR driven tumours in 
patients, we decided to use this inhibitor to target cross-talk in PDAC tumours. 
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Figure 3.5 Structure of FGFR inhibitors 
Structure of the FGFR inhibitors AZD4547 (A) and PD173074 (B) 
(Gavine et al., 2012, Mohammadi et al., 1998). 
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3.4.2 Cell viability 
Cell viability was determined using standard MTS assays. The growth inhibition to 50 
% viability (GI50) of the FGFR inhibitor AZD4547, for PS1, AsPC-1, MIA PaCa-2, 
COLO 357 and PANC-1 cell lines in 2D culture was calculated (Figure 3.6). 
 
Non-linear regression shows that all cell lines were insensitive to FGFR inhibition in 
2D culture. The lowest GI50 value was 6 µM (MIA PaCa-2). Therefore, selecting a 
dose below 6 µM for future experiments would ensure that cell viability is not impacted 
by treatment. In future experiments a dose of 1 µM AZD4547 was used, which has 
been previously established in endometrial cancer models in the laboratory (Fearon 
et al., 2018). This was a suitable concentration as it was above the active dose but 
below the toxic dose. 
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Figure 3.6 MTS assay dose response following AZD4547 treatment 
MTS cell viability assays were used to calculate a Cell Viability Index (absorbance in 
each well adjusted for background and normalised to control wells, Section 2.2.1). 
Linear regression was then used to determine a GI
50
 value of 6 µM (A), 9 µM (B), 9.9 
µM (C), 18 µM (D) and 8.8 µM (E) for AZD4547 with the MIA PaCa-2, PANC-1, AsPC-
1, COLO 357 and PS1 cell lines respectively. These values provide a starting value to 
use for drug treatment moving into co-culture and 3D models. The concentration of 
AZD4547 used should be below the GI
50
 value for all cell lines to ensure cell viability 
is not affected. The data points on the graph represent the mean cell viability from 
three technical repeats for each plate, with at least three biological replicates plotted 
for each cell line. 
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3.4.3 Mono- and co-culture proliferation 
CellTracker dyes were used to analyse PS1 and AsPC-1 proliferation in response to 
increasing concentrations of AZD4547 in mono- and co-culture conditions (Figure 
3.7). There was no difference between the response of either cell line to drug in mono 
or co-culture at 1 µM in 2D cultures (Two-way ANOVA analysis). 
 
1 µM AZD4547 will not decrease cell proliferation and, therefore, should be effective 
at selectively studying cross-talk between the cells.  
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Figure 3.7. Flow Cytometry analysis of AZD4547 dose response 
Flow Cytometry analysis assays showed that as the drug concentration increased, 
the proliferation of the cells decreased (measured by an increasing geometric mean 
indicating greater fluorescence intensity per cell and therefore less cell division, 
Section 2.2.2). The graph shows the change in cell proliferation of both cell lines in 
mono- or co-culture to AZD4547 treatment. The average geometric mean value from 
three biological replicates was calculated (relative geometric mean) and 1/relative 
geometric mean has been plotted with standard error of the mean (SEM). Two-way 
ANOVA analysis was carried out to analyse the data. There was no significant 
difference in response to AZD4547 treatment of each cell line in mono- or co-culture. 
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3.5 Nuclear FGFR1 
3.5.1 Localisation of FGFR1 in stellate cells 
Previous studies in our laboratory have demonstrated that FGFR1 can translocate to 
the nucleus in pancreatic stellate cells. I stained PS1 stellate cells, alongside primary 
cancer-associated stellate cells (M1090T and M1245, Section 2.1.1), for FGFR1 
localisation following culture on coverslips (Figure 3.8). The primary cells have 
previously been confirmed to be stellate cells by expression of PSC markers and 
reversion to quiescence upon ATRA treatment (Neuzillet et al., 2019). The FGFR1 
staining showed heterogeneity between different cells within each population, 
highlighting a sub-population of cells expressing nuclear FGFR1 speckles. 
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Figure 3.8 Nuclear FGFR1 speckles in pancreatic stellate cells 
The PS1 stellate cell line and primary cancer associated stellate cells (M1090T and 
M1245) were cultured on coverslips, fixed and stained for FGFR1 (ab10646, Abcam, 
performed according to Section 2.3.1). PS1, M1090T and M1245 all showed a sub-
population of cells with nuclear FGFR1 speckles (highlighted by the arrows). These 
images are representative of three technical repeats. Scale bar = 20 µm. 
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3.5.2 Nuclear localisation following FGFR inhibition 
The IN Cell 2200 high-throughput microscope was used to analyse the effect of FGFR 
inhibition with AZD4547 on FGFR1 nuclear localisation. One-way ANOVA analysis 
was performed on the levels of nuclear foci with increasing AZD4547 concentration 
(Figure 3.9). 
 
AZD4547 treatment, up to 1 µM at least, in 2D monoculture did not reduce the levels 
of nuclear FGFR1 in PS1 cells. This is in contrast to previous work showing a 
decrease in nuclear FGFR1 following treatment with 2 µM of FGFR inhibitor 
PD173074 for 48 hours (Coleman et al., 2014b). This difference could be due to 
experimental conditions, such as drug concentration and length of treatment. 
Moreover, FGFR signalling cross-talk interruption with AZD4547 should ideally be 
tested with both cell types (PSCs and cancer cells) in co-culture. It was difficult to test 
the effect of cross-talk within this assay as the two cell types (PSCs and cancer cells) 
could not be reliably distinguished following staining, preventing the automated 
quantification using the IN Cell Investigator Software from being performed on the 
PSC compartment only.  
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Figure 3.9 Nuclear FGFR1 following AZD4547 treatment 
PS1 cells seeded in a 96-well plate and treated with increasing concentrations of 
AZD4547 for 24 hours were fixed, stained for FGFR1 and analysed using the IN 
Cell 2200 high-throughput microscope (Section 2.3.5). The nuclear density of 
FGFR1 staining in PS1 cells did not decrease following treatment with increasing 
doses of the FGFR inhibitor AZD4547 in medium containing 10 % (v/v) FBS. This 
suggests that AZD4547 treatment does not decrease levels of nuclear FGFR1 in 24 
hours in stellate cells grown on plastic in 2D mono-culture conditions. One-way 
ANOVA analysis was used to compare the FGFR1 nuclear foci intensity. This data 
is from three biological replicates. 
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3.6 Discussion 
PDAC cell lines with a range of FGF and FGFR expression were used to investigate 
the role of FGF mediated cross-talk in pancreatic cancer. The PS1 stellate cell line 
was characterised and confirmed to have nuclear FGFR1, making it a suitable cell 
line to use in this study. Cancer-associated primary stellate cells also had nuclear 
FGFR1 staining, demonstrating that PS1 cell line is representative of stellate cells in 
PDAC patients. The 2D drug assays showed that only high concentrations of 
AZD4547 are toxic to PDAC cancer cell lines and the PS1 cell line. This finding 
showed that it was appropriate to use a concentration of 1 μM AZD4547 for FGFR1 
mediated cross-talk inhibition without affecting cell viability (Fearon et al., 2018).  
 
Treating cells in co-culture with 1 µM AZD4547 did not appear to affect proliferation 
of either cell type, which may be because FGF signalling cross-talk plays a role in 
invasion rather than proliferation in PDAC (Coleman et al., 2014b). Moreover, 
treatment of stellate cells in 2D with increasing concentrations of AZD4547 did not 
reduce the levels of nuclear FGFR1, in contrast to previously published data using 
another FGFR inhibitor, PD173074 (Coleman et al., 2014b). This could be due either 
to experimental differences or to the primary role of nuclear FGFR1 in mediating 
cross-talk led invasion in PSCs. Therefore the most appropriate assays to test the 
effect of AZD4547 treatment would be 3D co-culture PDAC models (Coetzee et al., 
2019). 
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Chapter 4 Results II: Interrupting FGF-
mediated cross-talk in PDAC 
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4.1 Introduction 
It is widely accepted that, whilst necessary, traditional 2D cell culture is not 
representative of human tumours (Kapałczyńska et al., 2018). This may be part of the 
reason that many promising therapies in the laboratory end up failing in patients. The 
use of 3D in vitro models in cancer research is increasing as these provide an 
alternative to 2D cell culture or expensive in vivo models (Bardeesy and DePinho, 
2002, Pérez–Mancera et al., 2012). 
 
4.1.1 Epithelial Organoids 
Many different PDAC 3D models have now been developed, allowing the complex 
cellular and ECM interactions to be studied (Baker et al., 2016, Coetzee et al., 2019, 
Moreira et al., 2018). Organoids can be grown from patient-derived tumour resections 
or biopsy tissue (Figure 4.1). One method implants patient tumour cells into matrigel 
domes, supplemented with a wide range of growth factors to mimic the signals from 
the desmoplastic stroma (Boj et al., 2015). This technique has successfully 
recapitulated PDAC-like structures in the laboratory and organoids can be frozen and 
thawed, making it a useful research tool. Another method uses patient-derived PDAC 
tissue to grow organoids on top of a matrigel layer. The cultures still require many 
additional growth factors to support the survival of the cancer cells (Huang et al., 
2015). Pancreatic organoids have also been grown on top of a collagen gel, in an air-
liquid interface model, from minced pancreatic tumour tissue (Li et al., 2014, Ootani 
et al., 2009). Organoids offer the potential to screen different targeted therapies for 
patients to allow for more effective and personalised treatment. This could be very 
useful in the clinic, however only in the patients who survive long enough to allow the 
cultures to be established and therapies to be screened. Furthermore, the need for 
primary patient tissue to establish organoids for research is a limiting factor.  Only 10-
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15 % of PDAC patients are eligible for surgery at the point of diagnosis (Ryan  et al., 
2014) and therefore it can be difficult to routinely obtain patient-derived tissue. 
Another method of culturing primary epithelial-based organoids is by inducing 
differentiation of pluripotent stem cells into pancreatic exocrine or endocrine cells in 
culture (Greggio et al., 2013, Huang et al., 2015, Scavuzzo et al., 2017, Sugiyama et 
al., 2013). These cultures can recapitulate pancreatic structures and are useful in 
investigating the development and progression of PDAC. Whilst useful, the scarce 
availability of patient tissue and absence of fibroblasts and PSCs make organoids 
impractical and non-informative for studying stroma-cancer cross-talk. 
 
4.1.2 Co-culture 
Other types of organoids use co-culture of cancer cells with stromal cells to reduce 
the number of growth factors needed in the culture media, reducing the complexity 
and the cost. A simple method is to include fibroblasts in the cultures alongside cancer 
cells, the fibroblasts can then provide many of the growth factors needed for cancer 
cell survival (Walsh et al., 2016). Furthermore, multi-cellular organoids have been 
developed by using tissue fragments from tumour resection, ascites or rapid autopsy 
and implanting them in matrigel domes. This makes a more complex tumour model 
and can allow the interactions between the cancer cells and the tumour 
microenvironment to be studied (Tsai et al., 2018).  
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Figure 4.1 Pancreatic cancer organoid methods 
Pancreatic tumours from a human or murine pancreas are broken down into their cellular components. The cancer cells can then be embedded into a 
pure matrigel dome (A) with growth factors added to the medium on top to stimulate cell growth.  Another method is to culture these primary cells in 
medium on top of a matrigel layer (B). The medium must also be supplemented with many growth factors to stimulate cellular survival and growth. 
Alternatively cancer cell spheroids can be co-cultured with stromal cells in a gel made up of 50% matrigel and 50% medium, drugs can be added to 
medium on top of the gel (C). To make the organoid model more complex, immune cells can be added to stellate cells and cancer cell spheroids in a 
matrigel dome. Medium can be added to the top of this dome but fewer growth factors are needed due to the presence of stromal cells in the gels (D). 
Another method to culture cancer spheroids is to place them into collagen in a Transwell insert. This gel can then be fed with medium from below to 
create an air-liquid interface (E) (Coetzee et al., 2019). 
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4.1.3 Other 3D cultures 
Other 3D PDAC models have been developed. For example, microfluidics can be 
used to grow PDAC cells on a collagen coated HepaChip® chamber. These cultures 
are quick to establish and can be adjusted to reflect the perfusion rates of tumours, 
which could make them useful for screening personalised therapies for patients (Beer 
et al., 2017b). Furthermore, different concentrations of Oligomer (type 1 collagen) can 
be used, along with matrigel, to create ECM gels with varying levels of stiffness to 
effectively model PDAC tumours in the laboratory (Puls et al., 2017). In order to 
faithfully reproduce all of the cellular interactions within PDAC tumours, tumour slice 
models have been developed. In this model, slices of fresh PDAC resections are 
placed onto collagen coated membranes, which are then supplemented with medium 
containing FBS, glutaMAX, NaHCO3, HEPES, L-cysteine and antibiotics. The tumour 
slices can be maintained for up to 6 days in culture (Jiang et al., 2017, Vaira et al., 
2010).  
 
All of these models vary in complexity and could offer invaluable tools for both 
studying PDAC development and screening potential therapies. However, they can 
be costly and time consuming to establish. Hence, for this project, I used two distinct 
3D methods (mini-organotypics and spheroids) to study the effect of FGF signalling 
cross-talk between cancer cells and stellate cells in PDAC. These were useful models 
to easily investigate the effect of targeting FGF cross-talk on PDAC invasion, however 
none of these experiments were performed under hypoxic conditions and still lack the 
full complexity of the desmoplastic stroma. This may be an important factor to 
consider in future when translating these results into PDAC tumours. 
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4.2 FGFR inhibition 
4.2.1 FGFR inhibitors in mini-organotypics 
To assess the role of FGF signalling cross-talk, 3D mini-organotypic co-cultures were 
treated with FGFR inhibitors and the effect on invasion was analysed. The mini-
organotypic model is a well-established 3D model in our laboratory, adapted from 
large organotypic models (Coleman et al., 2014c). Briefly, organotypic gels made up 
of a collagen/matrigel mix are placed into a 24 well plate (for large cultures) or 
Transwell inserts (for mini-cultures) and left to polymerise. Cells are then seeded in 
co-culture on top of the gel in a 2:1 PSC to PDAC cell ratio (Kadaba et al., 2013). The 
mini-organotypic model can then be fed with medium from below (day 0) to create an 
air-liquid interface model. After 24 hours the large cultures are raised on top of pre-
coated nylon membrane placed onto a metal grid. These can then be fed with medium 
from below to create an air-liquid interface (day 0). Relevant drugs can be added to 
the cultures through the medium. Following incubation for 7 days in mini-organotypics 
or up to 24 days in large organotypics, invasion can be studied or cultures can be 
stained for relevant markers (Figure 4.2 and Section 2.7.1). Mini-organotypics are 
quick and use fewer cells, and therefore, are useful for primary cell culture, whereas 
large organotypics can be maintained for longer, allowing treatment effects on more 
established cultures to be analysed. 
 
Three PDAC cancer cell lines (MIA PaCa-2, COLO 357 and PANC-1) were cultured 
in mini-organotypics either alone or with PS1 stellate cells and treated with two FGFR 
inhibitors, PD173074 and AZD4547, or vehicle control. These three PDAC cell lines 
had a varying expression of FGFR1 and FGF2 (Table 3.1 and Figures 3.1 and 3.2). 
MIA PaCa-2 and PANC-1 cells were both isolated from primary PDAC tumours, 
whereas COLO 357 cells were isolated from a lymph node metastasis (Appendix 1). 
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MIA PaCa-2 cells were isolated from a 65-year-old male with a tumour in the body 
and tail of the pancreas. This tumour did not express CEA and contained KRAS, 
TP53, INK4A mutations (Yunis et al., 1977). PANC-1 cells were isolated from a 56-
year-old male with a tumour in the head of the pancreas and a metastasis in the 
peripancreatic lymph node. The tumour did not express CEA and also contained 
KRAS, TP53, INK4A mutations (Lieber et al., 1975). COLO 357 cells were isolated 
from a lymph node metastasis in a 77-year-old female. The tumour expressed CEA 
and contained KRAS, SMAD4 mutations (Morgan et al., 1980). All three cell lines 
were classified as the quasi-mesenchymal sub-type (Section 1.2.8) (Collisson et al., 
2011). FGFR inhibition had no effect on PDAC cell mini-organotypic mono-cultures 
(Figure 4.3), but caused a significant decrease in the number of cells invading into 
the gels after 7 days of mini-organotypic co-culture (Figure 4.4). This is consistent 
with previous independent work showing that treatment with PD173074 can reduce 
invasion in large organotypic cultures (Coleman et al., 2014b). 
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Figure 4.2 Pancreatic cancer 3D in vitro models 
A. Mini-organotypic model - a mix of collagen and matrigel is set to form the organotypic gel within a Transwell insert. Cells can then be seeded in co-
culture on top of the gel and fed with medium from below, creating an air-liquid interface. At the end of the experiment, the gels can be harvested and 
analysed (Coetzee et al., 2019). B. Spheroid model - cancer and stellate cells are seeded in a 1:2 ratio in a methylcellulose hanging drop for 24 hours, 
allowing them to form spheres. These are then embedded in organotypic gels and fed with medium from above. This allows multi-directional invasion, 
which can be observed over time of incubation. 
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Figure 4.3 FGFR inhibition has no effect 3D PDAC mini-organotypic models 
A. Three PDAC cell lines (MIA PaCa-2, PANC-1 and COLO 357) were grown for 7 days 
in mini-organotypic models. Treatment with FGFR inhibitors AZD4547 (AZD, 1 µM) or 
PD173074 (PD, 2 µM) or vehicle control was given every other day (Section 2.6.1). B. No 
change in invasion or cell survival were observed when the cultures were treated with 
AZD or PD. These images are representative of at least three biological replicates. Scale 
bar = 200 µm.  
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Figure 4.4 FGFR inhibition reduces invasion in 3D co-culture mini-organotypic 
models 
A. Three PDAC cell lines (MIA PaCa-2, PANC-1 and COLO 357) were grown for 7 days in 
mini-organotypic models in co-culture with PSCs (PS1). Treatment with FGFR inhibitors 
AZD4547 (AZD, 1 µM) or PD173074 (PD, 2 µM) or vehicle control was given every other 
day (Section 2.6.1). B. Under vehicle conditions, cellular invasion into the gels can be seen 
(shown by the arrows). However, when the cultures were treated with AZD or PD, the 
invasion was significantly reduced. Scale bar = 200 µm. C. Quantification of the number of 
invading cells in each gel (points), the median (middle line) and inter-quartile range (box) for 
each condition is shown in the graph. This was analysed by Kruskal-Wallis test with Dunn’s 
multiple comparison of at least three biological replicates *p<0.05, **p<0.01, ***p<0.001. 
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4.2.2 FGFR inhibitors in a spheroid model 
Another approach developed within our laboratory is a hanging drop spheroid model 
(Figure 4.2 and Section 2.7.2). This model allows multi-directional invasion to be 
studied, as well as reducing the number of cells needed for each condition (as 
required for patient-derived primary cells). Briefly, cells are seeded in methylcellulose 
hanging drops and incubated for 24 hours to allow spheres to form. The cells are 
seeded in the same 2:1 ratio of PSCs to cancer cells as used in the organotypic 
cultures (Kadaba et al., 2013). The spheres are then harvested from the hanging 
drops and placed into organotypic gels for 2-5 days with an average of six spheres 
per gel. Treatments are added in medium placed on top of the gels. Gels can be 
imaged during incubation to monitor invasion, as well as being fixed and stained for 
specific markers. 
 
Treatment of co-cultures with the FGFR inhibitor AZD4547 significantly decreased 
invasion, replicating results from the mini-organotypic model (Figure 4.5). In the 
spheroid model, cells transduced with a fluorescent nuclear H2B construct were used 
(stellate cells with H2B-GFP and cancer cells with H2B-RFP). Reconstructed Z-stack 
images of these spheres demonstrate that there is often a leading stellate cell at the 
tip of each invasive protrusion, highlighting these cells as potential drivers of invasion 
in PDAC (Figure 4.6). 
 
All the work in this model has been carried out in collaboration with Dr Ed Carter, a 
post-doctoral researcher in our group, to independently confirm the role of FGF-
mediated invasion. 
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The invasion of each PDAC cell line in 3D co-culture models may be different (Figure 
4.6). Cancer cells can invade either in cohorts or single cells. Studies have shown the 
PANC-1 cells often invade as single cells, rather than as cohorts, which could explain 
the phenotype seen in the spheroid cultures (Stahle et al., 2003). Both MIA PaCa-2 
and PANC-1 cells are classified as invasive cell lines, however there have been 
conflicting reports as to which line is more invasive (Duxbury et al., 2004, Ellenrieder 
et al., 2001, Takada et al., 2002). COLO 357 cells are regarded as poorly invasive 
cancer cells (Huang et al., 2012). 
 
Each PDAC cell line appears to display a different invasive phenotype when placed 
in co-culture with PS1 cells in 3D in vitro models. In the spheroid cultures, both MIA 
PaCa-2 and PANC-1 cells follow PSCs out of the central sphere, whereas COLO 357 
cells mostly remain tightly packed within the central sphere (Figure 4.6). Additionally, 
in the mini-organotypic model, the more invasive MIA PaCa-2 and PANC-1 cells seem 
to have more collective invasion into the gels in the H&E sections (Figure 4.4), 
whereas the COLO 357 cells appear to invade as smaller cohorts or single cells. The 
difference in invasive phenotype could be due to both MIA PaCa-2 and PANC-1 cells 
being poorly differentiated and expressing mesenchymal markers, such as vimentin, 
whereas COLO 357 cells are well differentiated and express many epithelial markers, 
such as E-cadherin and β-catenin (Deer et al., 2010, Huang et al., 2012). However, 
the total number of invading cells or the invasive area in each model is not decreased 
in COLO 357 cultures, compared to the other two PDAC cell lines (Figure 4.4C and 
Figure 4.5C). To fully investigate any differences in invasion of the PDAC cell lines in 
both models, it will be important to quantify invasion of each cell type alone. This can 
be done from imaging of the labelled cells in the spheroid model (as in Figure 4.6) 
using light sheet microscopy and high-throughput quantification of each cell type in 
the invasive zone from Z stack images (Veelken et al., 2017, Lu et al., 2019).  
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Figure 4.5 FGFR inhibition reduces invasion in 3D co-culture spheroid models 
A. Three PDAC cell lines (MIA PaCa-2, PANC-1 and COLO 357) were grown in spheroid 
models in co-culture with PS1 stellate cells and were treated with the FGFR inhibitor 
AZD4547 (AZD, 1 µM) or vehicle control (Section 2.6.2). B. In control spheres cellular 
invasion into the gels can be seen (shown by the arrows). However, in AZD treated spheres, 
the invasion was significantly reduced. Scale bar = 100 µm. C. Quantification of the number 
of invading cells in each gel (points), the median (middle line) and inter-quartile range (box) 
for each condition is shown in the graph. This was analysed by Mann-Whitney U test of at 
least three biological replicates ****p<0.0001. 
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Figure 4.6 Stellate cells lead invasion 
Three PDAC cell lines (MIA PaCa-2, PANC-1 and COLO 357) labelled with H2B-RFP 
were grown in spheroid models in co-culture with PS1 stellate cells labelled with H2B-
GFP. Representative Z-stack reconstructions show that at the end of every protrusion 
leaving the central sphere (shown by dashed white line), a stellate cell is leading the 
invasion (shown by arrows). These images are representative of at least three 
biological replicates. Scale bar = 100 µm. 
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4.3 FGFR1 staining 
Immunofluorescent staining for FGFR1 was performed on sections from mini-
organotypic gels, to determine the subcellular localisation of FGFR1 in invading cells. 
Nuclear FGFR1 was visible in invading cells (Figure 4.7), supporting the hypothesis 
that nuclear translocation of the receptor plays a role in triggering stellate cell-led 
invasion. 
 
Further analysis will be conducted in the future to strengthen and support these 
findings. The labelled PSC and PDAC cell lines will be used in the spheroid model, 
which can then be stained for FGFR1 to demonstrate clearly whether the invading 
stellate cells have nuclear translocation of the receptor, and if this can be reduced 
with AZD4547 treatment. This will also show which cell type is invading and live 
imaging could illuminate the process of stellate-cell led invasion out of the spheres. 
These images could be viewed and quantified using 4-colour IN Cell high throughput 
analysis. 
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Figure 4.7 Nuclear FGFR1 is present in invading stellate cells 
Representative immunofluorescence staining of three biological replicates of co-culture 
mini-organotypic models of COLO 357 and PS1 cells (day 7) demonstrates that stellate 
cells invading into the gel, highlighted by positive green vimentin staining, have nuclear 
FGFR1, shown in red (arrows) (Section 2.3.3). The zoomed in image shows FGFR1 
staining localised to the nucleus in invading vimentin positive cells. 
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4.4 FGFR1 knockdown 
To confirm that the reduction in invasion upon FGF inhibition with AZD4547 treatment 
is due to FGFR1 specifically within the stellate cell compartment, three stable FGFR1 
shRNA cell lines were generated (as described in Section 2.6.3). The use of stable 
doxycycline-inducible shRNA cell lines allowed for efficient FGFR1 knockdown over 
time in longer term models, as well as more consistent knockdown compared to 
siRNA transfection of PS1 cells. 
 
Knockdown of FGFR1 within all three cell lines upon treatment with doxycycline was 
confirmed at protein and RNA level (Figure 4.8). It was also confirmed that FGFR1 
knockdown did not affect the proliferation rate of the PS1 cells (data not shown). 
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Figure 4.8 FGFR1 knockdown in PS1 shRNA inducible cell lines 
Three doxycycline-inducible FGFR1 shRNA PS1 stellate cell lines were generated. Efficient 
knockdown of FGFR1 following treatment with doxycycline for 48 hours was confirmed for 
all three cells lines by protein (A and B) and RNA (C) levels, compared to relevant 
housekeeping controls (HSC70 for Western blot and B2M and HPRT-1 for qPCR, Sections 
2.4 and 2.5). This data is from three biological repeats, graphs show mean and standard 
deviation of quantification, relative to control. 
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4.4.1 FGFR1 knockdown in mini-organotypics 
The three stable FGFR1 shRNA cell lines were then placed into mini-organotypic 
models with MIA PaCa-2 cells and invasion was quantified after seven days of culture 
with or without doxycycline treatment (Figure 4.9). 
 
Knockdown of FGFR1 reproduced the reduction in invasion seen with AZD4547 
treatment, suggesting that FGFR1 is a key mediator of stellate cell-led invasion. This 
reduction was statistically significant for two out of the three shRNA cell lines. 
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Figure 4.9 FGFR1 knockdown in stellate cells reduces invasion in co-culture mini-
organotypic models 
A. MIA PaCa-2 cancer cells were grown for 7 days in mini-organotypic models in co-culture 
with three inducible PS1 shRNA cell lines. Cultures were treated with doxycycline (dox, 1 
µg/ml) every other day to induce FGFR1 knockdown (Section2.6.1). B. Under control 
conditions, cellular invasion into the gels can be seen (shown by the arrows). However, 
upon FGFR1 knockdown in PSCs, the invasion was significantly reduced. Scale bar = 200 
µm C. Quantification of the number of invading cells in each gel (points), the median 
(middle line) and inter-quartile range (box) for each condition is shown in the graph. This 
was analysed by Mann-Whitney U test of at least three biological replicates ** p<0.01. 
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4.4.2 FGFR1 knockdown in spheroids 
Having shown that knockdown of FGFR1 in the stellate cell compartment 
recapitulates the reduction of invasion seen with FGFR inhibition, the result was 
confirmed in our spheroid model using the shRNA2 and shRNA3 PS1 cells (Figure 
4.10). Both the shRNA2 and shRNA3 cell lines demonstrated a significant reduction 
in multi-directional invasion following stellate cell specific knockdown of FGFR1. 
 
These findings highlight the key role that stellate cells play in leading invasion in 
PDAC and confirm that FGFR1, specifically, is an important mediator of this invasive 
phenotype. 
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Figure 4.10 FGFR1 knockdown in stellate cells reduces invasion in co-culture 
spheroid models 
A. MIA PaCa-2 cancer cells were grown in spheroid models in co-culture with two 
inducible PS1 shRNA cell lines. Cultures were treated with doxycycline (dox, 1 µg/ml) 
every other day to induce FGFR1 knockdown (Section 2.6.2). B. Under control conditions, 
cellular invasion into the gels can be seen (shown by the arrows). However, upon FGFR1 
knockdown in PSCs, the invasion was significantly reduced. Scale bar = 100 µm. C. 
Quantification of the number of invading cells in each gel (points), the median (middle line) 
and inter-quartile range (box) for each condition is shown in the graph. This was analysed 
by Mann-Whitney U test of at least three biological replicates **** p<0.0001. 
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4.5 Combination therapy 
PDAC stroma plays a vital role in tumour progression, demonstrated by the effective 
reduction in invasion when interrupting FGF-mediated cellular cross-talk in co-culture 
models. Co-targeting the tumour and the stroma has become a popular strategy for 
improving therapeutic options in PDAC patients. Therapies targeting the ECM (e.g. 
hyaluronic acid), key paracrine signalling pathways (e.g. Wnt and hedgehog 
signalling) and immune cells (e.g. immune checkpoint blockade inhibitors) have all 
been investigated and translated into clinical trials (Doherty et al., 2018, Gong et al., 
2018, Jacobetz et al., 2013, Kabacaoglu et al., 2018, Merika et al., 2012, Olive et al., 
2009, Richards et al., 2012, Thompson et al., 2010). By decreasing the desmoplastic 
stromal reaction and hypoxia within the tumours, chemotherapy may be given to 
patients with increased effect, improving prognosis. However, targeting the stroma is 
more complex than first thought, as shown when one promising avenue targeting 
hedgehog signalling or depleting activated PSCs gave disappointing results. In pre-
clinical studies and a clinical trial, tumours treated with anti-stromal therapies 
appeared to be more aggressive and patients survived longer on the control treatment 
arm, leading to early termination of the trial (Bailey et al., 2009, Feldmann et al., 2008, 
Rhim et al., 2014). 
 
In particular, targeting the activated stellate cells to return them to a quiescent 
phenotype has been an area of interest. Treatment of activated stellate cells with a 
metabolite of vitamin A (ATRA) can return them to their quiescent phenotype and 
induce vitamin storage within lipid droplets. Therefore, combination therapy regimens 
of gemcitabine and ATRA were tested in 3D in vitro assays and KPC mice. This study 
demonstrated that co-targeting the two cell types resulted in decreased cancer cell 
proliferation, stellate cell activation and increased apoptosis, compared to either 
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treatment given alone (Carapuça et al., 2016). This study has been translated into a 
phase 1b clinical trial in PDAC patients (NCT03307148). 
 
Following the success of combining treatments to target both the stellate and cancer 
cell compartments of PDAC tumours, I hypothesised that adding AZD4547 in 
combination with these therapies, thereby targeting cellular cross-talk and inhibiting 
stellate cell-led invasion, might augment the efficacy of ATRA/gemcitabine 
combination treatment. Therefore, these three different drugs were tested in mono- 
and combination therapy in the 3D mini-organotypic model (Figure 4.11). The dose 
of gemcitabine and ATRA were used according to previous optimisation in 3D in vitro 
models within the laboratory (Carapuça et al., 2016, Neuzillet et al., 2019). 
 
4.5.1 Effects on invasion 
AZD4547 was most effective at reducing invasion into gels, both alone and in 
combination with ATRA and/or gemcitabine. However, measuring the cell layer 
thickness on top of the gel, AZD4547 treatment alone did not appear to impact on cell 
proliferation, unless in combination with ATRA or in the triple therapy gels (Figure 
4.11). Cell layer thickness was measured at four representative points across each 
gel using the Pannoramic Viewer software (Section 2.6.1). 
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Figure 4.11 FGFR inhibition reduces invasion in co-culture mini-organotypic 
models alone and in combination therapy 
A. MIA PaCa-2 cancer cells were grown in co-culture with PS1 stellate cells in mini-
organotypics for 7 days and treated with AZD4547 (AZD, 1 µM), ATRA (1 µM) and 
gemcitabine (Gem, 100 nM) either alone or in combination with relevant controls. AZD 
and ATRA treatment was given daily, whilst Gem treatment was given weekly (once) 
(Section 2.6.1). B. Cellular invasion into the gels can be seen (shown by the arrows). 
However, when the cultures were treated with AZD4547 invasion was reduced. Scale bar 
= 200 µm. Quantification of the number of invading cells in each gel (points, C) or the cell 
layer thickness on top of the gel (points, D), with the median (middle line) and inter-quartile 
range (box) for each condition is shown in the graph. AZD4547 either alone or in 
combination with ATRA or gemcitabine plus ATRA significantly reduced invasion. 
Whereas AZD4547 alone did not affect the cell layer thickness on top of the gel, this was 
only reduced AZD4547 treatment was combined with ATRA or gemcitabine plus ATRA. 
Quantification was analysed by Kruskal-Wallis test with Dunn’s multiple comparison of 
three biological replicates *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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4.5.2 Effects on cell survival 
To determine the cellular effect of all three drugs, sections were stained for Ki67 and 
cleaved caspase 3 as markers of proliferation and apoptosis, respectively (Figures 
4.12 and 4.13). The percentage of Ki67 positive nuclei did not appear to change 
between the different treatments, indicating no change in the rate of proliferation. The 
percentage of cleaved caspase 3 positive nuclei seemed to increase in the 
gemcitabine plus AZD4547, ATRA plus AZD4547 and triple therapy combinations, 
indicating a potential change in apoptosis, however, not with statistical significance. 
This could be because the total cell number has decreased in the cultures treated 
with the triple combination; therefore, the percentage of proliferating cells remains the 
same. Furthermore, these cultures may have been too short to determine the true 
effect of combining gemcitabine, ATRA and AZD4547. 
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Figure 4.12 Proliferation rate is unchanged upon treatment with gemcitabine, ATRA 
and AZD4547 in combination 
All of the sections of the mini-organotypic co-cultures treated with combination therapies 
were stained for Ki67 as a marker of proliferation (Section 2.3.3). A. Representative 
staining from a control and treated section. B. The number of positive Ki67 nuclei was 
calculated as a percentage of the total nuclei in the section. For each treatment, the whole 
gel was imaged and at least 5 fields of view from the centre of the gel were quantified. 
Quantification was analysed using by Kruskal-Wallis test with Dunn’s multiple comparison 
of three biological replicates. Scale bar = 50 µm. 
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Figure 4.13 Apoptosis is increased upon treatment with gemcitabine, ATRA and 
AZD4547 in combination 
All of the sections of the mini-organotypic co-cultures treated with combination therapies 
were stained for cleaved caspase 3 as a marker of apoptosis (Section 2.3.4). A. 
Representative staining from a control and treated section. B. The number of positive 
cleaved caspase 3 nuclei was calculated as a percentage of the total nuclei in the whole 
section. Quantification was analysed by Kruskal-Wallis test with Dunn’s multiple 
comparison of three biological replicates. Scale bar = 200 µm. 
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4.6 Combination treatments in vivo 
Building on the triple combination therapy data in 3D mini-organotypic models, this 
combination was tested in a mouse model. In vivo testing allowed examination of the 
effect of the three drugs in a more complex system, to investigate whether this may 
be a viable clinical approach. 
 
4.6.1 Pilot experiments 
Pilot experiments to determine the response to AZD4547 in vivo were performed 
using subcutaneous nude (nu/nu, Foxn1nu) mice models. Nude mice lack a thymus 
and, therefore, have no T cell immunity, making them useful for tumour xenograft 
experiments (Szadvari et al., 2016). MIA PaCa-2 cells were injected in mono- or co-
culture with PS1 cells, whilst another group of mice was injected with PS1 cells alone 
as a control. Three pilot experiments were carried out, with different cell numbers 
used to find the optimal tumour growth. Short experiments of 21 days post-injection 
were designed, to ensure that the human stellate cells were not replaced by murine 
stromal cells recruited to the tumours. 
 
Unfortunately, in the first two pilot experiments the tumours failed to grow significantly 
in any of the mice (Figures 4.14 and 4.15). In these two experiments five mice were 
included in each group, with three mice in the PS1-only control group. Cells were 
injected subcutaneously in PBS into each flank, therefore there were two tumours per 
mouse. There was no difference in tumour growth whether mice were injected with 
cancer cells alone or in combination with stellate cells. During the first experiment, 
mice were treated with 12.5 mg/kg AZD4547 or vehicle control by oral gavage from 
day 7 post injection. Due to the limited growth of all the tumours in the first experiment, 
mice were only planned to be randomised for treatment once their tumours reached 
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a minimum size of 100 mm3 in the second pilot experiment. As no tumours reached 
this size limit, no treatment was given. 
 
Following the failure of the first two pilot experiments, a third was performed. In this 
experiment, cells were injected in mono- or co-culture at two different cell densities 
(four mice in total). One flank was injected using cells re-suspended in PBS alone 
and the other with cells in PBS plus matrigel. Mice were weighed twice a week and 
any tumours were measured (using callipers) three times a week. Two mice in this 
experiment grew tumours (Figure 4.16). It appeared that the presence of stellate cells 
may have slowed tumour growth in these models. However, due to the limited number 
of mice included in the experiment, it is difficult to conclude anything definitive. At the 
end of the experiment, tumours were harvested and stained with H&E. This showed 
large necrotic areas within the tumours and presence of cells which could be identified 
as innate immune infiltrate (Figure 4.17). These findings support the notion that this 
model will not reach the tumour volume required within the experimental time frame. 
 
4.6.2 NSG mice 
These pilot in vivo experiments demonstrated that nude mice could not reliably 
establish MIA PaCa-2 xenograft tumours, especially within the 21 day optimal time 
frame. Therefore a collaboration was developed with Professor Yaohe Wang’s group 
based at Zhengzhou University in China. This group are currently using MIA PaCa-2 
based subcutaneous and orthotopic xenograft models in non-obese diabetic (NOD) 
severe combined immunodeficiency (scid) gamma (NSG, NOD.Cg-
Prkdcscid Il2rg tm1Wjl/SzJ) mice in their research. These mice were developed in the 
Jackson laboratory and lack T cells, B cells and natural killer cells. This makes them 
highly immunodeficient and they have many defects in innate immunity, increasing 
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the chance of successful engraftment of human cell lines (Ishikawa et al., 2005, 
Shultz et al., 2005). Other groups have also demonstrated that MIA PaCa-2 cells can 
be successfully grown orthotopically and subcutaneously in NSG mice, highlighting 
that this is a suitable model (Almawash et al., 2018, Lim et al., 2019, Pal et al., 2018, 
Shannon et al., 2015). Pilot experiments are ongoing in these mice, MIA PaCa-2 cells 
have been injected alone and in combination with PS1 cells and tumour growth is 
being monitored. If during this pilot experiment tumours have established within the 
21 day time frame in the mice, this model will be used to test the three drugs 
(gemcitabine, ATRA and AZD4547) in combination. 
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Figure 4.14 MIA PaCa-2 xenograft tumours in nude mice 
A. Nude mice were injected subcutaneously into each flank and tumours were left for 7 
days to form. Mice were then either treated with AZD4547 or control by oral gavage daily, 
following a 5 day on, 2 day off protocol. Mice were euthanised and tumours were harvested 
on day 21 (Section 2.9). B. 5 mice were injected with either 1 x 106 MIA PaCa-2 cells alone 
(group 1 and 2) or in co-culture with 2 x 106 PS1 cells (group 3 and 4). A control group of 
3 mice was injected with PS1 cells alone (group 5), which confirmed these cells do not 
form tumours. C. Tumours were measured three times a week from day 7 to day 21. There 
appeared to be initial tumour formation on day 7 in all the groups, although the MIA PaCa-
2 alone tumours (groups 1 and 2) were very small. As the experiment progressed, the 
tumours shrank in all the groups, irrespective of treatment or initial cells injected. At day 
21, any remaining tumours were very small, all below 10 mm
3
. 
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Figure 4.15 MIA PaCa-2 xenograft tumours do not grow in 21 days 
A. Nude mice were injected subcutaneously into each flank and tumours were left to form. 
Tumour size was measured three times a week from 7 days post injection and mice were 
either recruited to AZD4547 or control treatment groups once their tumours reached 100 
mm
3
. Mice were euthanised and tumours were harvested on day 21 (Section 2.9). B. 5 
mice were injected with either 5 x 10
6
 MIA PaCa-2 cells alone (group 1 and 2) or in co-
culture with 10 x 10
6
 PS1 cells (group 3 and 4). A control group of 3 mice was injected with 
PS1 cells alone (group 5), which confirmed these cells do not form tumours. C. Tumours 
were measured three times a week from day 7 to day 21. All of the growths measured 
during this time were even smaller than the first experiment, indicating that in all the 
conditions the tumours did not grow. No mice were treated with either AZD4547 or control 
as no tumours grew to the required size of 100 mm
3
.   
183 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Optimising MIA PaCa-2 subcutaneous xenograft tumour conditions in 
nude mice  
A. Nude mice were injected subcutaneously into each flank and tumours were left to form. 
One flank was injected with cells resuspended in PBS, and the other with cells 
resuspended in PBS + matrigel. Tumour size was measured three times a week from 7 
days post injection until mice were euthanised and tumours were harvested on day 47 
(Section 2.9). B. One mouse was injected with either 2 x 10
6
 or 4 x 10
6 
MIA PaCa-2 cells 
alone (group 1 and 2 respectively) or in co-culture with 4 x 10
6 
or 8 x 10
6
 PS1 cells (group 
3 and 4 respectively). C. Tumours were measured three times a week from day 7 to day 
47.Tumours grew in two of the mice (group 2 and 3) and these began to increase in 
volume from day 20. The group 2 mouse had tumours that reached a significant size by 
the end of the experiment, with no difference between cells injected in PBS or PBS + 
matrigel. The group 3 mouse demonstrated significant growth in the PBS tumour, 
compared to the PBS + matrigel tumour.  
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Figure 4.17 Necrotic MIA PaCa-2 subcutaneous xenograft tumours infiltrated with 
immune cells  
H&E image of injected co-culture tumour from the group 3 mouse. Much of the tumour is 
necrotic (enclosed in the white dashed line). In the zoomed-in section, infiltrating immune 
cells can be identified at the edge of the tumour tissue and within the necrotic regions 
(black arrows).  
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4.7 Discussion 
Nuclear FGFR1 (nFGFR1) has been found in myofibroblast cells at the invasive edge 
of PDAC tumours, compared to reduced nuclear localisation of the receptor within the 
centre of the tumour (Coleman et al., 2014b). This indicates that nFGFR1 may play a 
role in PDAC progression and invasion. Previous work has shown that treatment with 
FGFR inhibitors can reduce invasion in 3D models, supporting a role for FGF 
signalling in PDAC invasion (Coleman et al., 2014b). During this project, I used two 
different and distinct 3D in vitro co-culture models to investigate the effect of targeting 
FGF signalling. I also used a clinically relevant FGFR inhibitor AZD4547 (Gavine et 
al., 2012) to examine the effects on invasion in these models. Treatment with 
AZD4547 in the mini-organotypic model reduced invasion, at a dose which does not 
inhibit proliferation in 2D cultures, supporting data demonstrating the same effect 
when treating PDAC co-cultures with a laboratory tool compound FGFR inhibitor, 
PD173074, (Coleman et al., 2014b). This result was also confirmed when examining 
multi-directional invasion using a novel spheroid model. At the end of each invasive 
protrusion in the spheroid model, a stellate cell can be found leading the way. This 
supports previous work showing that pancreatic stellate cells can act to indirectly 
increase cancer cell proliferation and invasion (Liu et al., 2019). It has also been 
shown that stellate cells can be found within the metastatic niche of PDAC patients, 
suggesting that PSCs leave the tumour and travel to distant sites with the cancer 
cells. PSCs may be responsible for re-modelling tissue to form suitable metastatic 
sites (Apte and Wilson, 2012, Apte et al., 2013, Hwang et al., 2012, Thomas and 
Radhakrishnan, 2019, Vonlaufen et al., 2008a, Xu et al., 2010). 
 
To ensure that the reduction in invasion was due to FGFR1 within the stellate cell 
compartment specifically, inducible FGFR1 shRNA PS1 cell lines were used. In both 
3D models, PS1-specific knockdown of FGFR1 reproduced the reduction in invasion 
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seen with AZD4547 treatment. This confirms that FGFR1 signalling within PSCs plays 
a significant role in PDAC invasion, and is targeted effectively by AZD4547 treatment. 
 
AZD4547 is effective at reducing PSC-led invasion in PDAC models, however, to 
improve patient prognosis in the clinic this will need to be combined with other 
therapies. Co-targeting the cancer and stromal cells together in PDAC can lead to 
improved treatment outcomes (Carapuça et al., 2016). Based on this previous work 
using ATRA and gemcitabine in combination, AZD4547 was added to these 
regimens. This work confirmed that inhibiting stromal-cancer cross-talk with AZD4547 
caused the biggest effect on invasion. However, combining AZD4547 with ATRA 
(returning the stellate cells to a quiescent phenotype) and gemcitabine (to target the 
cancer cells) led to decreased cell number shown by cell layer thickness on top of the 
gel, indicating superior anti-tumour effects over either drug alone. There appeared to 
be no significant changes in the percentage of Ki67 or cleaved caspase 3 positive 
nuclei between the different treatment conditions. Whilst this could be due to the total 
number of cells surviving at the end of the treatment being reduced in the triple 
combination treatment and, therefore, there was no change in the relative percentage 
of proliferating cells, it may be due to inhibition of cross-talk rather than proliferation 
or apoptosis. It is plausible that the surviving cells may be resistant to gemcitabine 
treatment. These cultures were also only maintained for a short time (7 days), with 
one snapshot quantification at the end of the culture, in contrast to previous work with 
gemcitabine and ATRA treatments in large 3D organotypic models, which were 
performed in cultures maintained for up to 24 days (Carapuça et al., 2016). 
Furthermore dynamic quantification over time may give more reliable results. 
Subsequent in vivo testing of the triple combination will confirm if this is a viable 
therapeutic option for translation into patients in the clinic. 
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Chapter 5 Results III: Role of FGFR1 in 
pancreatic stellate cells 
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5.1 Introduction 
Nuclear FGFR1 has been shown to regulate cell growth and differentiation through 
altering gene expression in neuronal cells (Section 1.6) (Stachowiak et al., 2007, 
Stachowiak and Stachowiak, 2016). Previous studies in our laboratory also showed 
FGFR1 organising into nuclear speckles and co-localising with SC35 in PS1 cells 
(Coleman et al., 2014b). This suggests that nFGFR1 could act as a transcription 
factor or part of a transcription complex within pancreatic stellate cells. ChIP-seq is a 
recognised method to identify genes regulated by specific transcription factors 
(Johnson et al., 2007). This was adopted to determine nFGFR1 target genes, to 
examine how this novel signalling method may be influencing PDAC invasion and 
metastasis in patients. 
 
5.2 HaloTag 
One of the requirements for successful ChIP is to have a specific and sensitive 
antibody against the protein of interest (Kidder et al., 2011). Many commercial 
antibodies are not ChIP-grade. They must bind to the protein of interest with sufficient 
efficacy to pull down enough DNA to analyse, whilst also ensuring that there is no 
non-specific binding to proteins with a similar structure, which could compromise the 
validity of the results. Monoclonal or polyclonal antibodies can be used in ChIP, but 
either must be validated for the protein within the cells of interest (Landt et al., 2012). 
Monoclonal antibodies only recognise one specific epitope of the protein, which may 
not be available due to DNA binding and formaldehyde cross-linking. Polyclonal 
antibodies can be raised against a whole protein, making it more likely that there will 
be positive binding. However, there is a limited amount of antibody-containing serum 
that can be produced for each batch of polyclonal antibody. Each new batch must be 
re-validated to ensure it is suitable for the ChIP assay (Wardle and Tan, 2015). 
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Many FGFR1 antibodies are not ChIP-grade and, therefore, are not suitable to use in 
this assay. A possible way to overcome this problem is to use a tagged version of 
FGFR1. HaloTag technology was therefore explored to circumvent the need for a 
ChIP-grade antibody. 
 
HaloTag is a modified bacterial haloalkane dehalogenase. It is a useful tag to use in 
biological assays as it can bind covalently to synthetic ligands in a quick, specific and 
irreversible way. This means that expression can be tracked inside a cell using 
fluorescent ligands, such as TMR (Figure 5.1). Furthermore, Halo-ChIP can be 
performed, where HaloTag expressed in cells can bind to a chloroalkane linker on 
beads to allow effective pull-down for ChIP without the need for an antibody (Los et 
al., 2008). 
 
A construct of FGFR1 with C-terminally linked HaloTag (FGFR1-HT, Figure 2.4) was 
purchased in the pCK14 plasmid (FHC10532, Kazusa DNA Research Institute). This 
was then used to express a tagged version of FGFR1 in cells. 
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Figure 5.1 HaloTag binding to TMR 
The HaloTag protein binds to the fluorescent ligand TMR. This interaction is 
irreversible and allows HaloTag expression to be viewed by immunofluorescence 
or live imaging (Los et al., 2008, Marchesan and Prato, 2015)  
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5.2.1 Transient transfection 
HEK293T and PS1 cells were transiently transfected with the FGFR1-HT, and 
fluorescent TMR ligand was added to determine successful transfection (Figure 5.2). 
Wherever HaloTag is expressed, TMR will bind and can be detected by fluorescence 
imaging. 
 
HEK293T cells showed successful transfection of the FGFR1-HT construct, albeit 
with a low efficiency. PS1 cells showed an even lower level of successful transfection 
with the construct. Therefore, due to the low transfection efficiency and the large 
number of cells required for ChIP analysis, transient transfection would not give 
sufficient expression of FGFR1-HT for determination of the nuclear targets. This 
approach was, hence, abandoned. 
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Figure 5.2 Transient transfection of FGFR1-HT 
HEK293T and PS1 cells were transiently transfected with the FGFR1-HT 
construct (Section 2.5.1). Successful transfection was determined using the 
fluorescent TMR ligand, which covalently binds to HaloTag directly. HEK293T 
cells demonstrated a low level of positive transfection, whereas no transfection 
was seen in the PS1 cells. The nuclei in the cells were co-stained with DAPI. 
This is representative data from two biological repeats. Scale bar = 20 µm. 
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5.2.2 HaloTag cloning 
Due to the limited success of transient transfection, PS1 cells with stable inducible 
expression of FGFR1-HT were created to isolate a sufficient amount of chromatin to 
perform successful Halo-ChIP. Primers were designed to amplify the FGFR1-HT 
construct to use for cloning (Table 2.1). Two template plasmids were used for PCR 
amplification of FGFR1-HT and confirmation of amplification was demonstrated by a 
band at ~3,200 bp after agarose gel electrophoresis (Figure 5.3).  
 
The pCK14 plasmid gave a product the correct size (~3,200 bp). Plasmid template 
only, with no Phusion polymerase enzyme, and water only with no plasmid DNA were 
used as negative controls. The product from this PCR was used in gateway cloning 
to create a lentiviral plasmid (see method 2.6.2). During this protocol, clones 
expressing the construct were selected after the BP and LR clonase recombination 
reactions to use in further steps. Construct expression was determined after 
restriction digest with BsrG1, giving two bands on an agarose gel at ~1,500 bp (Figure 
5.4). 
 
After the BP recombination reaction, colony 4 was selected as it showed two bands 
at ~1,500 bp following restriction digest, indicating successful transformation with the 
FGFR1-HT construct. This was used in the LR recombination reaction. Successful 
cloning into the pinducer21 plasmid was confirmed in clone 4 and this was used to 
generate lentiviral particles (Figure 5.4). 
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Figure 5.3 Amplification of FGFR1-HT for cloning 
PCR was used to amplify the FGFR1-HT construct to use in gateway 
cloning. Successful PCR was confirmed by running the products on 
an agarose gel. The construct size was 3,258 bp, as seen in the last 
lane of the gel and this was performed once (Section 2.5.2).  
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Figure 5.4 Gateway cloning reactions 
During the gateway cloning protocols, bacterial clones harbouring the construct 
were selected following restriction digest of miniprep DNA with BsrG1 and 
identification of the FGFR1-HT construct on an agarose gel. BsrG1 cuts in the 
middle of the construct, giving two bands of around 1,500 bp. Clones were 
selected after BP (A) and LR (B) recombination reactions and then sequenced 
before creating lentivirus (this was performed once, Section 2.5.2 and 2.5.3). 
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5.2.3 Lentiviral production 
Following gateway cloning of the FGFR1-HT construct into a pinducer21 plasmid, 
lentiviral particles were made and PS1 cells were infected (see method 2.6.4). 
Expression of the construct within cells was confirmed by TMR staining following 
doxycycline (dox) treatment (Figure 5.5). Different concentrations of dox were added 
to the cells and lysates were taken to check for the expression of the HaloTag protein, 
as well as the overexpression of FGFR1. A non-doxycycline treated control was 
included as well as a non-infected PS1 sample as a negative control (Figure 5.6). 
 
These results showed that the PS1 cells transduced with the FGFR1-HT construct 
and positively selected based on green fluorescent protein (GFP) expression (PS1-
HT) could successfully express a tagged FGFR1 construct, induced by the addition 
of doxycycline. 
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Figure 5.5 Inducible FGFR1-HT expression 
Doxycycline (dox) induction of expression of the FGFR1-HT construct was used to 
check the efficiency of PS1 infection and the generation of the PS1-HT cells. PS1-HT 
cells were treated with doxycycline or control conditions, 48 hours later the TMR ligand 
was used to detect HaloTag expression. TMR ligand binding in red demonstrates 
successful integration and expression of HaloTag within these cells. This is 
representative data from three biological replicates. Scale bar = 20 µm. 
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Figure 5.6 Increasing FGFR1-HT expression with increasing concentrations of 
doxycycline  
PS1-HT cells were treated with increasing concentrations of doxycycline for 48 hours and 
FGFR1-HT expression was analysed by Western blot (A) and immunofluorescent staining 
(B) (Sections 2.3.3 and 2.4). FGFR1 expression was analysed by a long and short Western 
blot exposure to show both endogenous and exogenous protein. Increasing concentrations 
of doxycycline (dox) demonstrated increasing expression of FGFR1 and HaloTag. The 
levels of p-ERK in doxycycline treated cells did not increase with increasing dox 
concentrations, suggesting that overexpression of FGFR1 was not causing ligand-
independent activation of the receptor and downstream signalling pathways. This is data 
from one biological replicate. Scale bar = 20 µm 
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5.2.4 PS1-HT validation 
To ensure that the newly generated PS1-HT cells still behaved as a typical stellate 
cell, immunofluorescence staining for the four stellate cell markers (GFAP, α-SMA, 
desmin and vimentin) was performed (Figure 5.7). The PS1-HT cells expressed all 
four of the stellate cell markers. To further confirm that these cells were behaving as 
PSCs, they were treated daily with ATRA or ethanol vehicle control. After fixing the 
cells, Oil Red O staining identified the formation of lipid droplets following the ATRA 
treatment (Figure 5.7). 
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Figure 5.7 PSC characterisation of PS1-HT cells 
A. PS1-HT cells grown on coverslips were fixed and stained for four different stellate cell 
markers: vimentin, GFAP, α-SMA and desmin (Section 2.3.1). The pictures show positive 
staining for all the markers, with an unstained negative control. Scale bar = 20 µm. B. 
PS1-HT cells grown on coverslips were treated daily with either ATRA or ethanol vehicle 
control. The cells were fixed and stained for lipid droplets using Oil Red O (Section 2.3.2). 
The ATRA treated cells showed a greater number of lipid droplets than the untreated 
controls (shown by the arrows). These slides were counter-stained with haematoxylin. 
These images are representative of at least three technical replicates. Scale bar = 10 µm. 
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5.2.5 PS1-HT signalling 
To use the dox-inducible PS1-HT cells for Halo-ChIP, I needed to confirm that the 
exogenous FGFR1-HT construct still behaved and signalled in the same way as 
endogenous FGFR1. 
 
FGFR1-HT within PS1-HT cells was labelled and tracked using live imaging of TMR 
ligand on the spinning disk confocal microscope (Figure 5.8). The TMR ligand can be 
used to accurately follow the FGFR1-HT construct in live PS1 cells. The staining 
showed that the construct appeared to be localised in vesicles in the cytoplasm, 
without reaching the plasma membrane or the nucleus. 
 
PS1 cells were treated with FGF2 and immunofluorescence was used to observe the 
co-localisation of FGFR1 and HaloTag within the cells. When FGFR1-HT expression 
was induced in the PS1 cells with doxycycline, the presence of the construct was 
seen by TMR binding. However, the majority of the tagged protein was located in the 
peri-nuclear region, rather than at the membrane or within the nucleus. Stimulation of 
the cells with FGF2 did not affect the localisation of FGFR1-HT, or increase p-ERK 
levels above those seen in endogenous FGFR1 expressing cells, indicating that this 
construct may not be able to signal effectively (Figure 5.9).  
 
The results demonstrated that FGFR1-HT did not show significant localisation to the 
plasma membrane or the nucleus, and stimulation with FGF2 did not increase 
signalling within the cells treated with doxycycline, despite expressing FGFR1 at a 
much higher level. Therefore, I decided to change from using Halo-ChIP with the PS1-
HT cells and focus on performing ChIP-seq with a recently ChIP-validated anti-
FGFR1 antibody instead (Baron et al., 2012, Terranova et al., 2015). 
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Figure 5.8 Live tracking of FGFR1-HT expression 
TMR binding to HaloTag was used to track expression of the FGFR1-HT construct 
using live imaging of PS1-HT cells. This image taken from the live video shows that 
FGFR1-HT can be found in vesicles within the stellate cells, however there was no clear 
staining at the plasma membrane or in the nucleus of the cells. This is representative 
data from two biological replicates. Scale bar = 20 µm. 
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Figure 5.9 Functionality of FGFR1-HT construct 
To determine whether FGFR1-HT was signalling and trafficking within the stellate cells 
as expected, expression was induced and FGF2 stimulation was performed, compared 
to relevant controls (Section 2.1.3). A. Upon doxycycline induction, FGFR1-HT was 
overexpressed and the HaloTag could be detected. However, there was no significant 
increase in p-ERK signalling upon 100 ng/ml FGF2 stimulation for 15 minutes in the 
cells overexpressing the receptor. B. TMR ligand binding confirmed HaloTag co-
localisation with FGFR1 in cells treated with doxycycline. However, this was not 
detected in the nuclei of the cells, even when stimulated with 100 ng/ml FGF2 for 15 
minutes. This is data from one biological replicate. Scale bar = 20 µm. 
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5.3 Nuclear FGFR1 
5.3.1 Introduction 
Chromatin immunoprecipitation is a method that can be used to determine where 
specific proteins are interacting with the DNA or to detect epigenetic regulation of 
gene expression. This method was originally used to look at protein-DNA interaction 
in bacteria in the 1980s (Gilmour and Lis, 1984), before moving on to Drosophila 
(Gilmour et al., 1986) and subsequently histone acetylation in chicken nuclei (Hebbes 
et al., 1988, Solomon et al., 1988). ChIP has now been used to study chromatin 
remodelling and gene expression in many different cell types. 
 
The role of nuclear FGFR1 has been studied using ChIP in neuronal cells 
(Stachowiak and Stachowiak, 2016), showing that nFGFR1 regulates a 
transcriptional programme triggering neuronal cell differentiation and migration. This 
not only supports the possible role of nFGFR1 in transcriptional regulation but also 
provides validation for using the ChIP-grade ab10646 FGFR1 antibody in ChIP-seq 
experiments. 
 
5.3.2 ChIP method optimisation 
A key challenge in successful ChIP is efficient chromatin harvesting and processing, 
and the most effective method must be validated for each different cell type. There 
are two methods for isolating chromatin: cross-linked ChIP (XChIP) or native ChIP 
(NChIP) (Table 5.1) (Carey et al., 2009, O’Neill and Turner, 2003, Orlando, 2000). In 
X-ChIP, formaldehyde is usually used to fix the chromatin. A nucleophilic group on an 
amino acid or DNA forms a covalent bond with formaldehyde, giving a methylol 
adduct that can be converted to a Schiff base. This is then stabilised by bonding with 
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another functional group to form a methylene bridge, which is achieved when 
quenching with glycine in ChIP assays, or by bonding with another macromolecule 
that is in close proximity. Due to the small size of formaldehyde, it will form bonds 
between groups that are ~2Ã apart making it useful to study molecules that are 
interacting. Formaldehyde is most reactive against available lysine residues (which 
are common mediators of interactions with DNA) and deoxyguanosine. Reversal of 
cross-links is usually performed by heating the sample (Hoffman et al., 2015). Given 
that FGFR1 is a potential transcription factor, XChIP was used to allow random 
shearing of DNA during sonication, rather than the digestion of linker DNA by 
micrococcal nucleases in NChIP, reducing bias in the results.  
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Table 5.1 Methods of chromatin isolation 
 Cross-linked (XChIP) Native ChIP (NChIP) 
Process 
Cells are fixed with 
formaldehyde, which cross-
links protein to the DNA. The 
DNA is sheared by sonication 
into small random fragments. 
The chromatin must be kept 
cool throughout the process of 
sonication to prevent protein 
denaturation 
DNA is sheared using 
micrococcal nuclease 
digestion of the linker DNA 
around nucleosomes. This will 
give defined small fragments 
Useful for 
Examining where proteins bind 
to DNA 
Histone modification and 
epigenetic gene regulation 
Advantage 
Less bias, as the 
fragmentation is random 
during sonication 
Can be used for proteins that 
may be disrupted by the fixing 
with formaldehyde 
Disadvantage 
Optimise fixing and sonication 
for each cell line. Must 
determine that the fragment 
sizes are correct following 
sonication (100-1,000 bp), 
which takes more time 
Results may be biased, as the 
enzymes will cut the DNA at 
specific locations on the 
genome 
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Three different methods of chromatin isolation were tested. The first was based on 
an Active Motif kit that was being used by another group within our institute, the 
second was a Millipore kit that had been used by a previous PhD student and the 
third was a protocol from another group currently performing ChIP. For each protocol, 
the time of formaldehyde fixation and the number of sonication cycles needed to be 
optimised. 
 
5.3.3 Chromatin isolation 
For successful ChIP-seq, a large amount of chromatin is required. Therefore these 
experiments were begun using 20 million cells per condition. PS1 cell fixation was 
optimal using formaldehyde for 5 minutes at room temperature, followed by sonication 
at 20 cycles in the bioruptor sonicator or 10 cycles in the bioruptor pico sonicator, 30 
seconds ON and 30 seconds OFF (Figures 5.10 and 5.11). If the sonication was not 
optimal for a sample, it was re-sonicated for 5 more cycles (Figure 5.12). Once 
sufficient fragmentation of each sample was achieved, the samples were 
immunoprecipitated using the FGFR1 ChIP-validated antibody and then DNA was 
extracted. Qubit was used to quantity the DNA (Table 5.2) and samples were sent to 
Oxford Genomics for library preparation and sequencing. 
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Figure 5.10 PS1 chromatin isolation and sonication optimisation 
Chromatin isolation and sonication (Son) was optimised using two different 
sonicators. The acceptable range of fragments is 100-500 bp, with 100-300 bp 
being optimal. The first Bioruptor sonicator demonstrated 20 cycles of 30 
seconds ON, 30 seconds OFF as the most efficient conditions, shown by a 
bright tight band of fragmented chromatin in the desired range (A). When using 
the Bioruptor pico sonicator, 10 cycles was used as a standard initial sonication, 
giving fragments in the desired range for shRNA1 samples tested (B). 
Unsonicated chromatin for each sample was included as a control. This data is 
representative of one biological replicate. 
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Figure 5.11 ChIP-seq chromatin sonication quality check 
Chromatin shearing following sonication (Son) from samples processed for ChIP-seq, 
AZD4547 (AZD), vehicle (Veh) or shRNA cells, from two different biological replicates 
(shown in A and B). The sonication was not optimal for the shRNA1, shRNA2 and 
shRNA3 cells in repeat 2 (B), therefore these samples were sonicated for another five 
cycles (Figure 5.12). Unsonicated chromatin for each sample was included as a 
control. 
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Figure 5.12 ChIP-seq chromatin sonication quality check (15 cycles) 
Chromatin shearing following sonication (Son) from samples from the second biological 
replicate processed for a further 5 cycles (Figure 5.11). Chromatin fragmentation was 
now producing brighter bands at the required size and therefore these samples were 
processed for ChIP-seq. Unsonicated chromatin for each sample was included as a 
control. 
 
211 
 
Table 5.2 Qubit DNA concentrations of ChIP-seq samples 
Sample DNA concentration (ng/µl) 
AZD rep 1 0.124 
Vehicle rep 1 too low 
shRNA1 + dox rep 1 0.644 
shRNA1 - dox rep 1 0.492 
shRNA2 + dox rep 1 0.248 
shRNA2 - dox rep 1 0.35 
shRNA3 + dox rep 1 0.416 
shRNA3 - dox rep 1 0.654 
AZD rep 2 0.296 
Vehicle rep 2 too low 
shRNA1 + dox rep 2 0.752 
shRNA1 - dox rep 2 0.406 
shRNA2 + dox rep 2 0.834 
shRNA2 - dox rep 2 0.382 
shRNA3 + dox rep 2 3.32 
shRNA3 – dox rep 2 0.306 
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5.3.4 ChIP-seq analysis 
Results from the ChIP-seq experiments were analysed bioinformatically in 
collaboration with two post-doctoral researchers within the Institute, Dr Firat Uyulur 
and Dr James Heward. The raw sequences were aligned to the human genome 
(hs37d5), the reads were mapped and peaks were called using the MACS2 
programme (Tables 5.3 and 5.4). The peaks were called against a relevant input 
control sample, where no enrichment using the FGFR1 antibody was performed. 
Differential peaks were analysed using the diffBind tool (Section 2.7). After looking at 
the peak enrichment and following data from the 3D models, shRNA1 was eliminated 
from the analysis due to very limited peaks and no statistically significant reduction in 
invasion with these cells (Figure 4.8). 
 
Firstly, the number of enriched peaks in the two vehicle samples was analysed to 
select the most reliable peaks relating to FGFR1 binding (Figure 5.13). Known 
blacklist regions, such as satellite regions, were removed from the data, giving 143 
common peaks between the two samples. These peaks were also related to the 
control shRNA samples. Most of the samples overlapped with the vehicle peaks, apart 
from shRNA3 – dox repeat 2. This could be due to the wide difference in the number 
of peaks called between the samples (Table 5.4). 
 
Comparison of the enriched peaks in the control samples with either the relevant 
drug-treated or FGFR1 knockdown samples was then performed. Heat maps (Figure 
5.14) show that comparing the 143 vehicle overlap peaks with shRNA2 – dox samples 
indicates many overlapping regions surrounding transcription start sites. However, if 
these 143 peaks are compared to shRNA2 + dox, where FGFR1 has been knocked 
down, there are fewer overlapping regions shown by the lighter heat map colours. 
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This looks similar but slightly less striking if all the peaks found in vehicle repeat 2 are 
compared to the two shRNA2 samples. There was a stronger correlation in the 
overlapped vehicle samples compared to the peaks enriched in vehicle repeat 2, 
suggesting many of these peaks may be background noise. 
 
Peaks enriched in control samples, compared to the relevant knockdown or treatment 
sample, were also compared. Overlapping enriched peaks from both shRNA2 and 
shRNA3, with or without doxycycline treatment, were combined with enriched peaks 
in vehicle samples, compared to relevant AZD4547 treated samples. This combined 
list of enriched peaks was then analysed using STRING to discover any networks of 
pathways that may be changing upon FGFR1 binding to DNA. Some networks 
emerged from this analysis (Figure 5.15) and interesting pathways, such as Hippo 
signalling, appeared to be changing between conditions (Table 5.5). These results 
will need to be put into context regarding relevant interactions and pathways related 
to the phenotype seen with FGFR inhibition or knockdown. Further analysis is 
ongoing and peaks will be validated by ChIP-PCR with FGFR1 and relevant IgG 
control antibodies. Hits will also be confirmed by phenotypic assays, such as the 
siRNA-mediated knockdown in the spheroid assay (Appendix 3.1 and Section 2.6.2) 
or changes in gene expression of targets in PSCs upon FGFR1 inhibition or 
knockdown (Section 2.5.5). 
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Table 5.3 Number of mapped reads 
Sample 
Number of uniquely 
mapped reads 
Vehicle input 64 million 
AZD rep 1 49 million 
AZD rep 2 46 million 
Vehicle rep 1 20 million 
Vehicle rep 2 29 million 
shRNA input 78 million 
shRNA1 + dox rep 1 46 million 
shRNA1 - dox rep 1 60 million 
shRNA1 + dox rep 2 56 million 
shRNA1 - dox rep 2 52 million 
shRNA2 + dox rep 1 64 million 
shRNA2 - dox rep 1 40 million 
shRNA2 + dox rep 2 43 million 
shRNA2 - dox rep 2 15 million 
shRNA3 + dox rep 1 55 million 
shRNA3 - dox rep 1 18 million 
shRNA3 + dox rep 2 47 million 
shRNA3 - dox rep 2 49 million 
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Table 5.4 Number of peaks called 
Sample 
Number of peaks called 
(q<0.01) 
Vehicle input 39 
AZD rep 1 398 
AZD rep 2 143 
Vehicle rep 1 1640 
Vehicle rep 2 112 
shRNA input 51 
shRNA1 + dox rep 1 29 
shRNA1 - dox rep 1 98 
shRNA1 + dox rep 2 91 
shRNA1 - dox rep 2 14025 
shRNA2 + dox rep 1 1763 
shRNA2 - dox rep 1 8741 
shRNA2 + dox rep 2 9 
shRNA2 - dox rep 2 68593 
shRNA3 + dox rep 1 2048 
shRNA3 - dox rep 1 29 
shRNA3 + dox rep 2 39 
shRNA3 - dox rep 2 398 
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Figure 5.13 Overlap of enriched peaks between control samples 
The enriched peaks in the two biological replicates of the vehicle control samples were 
compared and had 231 peaks overlapping (A). Following this, known blacklist regions 
were removed, such as satellite regions, leaving 143 common peaks. These were then 
compared to the enriched peaks in both biological replicates from the shRNA2 (B) and 
shRNA3 (C) control samples. Most of the samples had a good overlap of peaks, apart 
from shRNA3 repeat 2 (shRNA3_2-dox). 
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Figure 5.14 Peaks enriched in control samples are consistent 
Heat maps showing the correlation between peaks present in the combined vehicle (A) 
and vehicle repeat 2 (B) samples with shRNA2 samples. The left heat map in each set 
is the shRNA2 control sample, showing a high correlation of peaks in these expected 
regions, compared to the FGFR1 knockdown sample on the right.  
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Figure 5.15 Networks of enriched peaks 
STRING was used to examine any networks significantly enriched within the 
peaks from both the shRNA and AZD4547 treated samples in both biological 
replicates. Many hits were not linked, however a few networks did begin to 
emerge from this analysis, such as ubiquitination, proteasome and Hippo 
signalling pathways (Table 5.5). 
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Table 5.5 Enriched pathways in combined peaks from FGFR inhibitor and 
FGFR1 knockdown samples 
Enriched pathways 
Hippo signalling pathway 
E3:Ub:substrate 
Biochemical Reaction: Transfer of Ub from E2 to substrate 
and release of E2 
Biochemical Reaction: Polyubiquitination of substrate 
Catalysis 
Complex: Ag-substrate:E3:E2:Ub 
Antigen processing: Ubiquitination & Proteasome 
degradation 
Control 
Complex Assembly 
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5.3.5 Future ChIP-seq analysis 
The hits identified from the ChIP-seq analysis need to be validated. Firstly, FGFR1 
binding to these regions will be confirmed using ChIP-PCR. Functional validation of 
the top hits and pathways will then be performed using an siRNA-mediated 
knockdown screen in the co-culture in vitro spheroid model (Section 2.7.2). 
 
5.4 PSC FGF signalling flux 
To show FGFR1 moving between the sub-cellular compartments within the stellate 
cells, mass spectrometry was performed. Given that it is difficult to get enough protein 
from different sub-cellular compartments of stellate cells to analyse on Western blot, 
as well as inconsistent specificity of antibodies, mass spectrometry can offer a more 
sensitive approach (Aebersold and Mann, 2003, Diamandis, 2004, Ghaemmaghami 
et al., 2003). Additionally, mass spectrometry allowed me to analyse all of the different 
peptides changing within the stellate cells following FGFR inhibition, giving an 
indication of the role of nFGFR1 and FGFR signalling in general. 
 
5.4.1 Sub-cellular fractionation 
Two experimental approaches were tested. Stellate cells were either treated with 
AZD4547 compared to vehicle control or serum-starved overnight and then 
stimulated for 15 minutes with FGF2 compared to unstimulated control. The cells 
were then harvested and fractionated into four different sub-cellular fractions 
(nucleus, cytoplasm, intracellular organelles and plasma membrane). Each fraction 
was prepared for mass spectrometry and labelled with a different Tandem Mass Tag 
(TMT) (Section 2.8). 
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TMT isobaric mass tags methodology was first described in 2003 (Thompson et al., 
2003). Work then progressed to increase the number of labels that could be used 
within a single experiment. A 6-plex of mass tags was used to analyse protein 
mixtures within human cerebrospinal fluid samples, validating the method for 
quantitative proteomic studies (Dayon et al., 2008). These tags have four regions, a 
mass reporter region (M), a cleavable linker (F), a mass normalisation region (N) and 
a protein reactive group (R). The structures of the TMT reagents are the same but 
they contain different combinations of 13C and 15N isotopes in the mass reporter and 
balancer group to give different isobaric mass tags. This creates a specific reporter 
ion at m/z 126, 127, 128, 129, 130 and 131 (Figure 5.16). These can be detected 
during analysis to assign peptides to specific groups within a single experiment 
(Rauniyar and Yates, 2014). 
 
The samples were run to compare peptide localisation between the conditions, 
compared to a whole cell lysate of the relevant condition and basal PS1 control 
sample, which was the same across the four conditions (Section 2.8). The results 
were run and analysed by Dr Faraz Mardakheh (Barts Cancer Institute). Following 
analysis, the efficiency of the fractionation was confirmed (Figure 5.17). Sub-cellular 
fractionation appeared specific, with histone peptides enriched in the nuclear fraction 
and tetraspanin peptides enriched in the plasma membrane fraction (Figure 5.17). 
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Figure 5.16 Chemical structure of TMT sixplex reagents 
TMT tags are isobaric with a different distribution of isotopes between the reporter and 
balance groups. Blue asterisks show the positions of 
13
C and 
15
N isotopes to create the 
six different tags: 126, 127, 128, 129, 130 and 131 (Rauniyar and Yates, 2014). 
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Figure 5.17 Efficient sub-cellular fractionation of PSCs 
The efficiency of sub-cellular fraction of the samples was confirmed by looking for the 
location of control peptides. Histone peptides were enriched in the nuclear fraction 
compared to other sub-cellular compartments, such as the plasma membrane (A), 
whereas tetraspanin membrane-bound peptides were enriched in the plasma membrane 
fraction, compared to other sub-cellular compartments, such as the nucleus (B), as 
expected. This data is from one biological replicate. 
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5.4.2 FGFR1 localisation 
Unfortunately, following the mass spectrometry analysis, only one peptide of FGFR1 
was detected in the vehicle control sample. No FGFR1 peptides were detected in the 
AZD4547, unstimulated or stimulated samples. This could be due to the abundance 
of the peptides within the sample. Within the field, there is some controversy over 
whether the detection level for mass spectrometry is better in label-free or labelled 
methods, although quantitation of peptides is more reliable in labelled methods (Li et 
al., 2012, Megger et al., 2014, Patel et al., 2009). The detection level can drop as the 
number of multiplexed labels is increased. However, a study comparing sixplex and 
duplex TMT labelling showed that both methods had unique peptides identified from 
the same original sample (Rauniyar et al., 2013). This highlights the fact that the 
labelling efficiency and analysis can vary from experiment to experiment, making it 
harder to reliably identify low abundance peptides. Moreover, these peptides are 
more likely to be lost due to noise generated in the reporter ion region and from 
partially modified peptides (Beer et al., 2017a). Even though FGFR1 could not be 
detected, there was a significant change in total peptide levels and peptide flux upon 
AZD4547 treatment, which could highlight key mechanisms of invasion related to 
FGFR signalling in stellate cells. 
 
5.4.3 Total peptide changes 
Following analysis of the whole cell lysate samples from each condition, there were 
no significant changes between the unstimulated and stimulated samples (Figure 
5.18). This could be due to the quick timeframe of stimulation before harvesting (only 
15 minutes), therefore these samples were discarded from the analysis. Additionally, 
it has been shown that stimulation with high concentrations of FGF2 (100 ng/ml) can 
lead to ineffective phosphorylation of FRS2 and only transient activation of 
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downstream signalling pathways, which could explain the low number of changes 
between these two samples (Zhu et al., 2010). Excitingly however, there were 
pathways identified that significantly increased or decreased upon 24 hours of 
AZD4547 treatment (Table 5.6). The most significant peptide changes were 
determined using a cut-off value of two log2fold change between the conditions 
(Figure 5.19). The most significantly altered peptides were also analysed using 
STRING to form networks (Figure 5.20). These data highlighted some key peptides 
involved in cell migration and motility or FGF signalling regulation being altered upon 
AZD4547 treatment. We are currently validating three hits in the laboratory; 
MARCKSL1, FHOD1 and GPX1. 
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Figure 5.18 Expression of peptides in FGF2 stimulated samples 
The expression of peptides between PSCs stimulated with FGF2 was 
correlated with the control unstimulated sample (Sections 2.1.3 and 
2.8). This shows that stimulation with 100 ng/ml FGF2 for 15 minutes 
was not long enough to see significant proteomic changes. This data 
is from one biological replicate. 
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Table 5.6 Enriched pathways in whole cell lysate mass spectrometry data 
Enriched pathways N: Peptides N: Score p value 
Increased in AZD treated cells 
Cellular macromolecular 
complex subunit 
organization 
277 0.183377 3.62E-07 
Translational termination 77 0.275821 3.35E-05 
Viral transcription 76 0.269749 5.54E-05 
Translational elongation 83 0.256801 6.15E-05 
Protein targeting to ER 99 0.233161 7.35E-05 
Ribosome 77 0.250964 0.00016 
Nucleus 1098 0.077686 0.000174 
Reduced in AZD treated cells 
Leucine-rich repeat 34 -0.36857 0.000211 
Membrane 1375 -0.0719 0.000232 
Mitochondrion 505 -0.12825 3.40E-06 
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Figure 5.19 Peptides most significantly altered upon AZD4547 treatment 
The waterfall plot shows the peptides that were most significantly decreased (red) or increased (green) upon treatment with AZD4547 
(one biological replicate, Section 2.8). A cut off value of two log2fold change was used to highlight the most significant peptides. Many of 
the downregulated peptides are involved in cell migration and motility and many of the increased peptides are involved in transcriptional 
repression.  
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Figure 5.20 Networks of significantly changed total peptides 
STRING was used to examine any networks significantly changed in the whole cell lysate 
between AZD4547 treated PSCs and control. The significant hits (greater than two 
log2foldchange) were enriched into 8 categories, with red nodes being the mainly 
unconnected peptides (Table 5.6). Data is from one biological replicate. 
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5.4.4 Nuclear changes 
The sub-cellular fractionation analysis identified peptides moving between cellular 
compartments upon AZD4547 treatment. For the analysis, all the hits that were 
significantly changed within the nuclear compartment between the two conditions 
were examined. The most significantly changed pathways are listed in Table 5.7. The 
most increased or decreased 20 peptides within the nuclear compartment (Figure 
5.21) were then investigated. Within these hits, there were many peptides involved in 
transcriptional epi-genetic regulation. Network analysis was performed using the 
significantly changed nuclear peptides (Figure 5.22).  One of the interesting top 
nuclear hits was c-MET, which was present in all fractions but enriched in the nuclear 
fraction in the control cells, and this nuclear enrichment decreased significantly upon 
AZD4547 treatment (Figure 5.23). 
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Table 5.7 Enriched pathways in nuclear fraction of mass spectrometry data 
Enriched pathways 
Spliceosome 
Transcriptional misregulation in cancer 
Intron Large Complex 
RNA Polymerase II Pre-transcription Events 
Hepatocellular carcinoma 
Thermogenesis 
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 Figure 5.21 Peptides most significantly altered in the nuclear fraction upon AZD4547 treatment 
The waterfall plot shows the peptides that were most significantly decreased (red) or increased (green) within the nuclear fraction upon treatment 
with AZD4547 (one biological replicate, Section 2.8). The top 20 peptides in each direction were included to highlight the most significant peptides.  
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Figure 5.22 Networks of significantly changed nuclear peptides 
STRING was used to examine any networks changed in the nuclear fraction between 
AZD4547 treated PSCs and control. The top 20 increased or decreased hits were 
enriched into 8 categories (Table 5.7). Data is from one biological replicate. 
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Figure 5.23 c-MET enrichment in the nucleus of PSCs is lost upon AZD4547 
treatment 
Analysis of the sub-cellular location of peptides detected by mass spectrometry 
indicated that c-MET is enriched in the nuclear fraction of control PS1 cells (A). 
However, when these cells are treated with the FGFR inhibitor, AZD4547, c-MET is 
decreased in the nuclear fraction (B). Data is from one biological replicate. 
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5.5 Discussion 
Nuclear FGFR1 can be found in PSCs in nuclear speckles and co-localising with the 
splicing factor sc35 (Coleman et al., 2014b). These data, as well as previous findings 
in other cells, suggests that nFGFR1 can bind to DNA either directly or as part of a 
complex to trigger transcriptional changes. The novel role of nuclear FGFR1 within 
pancreatic stellate cells was investigated using chromatin immunoprecipitation. 
 
A tagged version of FGFR1 was created using the HaloTag technology (Los et al., 
2008). PS1 cells that had inducible expression of an FGFR1-HT construct were 
successfully created and overexpression of FGFR1-HT upon doxycycline treatment 
was confirmed. Using HaloTag allows the construct to be followed using the 
fluorescent TMR ligand, which is particularly useful in live imaging. Additionally, 
covalent binding of HaloTag to beads means that ChIP can be performed without the 
need for an antibody (HaloChIP). This would have been a significant advantage as 
many FGFR1 antibodies are not specific or sensitive enough for ChIP-seq analysis 
(Kidder et al., 2011). However, upon validation of the PS1-HT cells, it became 
apparent that even though the FGFR1-HT construct could be expressed inducibly, it 
could not translocate correctly between the sub-cellular compartments or signal 
effectively. Therefore, this was not suitable for use in ChIP-seq experiments. 
 
Instead of using Halo-ChIP, an FGFR1 anitbody that has been used recently for ChIP-
seq in neuronal cells was selected to perform this analysis (Stachowiak and 
Stachowiak, 2016). After optimisation, succesful ChIP-seq was performed on PS1 
cells treated with either AZD4547 or subjected to shRNA-mediated FGFR1 
knockdown, compared to relevant controls. Initial analysis of the sequencing data 
demonstrated enrichment of peaks indicating regions where FGFR1 is interacting 
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either directly or indirectly with DNA in these cells. Peaks overlapped between all the 
control conditions provide the most reliable peaks to validate. STRING analysis 
comparing the most significantly enriched peaks between all the conditions gave 
Hippo signalling and ubiquitination as key pathways mediated by nuclear FGFR1. 
These will warrant further validation and investigation, especially a potential novel 
cross-talk mechanism between FGF and Hippo signalling pathways. Interaction 
between the FGF and Hippo pathways has been previously reported in cancer. For 
example, in cholangiocarcinoma nuclear YAP can enter into an autocrine signalling 
loop with FGFR2/FGF5 (Rizvi et al., 2016). In bladder cancer, mutant FGFR3 has 
been shown to increase TAZ levels and in HER2 positive breast cancer, FGFR4 has 
been correlated with increased YAP activity (di Martino et al., 2019, Turunen et al., 
2019). Furthermore in colorectal cancer, YAP1 has been identified as a downstream 
target of FGF8 (Liu et al., 2015). Another pathway that will be interesting to investigate 
is the TGF-β signalling pathway as SMAD3 was a central node for the network 
analysis in STRING (Figure 5.15) 
 
In tandem, sub-cellular mass spectrometry analysis was performed on PS1 cells to 
observe the changes in localisation of FGFR1 within these cells. PSCs treated with 
AZD4547 or stimulated with FGF2 to either reduce or increase FGFR1 nuclear 
translocation respectively, were compared to relevant controls. Although FGFR1 
peptides could not be detected reliably in all of the conditions, there were significant 
changes in both total and sub-cellular peptides in PS1 cells upon FGFR inhibition with 
AZD4547. Some of the key peptides decreased upon AZD4547 treatment in the 
whole cell lysate fraction are now being validated (MARCKSL1, FHOD1 and GPX1), 
as well as the change in nuclear localisation of c-MET and epi-genetic regulators upon 
FGFR inhibition. This was a pilot experiment that will need to be optimised and 
repeated in the future. STRING analyses may be useful to identify networks of 
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proteins that are changing in response to FGFR inhibition in PSCs over multiple 
conditions and repeats. These results will help to deconstruct the downstream effects 
of nuclear translocation of FGFR1 within stellate cells, providing incerased 
understanding of this novel mechanism of invasion in PDAC.  
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Chapter 6: Final Discussion 
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6.1 Introduction 
Currently, PDAC is a cancer of high unmet clinical need. Understanding the biology 
of PDAC’s characteristic desmoplastic stroma represents a critical challenge in 
potentially improving patient outcomes (Sections 1.3 and 1.4). Recent research has 
demonstrated that activated PSCs are vital for the construction of the dense 
desmoplastic stroma, as well as tumour progression and invasion, making these cells 
an attractive therapeutic target. FGF signalling has been identified as a key pathway 
involved in cross-talk between cancer and stellate cells within the desmoplastic 
stroma of PDAC tumours (Kang et al., 2019b, Rhim and Stanger, 2010). 
 
Due to the importance of FGF signalling in PDAC development, we previously 
investigated the role of FGF ligands and receptors in both cancer cells and activated 
stellate cells. This highlighted that nuclear translocation of FGFR1 occurs within 
activated PSCs at the invasive edge of PDAC tumours (Section 1.6.3) (Coleman et 
al., 2014b). Nuclear FGFR1 in PSCs was co-localised with FGF2 and nuclear 
translocation increased upon FGF2 stimulation. In the novel 3D in vitro organotypic 
models, nuclear translocation of FGFR1 was reduced upon FGFR inhibition with 
PD173074, leading to decreased invasion. Thus I started exploring the importance of 
FGF-mediated cross-talk between the tumour and stroma in PDAC invasion in further 
detail. 
 
The aims of my project were to investigate the specificity of targeting FGFR1 in PSCs 
to disrupt cellular cross-talk, to identify the mechanisms of FGFR1-mediated changes 
in PSCs and to explore the utility of FGFR1 targeting to improve current and 
developing PDAC therapies. I will now put into context my findings in relation to the 
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explicit aim and the current literature, including clinical trials, in each of the following 
Sections (6.2, 6.3 and 6.4). 
 
6.2 Targeting FGFR1 in PSCs 
6.2.1 FGF signalling mediates PDAC invasion 
During this project, the previous findings targeting FGF signalling within PSCs were 
translated into a clinically relevant model. Two novel 3D in vitro co-culture models 
were used, mini-organotypics and spheroids (Section 2.6), to demonstrate that 
stellate cell-led invasion is decreased upon treatment with the clinically relevant drug, 
AZD4547 (Figures 4.2, 4.3 and 4.4). These two models can be used to interrogate 
invasive phenotypes at both the single cell and multi-cellular level. 
 
6.2.1.1 FGFR inhibition  
Recent activity has resulted in development of many FGFR inhibitors (Section 1.5.7) 
(Table 6.1). AZD4547 was selected since it has specificity against FGFR1-3 (Table 
6.2) (Gavine et al., 2012). Furthermore, AZD4547 is currently in clinical trials in 
patients with gastric, lung, breast and bladder cancers (NCT00979134, 
NCT01202591, NCT01213160, NCT01457846, NCT01791985, NCT01795768, 
NCT01824901, NCT02117167, NCT02154490, NCT02299999, NCT02465060, 
NCT02546661, NCT02664935, NCT02824133 and NCT02965378). The breadth of 
these clinical trials underscore the clinical relevance of AZD4547 and suggest that it 
could be adopted to interrupt cellular cross-talk in PDAC patients. Furthermore, it has 
been shown that AZD4547 treatment can reduce the proliferation and invasion of 
primary fibroblasts isolated from juvenile nasopharyngeal angiofibromas (Le et al., 
2017). Additionally, AZD4547 can reduce FGF21-mediated tumour progression and 
invasion in papillary thyroid cancer cells (Kang et al., 2019c). In breast cancer in vitro 
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and in vivo models, AZD4547 treatment decreases cell proliferation and invasion, as 
well as the formation of lung metastases (Liu et al., 2014). This indicates that FGFR 
inhibition with AZD4547 can have an anti-invasive effect. 
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Table 6.1 The action of FGFR inhibitors in pancreatic cancer 
Inhibitor Targets Function References 
AZD4547 
FGFR1-4 
VEGFR2 
IGFR 
Inhibits downstream 
signalling, decreases 
cell survival and induces 
tumour stasis 
(Gavine et al., 2012, 
Guan et al., 2019, 
Kang et al., 2019a) 
BGJ398 FGFR1-3 
Inhibits cancer cell 
proliferation 
(Lehnen et al., 2013) 
Dovitinib 
FGFR1-4 
PDGFRβ 
VEGFR2 
Inhibits tumour growth, 
motility and metastasis. 
Increases response to 
gemcitabine and 
capecitabine 
(Ma et al., 2019, 
Taeger et al., 2011, 
Zhang et al., 2014a) 
 
Lanvatinib 
FGFR1-4 
VEGFR1-3 
PDGFRα 
RET 
c-KIT 
Decreases 
angiogenesis and 
inhibits tumour growth 
(Yamamoto et al., 
2014) 
Masitinib 
c-KIT 
FGFR1-4 
PDGFR 
Decreases inflammation 
and pain. Increases 
response to 
gemcitabine 
(Deplanque et al., 
2015, Humbert et al., 
2010, Mitry et al., 
2010, Waheed et al., 
2018) 
Nintedanib 
FGFR1-3 
VEGFR1-3 
PDGFRα/β 
Inhibits tumour growth, 
cancer cell proliferation, 
angiogenesis and 
metastasis. Enhances 
response to 
gemcitabine or afatinib 
(Awasthi et al., 2015, 
Bahleda et al., 2015, 
Bill et al., 2015, 
Kutluk Cenik et al., 
2013) 
PD173074 
FGFR1-4 
VEGFR2 
Inhibits angiogenesis 
and tumour growth. 
Induces cancer cell 
apoptosis and reduces 
cancer stem cells 
(Buchler et al., 2007, 
Greggio et al., 2013, 
Lai et al., 2018, 
Memon et al., 2018) 
Ponatinib 
FGFR1-4 
BCR-ABL 
SRC 
PDGFRα 
VEGFR2 
AKT 
ERK1/2 
Inhibits cell proliferation, 
enhanced activity with 
MEK inhibitor 
(Musumeci et al., 
2018, Sahu et al., 
2017) 
SSR128129E FGFR1-4 
Inhibits PDAC cell 
proliferation and 
migration 
(Bono et al., 2013) 
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Table 6.2 IC50 values of AZD4547 against target receptors 
Receptor IC50 value (nM) 
FGFR1 0.2 
FGFR2 2.5 
FGFR3 1.8 
FGFR4 165 
VEGFR2 24 
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6.2.1.2 FGFR1 within PSCs facilitates cancer cell invasion 
FGFR inhibition within PSCs with the clinically relevant agent AZD4547, at a dose 
well below the GI50 level (Figure 3.6), reduced cancer cell invasion in 3D co-culture in 
vitro models. This supported previous work with the laboratory compound, 
PD173074, and independently validates the importance of FGF signalling as a key 
pathway regulating stromal-cancer cross-talk mediated invasion (Coleman et al., 
2014b). Stellate cells with inducible FGFR1 shRNA knockdown replicated the results 
of FGFR pharmacological inhibition (Figures 4.8 and 4.9), confirming that the pro-
invasive effect of FGF signalling in PDAC is mediated specifically by FGFR1 
expression and activation in the stellate cells. This highlights the notion that targeting 
FGF signalling with AZD4547 is a viable clinical option for patients with PDAC. 
 
6.2.2 Stellate cell-led invasion 
6.2.2.1 Cancer-associated fibroblasts promote invasion 
Previous work has suggested that cancer-associated fibroblasts (CAFs) are key 
mediators of tumour invasion and metastasis (Section 1.3) (Barbazán and Matic 
Vignjevic, 2019, McCarthy et al., 2018). CAFs can be seen leading invasion, creating 
tracks to allow collective invasion of cancer cells behind (Gaggioli et al., 2007). This 
has been attributed to cytokine signalling through GP130-IL6ST and JAK1 activating 
Rho-kinase dependent signalling and actomyosin contractility within both tumour and 
stromal cells in oral squamous cell carcinoma (Sanz-Moreno et al., 2011). This was 
also shown to be a key mechanism allowing migration of individual melanoma cells 
in an amoeboid mode (Sanz-Moreno et al., 2011). YAP and endoglin/BMP9 have 
been demonstrated as key signalling mechanisms within CAFs to promote invasion, 
which can be blocked by ROCK or endoglin inhibition respectively (Calvo et al., 2013, 
Paauwe et al., 2018). It has also been postulated that apart from cytokine signalling, 
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CAFs may physically pull cancer cells out of tumours. The physical force exerted by 
CAFs onto cancer cells is mediated by heterophilic adhesion of N-cadherin 
(expressed on CAFs) with E-cadherin (expressed on cancer cells). This interaction 
recruits downstream signalling, such as β-catenin recruitment and polarises the CAFs 
to move actively away from the cancer cell population (Labernadie et al., 2017). 
Additionally, CAFs have been shown to drive invasion in cancer cells via integrin 
signalling between the two cell types (Attieh et al., 2017, Wen et al., 2019), as well as 
packaging pro-invasive signalling molecules into extracellular vesicles (Dourado et 
al., 2019). Additionally, integrins and N-cadherin have been shown to bind to FGFs 
and FGFRs to regulate FGF signalling within cells (Section 1.5.1) (Nguyen et al., 
2019, Tanghetti et al., 2002). Whilst a variety of mechanisms have been suggested 
in different cancers, and this may be context- and disease-specific, it demonstrates 
the biological importance of CAFs in tumour progression and invasion. 
 
Specifically within PDAC, activated PSCs make up the main proportion of CAFs and 
have been shown to facilitate tumour progression and invasion (Section 1.3) (Apte et 
al., 2013). Sex mismatch in vivo studies have shown the presence of PSCs at distant 
metastatic sites, indicating their critical role in PDAC progression, though the 
signalling mechanism responsible for this has not been elucidated (Apte and Wilson, 
2012, Apte et al., 2013, Hwang et al., 2012, Thomas and Radhakrishnan, 2019, 
Vonlaufen et al., 2008b, Vonlaufen et al., 2008a, Xu et al., 2010, Yuan et al., 2019). 
In my work I have confirmed the importance of activated PSCs in invasion, particularly 
in the spheroid model, where a leading stellate cell can be seen at the end of each 
protrusion, with cancer cells following behind (Figure 4.5). 
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6.2.2.2 PSCs use multiple mechanisms to trigger PDAC invasion 
A number of potential mechanisms of stellate cell-led invasion have been identified, 
including PSC activation, direct contact with cancer cells or ECM proteins and 
secretion of paracrine signals, such as FGF-mediated cellular cross-talk (Coleman et 
al., 2014b). Trefoil factor 1 expression on both PSCs and cancer cells has been 
shown to induce invasion and metastasis in orthotopic xenograft in vivo models 
(Arumugam et al., 2011). In patient derived organoids, addition of PSCs caused 
destruction of basement membrane structures and triggered invasion through direct 
binding of MMP2 with membrane type-1 MMP (Koikawa et al., 2018).  Additionally, 
expression of the co-chaperone protein Bcl2-associated athanogene 3 (BAG3) on 
PSCs has been shown to promote paracrine invasion of cancer cells through IL-8, 
MCP1, TGF-β2 and IGFBP2 (Yuan et al., 2019). 
 
Analysis of the secretome of activated PSCs highlighted some key proteins that could 
be involved in re-modelling PDAC stroma to allow tumour invasion (Wehr et al., 2011). 
Proteins associated with cell adhesion, migration and cancer invasion were identified, 
such as members of the urokinase plasminogen activator pathway, annexin A2 
(ANXA2) and serpin peptidase inhibitor, clade I (pancpin) member 2 (SERPINI2), as 
well as transforming growth factor beta induced (TGFBI), ubiquitin carboxyl-terminal 
esterase L1 (UCHL1) and ezrin (EZR). Furthermore galectin-3-binding protein 
(LGALS3BP), which is expressed in PDAC metastases, and galectin-1, which can 
increase both stellate and cancer cell invasion, have been found to be secreted by 
activated PSCs (Berberat et al., 2001, Wehr et al., 2011, Xue et al., 2011). 
Furthermore, secretion of ligands such as PDGF, TGF-β, FGF2 and CTGF by 
activated PSCs has been shown to promote cancer cell proliferation and invasion 
(Charrier and Brigstock, 2013, Habisch et al., 2010, Mahadevan and Von Hoff, 2007). 
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Reversal of PSC activation, by ATRA or inhibition of G protein-coupled oestrogen 
receptor (GPER) by tamoxifen, can decrease actomyosin contractility and, therefore, 
prevent ECM remodelling and invasion, as well as reducing cancer cell proliferation 
(Chronopoulos et al., 2016, Cortes et al., 2019, Froeling et al., 2011). This supports 
the notion that activated stellate cells are the key drivers of invasion in PDAC (Section 
1.3). I focused on FGF signalling, as it is critically important in pancreas development 
(Gittes, 2009, Kim and Hebrok, 2001), and it is generally believed that embryonic 
signalling mechanisms are hijacked by cancer in an organ-specific manner (Aiello 
and Stanger, 2016). 
 
Specifically, I have shown that despite using different cancer cell lines, I can 
universally block FGFR1 in PSCs and the resultant cancer cell invasion. Interestingly, 
in both 3D in vitro models used in this project, the invasive phenotype of the co-
cultures was different between the three PDAC cell lines. This was shown very clearly 
in the spheroid model (Figure 4.5). This could be due to activated PSCs triggering 
invasion through a number of mechanisms, which may be specific to cancer cell type. 
Moreover, the three PDAC cell lines have different invasive capacity (Section 4.2.1). 
PANC-1 and MIA PaCa-2 cells are poorly differentiated and express mesenchymal 
markers (Deer et al., 2010). Both cell lines have been reported to be invasive and 
PANC-1 cells can invade as single cells (Ellenrieder et al., 2001, Duxbury et al., 2004, 
Stahle et al., 2003, Takada et al., 2002). On the other hand, COLO 357 cells express 
epithelial markers and are regarded as a poorly invasive cell line (Huang et al., 2012). 
Hence, I explored the potential different mechanisms by which FGFR1 within PSCs 
may trigger invasion of cancer cells. 
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6.3 Mechanisms of FGFR1-mediated changes in PSCs 
Based on previous observations (Coleman et al., 2014b, Santolla et al., 2019) I had 
two potential leads for mechanisms of FGFR1 mediated cancer cell invasion, a 
nuclear FGFR1 role and the intracellular flux related to FGF signalling in PSCs.  
 
6.3.1 Nuclear translocation of FGFR1 
Nuclear localisation of FGFR1 can relate to cell migration and invasion (Section 1.6) 
(Chioni and Grose, 2012, Coleman et al., 2014b, Nguyen et al., 2013, Stachowiak et 
al., 2007, Stachowiak and Stachowiak, 2016). Upon FGFR inhibition in stellate cells, 
nuclear FGFR1 is decreased. Whilst this was not replicated using AZD4547 treatment 
in short term stellate cell mono-culture in 2D (Figure 3.9), it is very evident in 3D 
models that vimentin positive PS1 cells invading into the gel have nuclear FGFR1 
(Figure 4.6). This indicates that nuclear translocation of FGFR1 could be linked with 
cellular cross-talk and stellate cell-led invasion in a context-specific manner, 
especially when co-cultures are constructed in a physiological manner with relevant 
surrounding matrix proteins. 
 
The method of translocation of FGFR1 into the nucleus has not been fully elucidated 
(Section 1.6.2 and 1.6.3). It was previously confirmed that, in pancreatic stellate cells, 
this was full-length FGFR1 (Coleman et al., 2014b), unlike in breast cancer where 
Granzyme B cleavage causes translocation of a truncated form of the receptor (Chioni 
and Grose, 2012). FGFR1 also localises with FGF2 within the nucleus, and may 
piggyback using the FGF2 nuclear localisation signal (Coleman et al., 2014b, Myers 
et al., 2003, Peng et al., 2002). Moreover, it has been confirmed that translocation of 
FGFR1 is dependent on importin-β (Reilly and Maher, 2001). FGFR1 travelling to the 
nucleus could be from receptor trafficking upon activation at the plasma membrane, 
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or alternatively translocation from an intracellular pool, possibly by retrograde 
transport from the endoplasmic reticulum (Stachowiak et al., 2007, Stachowiak and 
Stachowiak, 2016). This could be an area of future work to fully understand how this 
nuclear localisation is occurring, and furthermore, if there are other methods to target 
this translocation to avoid tyrosine kinase inhibitor resistance (Babina and Turner, 
2017, Camidge et al., 2014). It will also be important to determine whether AZD4547 
treatment prevents receptor translocation to the nucleus or if it interrupts its function 
whilst there, such as preventing DNA binding.  
 
6.3.1.1 Transcriptional role of nFGFR1 in PSCs 
Given that FGFR1 signalling is essential for stellate cell invasion and translocation of 
the receptor occurs in invasive cells in 3D models, as well as at the invasive edge of 
PDAC tumours, the novel role of nFGFR1 was investigated. Previous work 
demonstrated that FGFR1 in the nucleus co-localises with sc35 in nuclear speckles, 
indicating that it may play a role in transcriptional regulation (Section 1.6.3) (Coleman 
et al., 2014b). Moreover, nFGFR1 has been demonstrated to have a role in 
transcriptional regulation in neuronal and breast cancer cells (Chioni and Grose, 
2012, Stachowiak and Stachowiak, 2016). 
 
Therefore, chromatin immunoprecipitation was used to discover where FGFR1 may 
be binding to DNA or chromatin in stellate cells. This was a challenging aspect to 
develop, since the amount of FGFR1 translocating to the nucleus is small; and this is 
relevant since most ChIP-seq analysis has been developed for histone proteins to 
which DNA is bound in abundance (Kidder et al., 2011, Park, 2009). I tried different 
methods to enhance my yield whilst retaining specificity to FGFR1, such as HaloTag 
(Los et al., 2008), and using chemical and genetic manipulation of FGFR1 as well as 
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developing the steps to shear and isolate sufficient DNA. Finally, PS1 cells treated 
with AZD4547 compared to control, as well as three different shRNA cell lines were 
used to decipher the genes under transcriptional control of FGFR1. Excitingly, 
preliminary analyses showed that there was clear enrichment of peaks, indicating that 
FGFR1 is associating either directly or indirectly with the DNA. There was also 
overlap between the shRNA2 and shRNA3 samples across the biological repeats. I 
will be validating this in the near future. 
 
6.3.1.2 Hippo signalling 
Analysis of the ChIP-seq peaks from between either AZD4547 treated or FGFR1 
knockdown, with their relevant control, demonstrated that one of the significantly 
enriched pathways was Hippo signalling (Figure 5.15 and Table 5.5). Peaks were 
identified in 152 proteins associated with this pathway, including BMP8A, SMAD3, 
PPP2R2C, SCRIB and LATS2. The Hippo signalling pathway is a key developmental 
regulatory kinase cascade that regulates organ size and can be switched on to drive 
cancer progression (Pan, 2010). I will, therefore, elaborate on Hippo signalling as one 
of the many novel leads from ChIP-seq data which I hope to take further to investigate 
PSC-mediated cancer cell invasion. I summarise the intra-cellular cascade involved 
in the Hippo pathway which can signal to the microenvironment, promote EMT, 
mediate angiogenesis and promote cell survival and proliferation (Figure 6.1).  
251 
 
 
Figure 6.1 Hippo signalling pathway 
Hippo signalling is a major regulator of cell survival and organ size. A. When the core Hippo signalling pathway is switched on, signals feed into the 
cascade to phosphorylate MST1/2 and SAV1. These in turn phosphorylate LATS1/2 and Mob1, which then phosphorylate YAP/TAZ and sequester them 
in the cytoplasm. YAP/TAZ can then bind with other mediators, such as 14-3-3 to be retained in the cytoplasm or ubiquitinated for proteasome degradation. 
B. When Hippo signalling is switched off MST1/2, SAV1, LATS1/2 and Mob1 remain unphosphorylated. Therefore YAP/TAZ are not phosphorylated and 
translocate into the nucleus. YAP/TAZ can then bind to transcription factors, such as TEAD1-4, to trigger the expression of downstream proteins such as 
CTGF, BIRC5, CYR61, AREG, EDN2 and CXCL5 (Boopathy and Hong, 2019). 
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6.3.1.3 Hippo signalling in PDAC 
Novel cross-talk between FGF and Hippo signalling could be important to mediate 
PSC-led invasion and tumour progression. In fact, YAP/TAZ are overexpressed in 
PDAC patient tumours and have been described as a potential prognostic marker for 
patient survival (Ansari et al., 2019, Kapoor et al., 2014, Salcedo Allende et al., 2017). 
YAP has also been linked to acinar-to-ductal metaplasia (ADM) and PanIN 
progression in PDAC (Gruber et al., 2016, Jiang et al., 2018, Zhang et al., 2014b).  
 
6.3.1.4 FGF and Hippo signalling cross-talk 
The Hippo pathway can cross-talk with many other signalling cascades, such as BMP, 
TGF-β, Wnt, EGF and hedgehog signalling, as well as with other cells and the ECM 
through integrins and adhesion molecules present on the cell surface (Figures 6.2 
and 6.3) (Alarcon et al., 2009, Barron and Kagey, 2014, Boopathy and Hong, 2019, 
Camargo et al., 2007, Cravo et al., 2015, Das Thakur et al., 2010, Fernandez et al., 
2009, Grusche et al., 2010, He et al., 2015, Polesello et al., 2006, Varelas et al., 2010, 
Varelas et al., 2008, Zhao et al., 2010). The interaction between Hippo and FGF 
signalling remains unexplored and I would like to take this further to identify additional 
druggable options for PDAC. 
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Figure 6.2 Activated Hippo signalling pathway interactions 
Hippo signalling can be controlled by many different cell processes. When the pathway is switched on KIBRA, NF2 and TAOK1-3 can phosphorylate the 
MST1/2 and SAV1 complex to trigger the phosphorylation of Mob1 and LATS1/2, causing retention of YAP/TAZ in the cytoplasm, leading to ubiquitination and 
proteasomal degradation. Phosphorylated YAP/TAZ can also be retained within the cytoplasm by binding to mediators such as 14-3-3, or through cellular 
interactions by cadherins and tight junctions leading to activation of proteins such as α-catenin, ZO-2, PTPN14 and AMOT (Boopathy and Hong, 2019). 
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Figure 6.3 Un-activated Hippo signalling pathway interactions 
Hippo signalling can be controlled by many different cell processes. Signalling through GPCRs, integrins and mechanical cues indicating ECM stiffness can 
activate Rho and reorganise F-actin within cells, which in turn can switch off the Hippo pathway and trigger nuclear localisation of YAP/TAZ. Additionally, 
receptor tyrosine kinase activation and downstream signalling, as well as adaptor proteins such as Ajuba and RASSFs, can inhibit the core Hippo complexes 
and activate gene transcription through YAP/TAZ nuclear translocation. In the nucleus, YAP/TAZ can bind with transcription factors, such as TEAD 1-4 and 
Smad1-3, to control gene expression (Boopathy and Hong, 2019). 
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This cross-talk may be relevant since FGF and Hippo signalling have been linked 
previously in studies in ovarian high grade serous carcinoma (HGSC), with a 
paracrine loop between FGF and YAP signalling in fallopian tube secretory epithelial 
cells (FTSECs) driving HGSC, presenting a novel combination therapeutic strategy 
(Hua et al., 2015). Moreover mutant FGFR3 in bladder cancer has been shown to 
increase TAZ levels through expression of the ETS-family transcription factor, ETV5 
(di Martino et al., 2019). In breast cancer cells, YAP can bind to the KLF5 transcription 
factor, which in turn promotes cell survival. One of the downstream targets found to 
be activated through YAP-mediated KLF5 expression was FGFBP (Zhi et al., 2012). 
Additionally, MST1/2 have been identified as substrates for FGFR4 and in HER2 
positive breast cancer cells FGFR4 expression has been correlated with increased 
nuclear YAP activity. Moreover, in 3D in vitro breast cancer sphere models FGFR4 
knockdown increased phosphorylated MST1/2 and membrane-associated YAP 
(Turunen et al., 2019).  In a study looking at genetic changes upon KRAS 
suppression, 147 genes were found to promote cell survival and rescue the KRAS 
phenotype. From these 147 genes, the highest hits were sterile α motif (SAM) post-
transcriptional regulators, YAP1, WWTR1 and the FGF family (such as FGF3, 6 and 
10) (Shao et al., 2014). 
 
Cross-talk between these two pathways has also been described in the lung stem cell 
niche through YAP induced expression of FGF10, promoting regeneration and wound 
repair (Volckaert et al., 2017). Additionally, in colorectal cancer, YAP1 was identified 
as a downstream target of FGF8, which is correlated with a poor patient survival (Liu 
et al., 2015). In cholangiocarcinoma, YAP has been shown to play a key role in tumour 
progression and chemo-resistance (Marti et al., 2015). Nuclear YAP localisation and 
activation of TBX5 triggered the expression of FGFR1, -2 and -4. Additionally, FGF 
signalling in cell lines induced YAP expression and nuclear localisation, indicating 
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reciprocal cross-talk. Inhibition of FGF signalling with BGJ398 decreased YAP 
activation through FGF5-FGFR2, suggesting a novel clinical approach and 
demonstrating that YAP may be a biomarker of response to FGFR inhibition in these 
patients (Rizvi et al., 2016, Sugihara et al., 2019). Therefore, Hippo signalling may 
form complex cross-talk FGF signalling, to regulate cancer development and 
progression. 
 
In addition to playing a key role in cancer cell survival, YAP1 has been reported to 
induce activation of CAFs within the stroma of breast and liver tumours (Calvo et al., 
2013, Hao et al., 2017, Mannaerts et al., 2015). YAP1 was also found to be highly 
expressed in the nuclei of activated PSCs. Inhibition of YAP1 by RUNX1 or 
knockdown interrupted TGF-β signalling and caused PSCs to revert to a quiescent 
phenotype, indicating that Hippo signalling could play a key role in the desmoplastic 
stroma of PDAC. The stimulation of YAP1 expression in PSCs caused increased 
SPARC expression (Jiang et al., 2018, Xiao et al., 2019). High levels of SPARC within 
PDAC stroma has been correlated with poor patient prognosis (Guweidhi et al., 2005, 
Infante et al., 2007, Murakawa et al., 2019). However, the effect of SPARC in 
resectable compared to metastatic patients and how this affects response to 
treatment is complex and still not understood (Gundewar et al., 2015, Hidalgo et al., 
2015, Mantoni et al., 2008, Miyoshi et al., 2010, Ormanns et al., 2016, Prenzel et al., 
2006, Rossi et al., 2016, Sinn et al., 2014, Von Hoff et al., 2011). It has been shown 
that SPARC can decrease VEGF and Notch levels in cancer cells, decreasing 
angiogenesis and increasing stromal metabolic activity. Furthermore, SPARC levels 
can regulate MMP-2 expression. This contributes to tumour progression and the 
formation of the characteristic stiff, hypoxic tumour microenvironment in PDAC 
(Guweidhi et al., 2005). Additionally, studies have shown that conditioned media from 
PDAC cells can decrease endogenous PSC SPARC expression, whereas co-cultures 
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with PDAC cells can increase SPARC expression in stromal fibroblasts (Chen et al., 
2010, Sato et al., 2003). This highlights the potential role of SPARC in mediating 
stromal-cancer cross-talk in tumours. 
 
In contrast to stromal-derived SPARC, there has been a low level of expression 
detected in cancer cells (Mantoni et al., 2008). SPARC has been linked to increased 
invasiveness in cancer cells, evidenced by its expression in circulating tumour cells 
(Ting et al., 2014). However in other studies, SPARC expression in tumour cells has 
been associated with decreased invasion and proliferation. This was shown to be 
regulated by FGFR1 isoform expression, as FGFR1b increased SPARC levels 
whereas FGFR1c decreased expression (Chen et al., 2010). Therefore, cross-talk 
between FGF and Hippo signalling could modulate PDAC progression and invasion 
through secretion of proteins such as SPARC. This indicates the complexity of 
stromal-cancer cross-talk in PDAC and the difficulty in achieving effective stromal 
targeting in the clinic. 
 
The novel role of nFGFR1 in PSCs in relation to Hippo signalling and other 
downstream targets will need to be validated. This will demonstrate if there are key 
nuclear targets that can be investigated further or if FGFR1 translocation triggers a 
total reprogramming of PSCs into invasive cells by multiple gene expression changes, 
such as the role of nFGFR1 in neural reprogramming (Stachowiak et al., 2007). 
 
Hippo signalling is just one of the many promising avenues which could be explored 
further from my exciting, though preliminary, ChIP-seq data. Several other potential 
targets can be investigated, such as scribble planar cell polarity protein (SCRIB), 
myosin XVA (MYO15A), bone morphogenetic protein 8A (BMP8A), desert hedgehog 
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(DHH), mucin 2 (MUC2) and protocadherin beta 15 (PCDHB15), as well as the role 
of FGFR1 in ubiquitination and sub-cellular organisation pathways. 
 
6.3.1.5 FGF and TGF-β signalling cross-talk 
STRING analysis of networks enriched in the significant peaks from ChIP-seq 
analysis (Figure 5.15) identified SMAD3 as a central node, suggesting that this may 
be related to critical pathway changes upon FGFR inhibition or knockdown in PSCs. 
TGF-β signalling has been reported to interact with many other intracellular pathways 
to induce a range of responses, such as the Wnt, Hippo and Hedgehog pathways 
(Luo, 2017). It has been shown that activation of FGF signalling in smooth muscle 
cells causes a decrease in TGF-β signalling, switching the cells from a contractile to 
a proliferative phenotype (Chen et al., 2016a). Cross-talk between these pathways 
has also been confirmed in human atherosclerosis patients, where increased FGF 
and decreased TGF-β signalling causes more severe disease. This highlights the 
importance of the FGF driven phenotype switch in smooth muscle cells in the 
formation of atherosclerotic plaques (Chen et al., 2016b). Moreover, TGF-β signalling 
is a key driver of pancreatic fibrosis and pancreatic stellate cell activation (Bailey and 
Leach, 2012). Therefore, cross-talk between FGFR and SMAD3 in PSCs could be 
important for switching on the invasive phenotype and driving PDAC progression. 
This will warrant further investigation in the future. 
 
6.3.2 FGF signalling in PSCs 
In addition to the role of nFGFR1 in PSCs, sub-cellular fractionation and mass 
spectrometry was used to determine the protein flux upon FGFR inhibition. Proteomic 
analysis following FGFR1 inhibition with AZD4547 showed significant changes in both 
total peptide abundance and sub-cellular peptide localisation, compared to vehicle 
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control. Analysis showed that the most significantly decreased peptide was 
MARCKSL1, whilst the most significantly increased peptide was Zinc finger C3H1 
domain-containing protein (ZFC3H1) (Figure 5.19). The results indicated that upon 
FGFR inhibition, there was a decrease in peptides related to actin cytoskeleton and 
cell migration (MARCKSL1 and FHOD1), as well as response to oxidative stress 
(GPX1). These hits, amongst other exciting mechanisms, are being validated 
currently in the laboratory. I will discuss the relevance and importance of these 
potential hits and their targeting. 
 
6.3.2.1 Myristoylated alanine-rich c-kinase substrate-like protein 1 
MARCKSL1 is a member of the MARCKS family of proteins, which play a role in cell 
migration and actin cytoskeleton remodelling (Aderem, 1992, El Amri et al., 2018, 
Yarmola et al., 2001). Phosphorylation of MARCKSL1 by PKC, or binding to 
calmodulin, causes the protein to dissociate from the plasma membrane and move 
into the cytosol (Hartwig et al., 1992). In the cytoplasm, MARCKSL1 can interact with 
actin or PLC and PI3K to trigger downstream signalling. It has been reported that 
MARCKS plays a role in cell motility, phagocytosis and membrane trafficking through 
its interaction with the actin cytoskeleton. It is also important for neural tube closure 
in early brain development and regulates fibroblast migration (Chen et al., 1996, Ott 
et al., 2013). Phosphorylation of MARCKS has been associated with cancer 
progression (Fong et al., 2017). However, it has been linked with both increasing and 
decreasing cancer cell invasion in different contexts (Bjorkblom et al., 2012, Dorris et 
al., 2017). Phosphorylated MARCKS is expressed by invasive lung cancer cell lines 
and promotes migration of melanoma cells (Chen and Rotenberg, 2010, Chen et al., 
2014). It has been suggested that when the MARCKS family is phosphorylated, PIP2 
is available to PI3K and PLCγ and downstream Akt/PKC signalling is activated (Chin 
and Toker, 2009, El Amri et al., 2018). 
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Validation work has shown a decrease in invasion following siRNA-mediated 
knockdown of MARCKSL1 in the 3D spheroid co-culture in vitro model, replicating 
FGFR1 knockdown or inhibition (data not shown). Due to the opposing role of the 
MARCKS family in cell migration depending on the phosphorylation status, it may be 
imperative in future studies to investigate MARCKSL1 phosphorylation following 
FGFR1 knockdown or inhibition (Bjorkblom et al., 2012).  
 
6.3.2.2 Formin homology-2-domain containing protein 1 
FHOD1 is associated with actin cytoskeleton rearrangements in the process of EMT, 
contributing to cell migration (Gardberg et al., 2013). It can be modulated by PKC 
binding and MAPK signalling; therefore this may be a method of downstream 
signalling by FGFR1 within PSCs (Boehm et al., 2005). FHOD1 is also reported to be 
activated by ROCK by phosphorylation (Takeya et al., 2008) and can be upregulated 
in EMT during cancer cell migration (Gardberg et al., 2013). In particular, FHOD1 
expression has been inversely correlated with miR200c, which can decrease invasion 
in cancer. The expression of miR200c has been shown to be decreased at the 
invasive front of PDAC tumours (Yu et al., 2010). Furthermore, overexpression of 
miR200c can decrease invasion and stress fibre formation in breast cancer cells, 
indicating that this could play an important role in tumour invasion and metastasis 
(Jurmeister et al., 2012). This points to a potential role for FHOD1 at the invasive 
edge of PDAC tumours, which is being validated in the context of nuclear FGFR1 
signalling currently in the laboratory. 
 
6.3.2.3 Glutathione peroxidase 1 
GPX1 is a key protein involved in the response to oxidative stress and catalyses the 
conversion of glutathione and hydrogen peroxide into glutathione disulphide and 
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water (Mills, 1957). Activated FGF signalling in wound repair has been shown to 
regulate the expression of GPX1 (Frank et al., 1997, Munz et al., 1997). FGF7 can 
promote the expression of GPX1 to promote wound healing and protect keratinocytes 
from ROS in skin cancer formation (Marchese et al., 1995, Pentland, 1994). 
Moreover, following treatment with FGFR1 neutralising antisera, breast cancer and 
osteosarcoma cells displayed a decrease in GPX1 expression. This indicates a 
positive link between FGF signalling and GPX1 expression (Ling et al., 2015). GPX1 
has been reported to be overexpressed in some cancers, such as colorectal, 
oesophageal and breast tumours (Hughes et al., 2018, Mahbouli et al., 2018, Peng 
et al., 2009). GPX1 expression has also been correlated with invasion in oesophageal 
cancer (Gan et al., 2014). Increased expression of GPX1 has been reported in 
activated hepatic stellate cells (HSCs) (Dunning et al., 2013). In PDAC, a decrease 
in GPX1 triggers EMT and chemotherapy resistance, indicating the complex 
response to ROS within tumours (Meng et al., 2018). 
 
Validation work has shown that siRNA-mediated knockdown of GPX1 decreased 
invasion in the spheroid 3D co-culture in vitro model, replicating the results seen 
following FGFR1 knockdown or inhibition (data not shown). Oxidative stress is a 
central regulator of fibrosis and therefore GPX1 may be a key regulator in activated 
stellate cells in response to ROS (Richter and Kietzmann, 2016). 
 
6.3.2.4 Sub-cellular peptide changes 
Sub-cellular localisation of peptides upon FGFR inhibition was also determined using 
mass spectrometry. This highlighted many significant changes in different 
compartments within PSCs, which could indicate the critical role of FGFR1 within 
PDAC invasion and metastasis. Focusing on the changes occurring within the nuclear 
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compartment, potentially alongside, or as a result of, nuclear translocation of FGFR1, 
some key pathways are being altered (Table 5.7). In particular, epigenetic regulatory 
proteins are being changed, which could provide evidence for a role of nFGFR1 in 
regulating gene expression in PSCs (Figures 5.21 and 5.22). Furthermore, upon 
FGFR inhibition, the levels of the receptor tyrosine kinase c-MET within the nucleus 
are decreased (Figure 5.23). This could indicate a novel interaction between FGFR1 
and c-Met in PSCs. 
 
6.3.2.5 c-MET 
The only known ligand of c-MET is hepatocyte growth factor (HGF). This binds to the 
receptor, triggering dimerization and phosphorylation to activate downstream 
signalling pathways (Organ and Tsao, 2011). Overexpression of c-MET has been 
detected in PDAC and correlated with decreased survival (Kim et al., 2017). Studies 
have also demonstrated that HGF produced by PSCs in PDAC stroma can activate 
c-MET on cancer cells, triggering proliferation and migration (Pothula et al., 2017). 
This c-MET mediated cross-talk can also promote perineural invasion of cancer cells 
(Nan et al., 2019). Furthermore, c-MET cross-talk in PDAC can enhance glycolysis 
and induce cancer stem cell properties in tumour cells (Yan et al., 2018). 
 
Nuclear translocation of c-MET has been previously reported, triggering activation of 
calcium signals and downstream pathways. In particular c-MET translocation has 
been shown to be dependent on Gab1 and importin β1 (Gomes et al., 2008). 
Additionally, it has been shown that hydrogen peroxide can induce retrograde 
transport of c-MET into the nucleus in breast cancer cells, indicating a role of c-MET 
in ROS-induced DNA damage repair (Chen et al., 2019). 
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6.3.2.6 c-MET signalling cross-talk 
c-MET can interact with EGFR in tumour cells, triggering receptor activation in the 
absence of HGF (Jo et al., 2000). Moreover, EGF stimulation of NSCLC cells can 
lead to phosphorylation of c-MET, indicating significant cross-talk between these two 
pathways (Puri and Salgia, 2008). Both ERBB2 and ERBB3 have also been shown 
to interact with and activate c-MET (Bachleitner-Hofmann et al., 2008, Khoury et al., 
2005). Cross-talk has also been reported between c-MET and recepteur d'origine 
Nantais (RON) kinase, leading to transactivation in cancer cells (Benvenuti et al., 
2011, Follenzi et al., 2000). In bladder cancer, cross-talk between c-MET, Axl and 
PDGFRα has been shown to cause tumour progression (Yeh et al., 2011). A study 
investigating the effect of FGFR inhibition with AZD4547 in lung cancer cell lines 
showed that upon acquired resistance developing, cells demonstrated 
overexpression and activation of c-MET. Using a combination therapy of FGFR 
inhibitors with the c-MET inhibitor crizotinib or c-MET knockdown restored sensitivity. 
This indicates that c-MET signalling may be used to bypass FGF inhibition in cells 
and there could be synergistic benefits of combining FGFR and c-MET inhibitors (Kim 
et al., 2016). 
 
The downstream sub-cellular peptide changes discovered in PSCs following FGFR 
inhibition are now being validated and investigated, with a particular focus on the 
interaction with c-MET. This will demonstrate the functional importance of these hits 
in PDAC progression and invasion. 
 
In summary, in Section 6.3, I have demonstrated that whilst elucidating intra-cellular 
mechanisms for FGFR1 signalling within PSCs is challenging, I have made significant 
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progress to yield many exciting and relevant biological leads which merit further 
investigation; thus opening new areas of research for PSC. 
 
6.4 Introducing FGFR1-targeting into PDAC therapies 
Following the exciting results showing a significant impact on stroma-cancer cross-
talk in PDAC when targeting FGFR1 within PSCs, particularly in respect of invasion, 
I further validated this approach in the context of current and developing PDAC 
therapy combinations. A big focus in PDAC research is stromal targeting to improve 
treatment outcomes (Section 1.4). Therefore, I considered current stromal targeting 
combinations in promising PDAC clinical trials and investigated the effect of 
introducing FGFR1-targeting therapies to disrupt cellular cross-talk. 
 
6.4.1 Stromal targeting 
6.4.1.1 Stromal therapies in cancer 
Tumours are not comprised of cancer cells alone, they include many other cell types, 
which can all make up the tumour microenvironment or stroma. It is now well accepted 
that the stroma can play a key role in tumour progression and contribute to therapeutic 
resistance (Section 1.3). Therefore, clinical targeting of the stromal compartment of 
tumours has attracted interest over recent years (Section 1.4) (Valkenburg et al., 
2018). A number of stromal-targeting agents are in clinical trials, such as defactinib 
(a FAK kinase inhibitor) in ovarian cancer (NCT03287271) and fresolimumab (to 
target TGF-β) in NSCLC (NCT02581787). 
 
Targeting the ECM is an area of interest in stromal therapies. In melanoma xenograft 
models treatment with halofuginone, a collagen type 1 inhibitor, was shown to reduce 
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metastasis (Juarez et al., 2012). Furthermore, lysyl oxidase catalyses collagen 
crosslinking and has been reported to play a role in metastasis, making it a potential 
therapeutic target (Erler et al., 2006).  
 
Other approaches that are being considered are to target specific proteins on stromal 
cells, such as FAP on CAFs. Combining anti-FAP antibodies with drugs or 
radiotherapy to enhance delivery to the cancer stroma have demonstrated tumour 
regression in xenograft models of pancreatic, lung, colorectal and head and neck 
cancers, as well as melanoma (Erickson et al., 2006, Fischer et al., 2012, Ostermann 
et al., 2008). Another approach that demonstrates improved anti-tumour effects is to 
treat cancers with the prodrug promelittin, which is then cleaved by FAP to release a 
toxin within the tumour (LeBeau et al., 2009). 
 
Immunotherapies have had significant success in a subset of tumours within the 
clinic. Immunotherapeutic targeting can include chimeric antigen receptor T (CAR T) 
cells, oncolytic virus therapy, adoptive cell therapy, cancer vaccines and antibodies 
(Farkona et al., 2016). Particular success has been achieved with immune checkpoint 
blockade of CTLA-4 or PD1/PDL1. Ipilimumab, an anti-CTLA4 antibody, has been 
approved for use in metastatic melanoma following successful trials showing an 
increase in overall survival (Hodi et al., 2010, Robert et al., 2011). Additionally anti-
PD1 antibodies, pembrolizumab and nivolumab, have been approved for use in 
melanoma and NSCLC. Nivolumab has also been approved for renal cell carcinoma 
(Sharma and Allison, 2015, Topalian et al., 2012). Antibodies targeting PDL1 have 
also shown efficacy in melanoma, renal cell carcinoma, NSCLC and bladder cancer 
(Brahmer et al., 2012). 
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The explosion of stromal targeting therapies being investigated in the context of 
cancer, with translation into clinical trials, demonstrates the importance of the tumour 
microenvironment in a multitude of tumours. Clinical success of therapies such as 
immune checkpoint blockade antibodies highlights the significant benefit stromal-
targeted therapies could have on patient prognosis. 
 
6.4.1.2 Stromal therapies in PDAC 
The characteristic desmoplastic stroma present in PDAC tumours has meant that 
stromal-therapeutic targeting has gathered significant interest in recent years, leading 
to several clinical trials, including hedgehog pathway inhibition, hyaluronic acid 
degradation, and a variety of immunotherapy concepts (summarised in Table 6.3 and 
Section 1.4) (Doherty et al., 2018, Gong et al., 2018, Jacobetz et al., 2013, 
Kabacaoglu et al., 2018, McCarroll et al., 2014, Merika et al., 2012, Olive et al., 2009, 
Richards et al., 2012, Thompson et al., 2010). PSCs, which form a key part of this 
desmoplastic stroma, become activated in response to tumour development. 
Activated PSCs engage in cross-talk with cancer cells to induce tumour cell 
proliferation and invasion, leading to metastatic spread, making these cells an 
attractive therapeutic target (Apte et al., 2013, Liu et al., 2019). 
 
However, modifying the stroma has been shown to be more complicated than 
expected. Removal of activated PSCs in pancreatic tumours, or inhibition of 
hedgehog signalling, can lead to increased cancer cell proliferation and therefore 
result in shorter patient survival (Bailey et al., 2009, Feldmann et al., 2008, Rhim et 
al., 2014). This emphasises the importance of fully understanding the complex 
network of cellular interactions that characterise PDAC stroma, in particular the 
interactions between cancer cells and the activated PSCs. 
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I have shown that FGFR inhibition with AZD4547 does not affect the proliferation or 
survival of the cancer or stellate cells (Figure 3.6), but rather disrupts essential cellular 
cross-talk. Therefore the aim of treating patients with AZD4547 would be not to 
destroy the stroma but instead re-programme it into a less tumorigenic 
microenvironment. 
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Table 6.3 Stromal therapies in PDAC 
Compound Targets Combination 
Patient 
cohort 
Trial 
phase 
Ref 
ATRA CAFs 
Gemcitabine, 
nab-paclitaxel 
PDAC 
Phase 
I 
NCT0330
7148 
Cabiralizumab 
Colony-
stimulating 
factor-1 
receptor 
Nivolumab Solid tumour 
Phase 
I 
NCT0252
6017 
EF-002 
Macrophage 
activity 
Dose escalation Solid tumour 
Phase 
I 
NCT0205
2492 
Paricalcitol 
Metabolic 
pathway 
Gemcitabine, 
nab-paclitaxel 
Advanced 
PC 
Phase 
I 
NCT0203
0860 
Pembrolizumab PD-1 
Paricalcitol, 
gemcitabine, 
nab-paclitaxel 
Resectable 
PC 
Phase 
I 
NCT0293
0902 
Defactinib 
FAK 
signalling 
PD-1 Solid tumour 
Phase 
I/II 
NCT0275
8587 
MEDI4736 
C-X-C 
chemokine 
receptor type 
2 
Gemcitabine, 
nab-paclitaxel 
Stage IV 
PDAC 
Phase 
I/II 
NCT0258
3477 
Sonidegib 
Hedgehog 
signalling 
Gemcitabine, 
nab-paclitaxel 
Stage IV 
PDAC 
Phase 
I/II 
2013-
002370-
51 
Vismodegib 
Hedgehog 
signalling 
Gemcitabine 
Stage IV 
PDAC 
Phase 
I/II 
NCT0106
4622 
GSK2256098 
FAK 
signalling 
Tremetinib PDAC 
Phase 
II 
NCT0242
8270 
PEGPH20 
Hyaluronic 
acid 
Gemcitabine, 
nab-paclitaxel 
Stage IV 
PDAC 
Phase 
II 
NCT0183
9487 
AM0010 IL-10 
FOLFOX, 5-FU, 
leucovorin 
Solid tumour 
Phase 
III 
NCT0292
3921 
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6.4.1.3 Targeting activated PSCs and cancer cells in combination 
One of the most promising PDAC stromal targets is activated PSCs. Previous work 
carried out by our group showed that returning PSCs to their quiescent phenotype 
with all-trans retinoic acid (ATRA) improved response to gemcitabine in 3D in vitro 
models and the KPC mouse (Carapuça et al., 2016, Froeling et al., 2011). This work 
has now been translated into the STARPAC phase 1b clinical trial with the aim of re-
educating stromal PSCs to improve response to current therapies (NCT03307148). 
This shows the importance of combining PSC targeting with current approved PDAC 
therapies in the clinic. Moreover, by re-educating the stroma rather than depleting it, 
the delivery of therapeutics to the tumour can be increased, without causing tumour 
progression. 
 
Building on the successful translation of combining ATRA and gemcitabine to target 
PSCs and cancer cells, I selected these drugs to combine with AZD4547 to 
additionally target FGFR-mediated cellular cross-talk, with particular reference to 
reducing invasion. 
 
6.4.2 Targeting FGFR-mediated cellular cross-talk 
6.4.2.1 Addition of AZD4547 to current PDAC therapies 
I have demonstrated that FGF signalling is a vital cross-talk mechanism between 
PSCs and cancer cells that leads to PDAC progression and invasion. Additionally, 
FGFR inhibition with AZD4547 can successfully disrupt FGF-mediated cellular cross-
talk. Therefore, combination therapies of AZD4547, ATRA and gemcitabine were 
examined in the mini-organotypic 3D in vitro model, treating with ATRA and AZD4547 
daily and gemcitabine weekly to match patient protocols. These results further 
demonstrated the importance of FGF signalling in PDAC invasion, with the 
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combinations containing AZD4547 displaying significantly reduced invasion (Figure 
4.10). Additionally, AZD4547 treatment in combination with ATRA or both ATRA and 
gemcitabine resulted in a decreased cell layer on the surface of the gel, indicating 
that these treatment combinations may affect cell survival. 
 
6.4.2.2 Development of triple therapy 
The initial analysis combining ATRA, gemcitabine and AZD4547 therapeutically looks 
promising. However, these 3D models were only maintained for a short time (7 days) 
and the results obtained were a snapshot at one time-point, which may explain the 
lack of difference in proliferation and apoptosis between treatment conditions. The full 
effects of targeting the cancer, stroma and cross-talk still need to be determined, 
including a comprehensive investigation of the effect on cancer cell survival and PSC 
activation. Additionally, it will be useful to perform a dynamic analysis of cell 
behaviours with the different treatment combinations over time. Longer therapeutic 
regimens, with more treatments of relevant chemotherapies, may give a better 
representation of whether co-targeting the cross-talk alongside stellate and cancer 
cells is effective. Other 3D in vitro models could be used for this, such as organoids 
or microfluidic cultures. Furthermore, the effect of this combination treatment on 
tumour growth will be assessed using an in vivo model, which will give in-depth 
analysis of whether the three drugs together give an improved anti-tumour response. 
However, subcutaneous models in NSG mice will not include the response of all the 
surrounding stromal cells found within the pancreas, as well as not modelling the 
immune response, which could be extremely important in translating this data to 
patients in the clinic. 
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Any increased side effects will also need to be considered before applying these 
results to the clinic. Gemcitabine and ATRA are already being used in combination in 
patients in the STARPAC clinical trial (NCT03307148), however adding AZD4547 
could increase side effects in patients. FGF tyrosine kinase inhibitors can have 
adverse effects on the cardiovascular system and the liver, as well as causing 
hypertension, bleeding and thrombosis due to their anti-angiogenetic action. 
Gastrointestinal and dermatological side effects have also been reported (Katoh, 
2016, Paik et al., 2017, Saka et al., 2017). 
 
6.5 Future work 
Ongoing experiments are being performed to repeat and extend the mass 
spectrometry analysis to include FGFR1 shRNA knockdown cells. The results from 
these repeats will confirm which hits are important for mediating FGFR1 invasion in 
stellate cells. The full sub-cellular mass spectrometry and ChIP-seq results will also 
need to be analysed and validated, such as the role of MARCKSL1, GPX1, FHOD1, 
c-MET, epi-genetic regulators, Hippo signalling, ubiquitination and subcellular unit 
organisation. ChIP-PCR will confirm the validity of the ChIP hits. Furthermore, an 
siRNA screen will be used in the spheroid 3D in vitro model to confirm which hits are 
the most important for mediating stellate cell invasion in PDAC. 
 
The critical role of nuclear FGFR1 could be determined in pancreatic stellate cells by 
further investigation into the upstream signalling causing this phenomenon at the 
invasive edge of tumours. This will provide a greater insight into the complex cross-
talk that occurs in PDAC, improving understanding and therefore providing validation 
of therapeutic targeting that will lead to increased patient prognosis. 
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Using primary stellate cell cultures or patient-derived tissue will also provide further 
clinical validation of the importance of FGF-mediated cellular cross-talk and the 
potential for targeting this in the clinical setting. Longer term 3D in vitro models and 
in vivo targeting of FGF signalling cross-talk, alongside targeting cancer and stellate 
cells directly, will demonstrate whether this triple combination with gemcitabine, 
ATRA and AZD4547 is a valid clinical regimen to transfer into patients. By improving 
therapeutic targeting, especially of invasion, patient prognosis can be improved. 
 
6.6 Conclusion 
PDAC has a poor prognosis with a 5-year survival rate of less than 5 %. PDAC 
tumours consist of a desmoplastic stroma, which limits the effectiveness of 
chemotherapy. PSCs, which form a key part of this stroma, become activated in 
response to tumour development and enter a cross-talk with cancer cells to induce 
tumour cell proliferation and invasion, leading to metastatic spread. I have 
demonstrated that FGFR1 signalling is critical in mediating PSC-led invasion in 
PDAC. Inhibition or knockdown of FGFR1 in stellate cells decreases invasion in novel 
3D co-culture in vitro models, highlighting this as a potential therapeutic target in 
patients. 
 
Nuclear translocation of FGFR1 in PSCs appears to be a vital mechanism that 
triggers the transcription of key proteins involved in PDAC invasion. Chromatin 
immunoprecipitation (ChIP-seq) and sub-cellular mass spectrometry have been used 
to determine the potential role nFGFR1 and consequent sub-cellular protein flux upon 
FGFR inhibition in PSCs. These techniques have dissected the functional 
consequences of FGFR1 knockdown or inhibition in stellate cells. Candidate drivers 
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of invasion have been identified, as well as novel nuclear cross-talk mechanisms and 
these are now being validated in state-of-the-art 3D in vitro PDAC models. 
 
Targeting cellular cross-talk with a clinically relevant FGFR inhibitor (AZD4547) has 
been extended to examine potential combination therapy regimens with the 
chemotherapeutic agent gemcitabine (targeting cancer cells) and ATRA (modulating 
PSCs), providing translational relevance for my findings. I am currently validating this 
novel strategy using in vivo co-culture xenograft models with specific reference to 
FGFR1. 
 
Effectively disrupting FGFR-mediated cross-talk between the tumour and stroma, 
either alone or in combination with other therapies, could translate to improved 
therapeutic responses in PDAC patients by providing novel treatment options in the 
clinic.  
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Appendix 1: PDAC Cell Lines 
Appendix 1.1 Cell line details 
The details of all the PDAC cell lines used during this project are described in 
Appendix Table 1.1 
 
Appendix 1.2 STR profiles 
All of the STR profiles for the PDAC cell lines and the PS1 cell line are in Appendix 
Figures 1.1-1.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
337 
 
Appendix Table 1.1 PDAC cell line characteristics 
Cell Line Origin Site Differentiation Mutations 
AsPC-1 
Female age 
62 
Ascites Poor 
KRAS, 
TP53, 
INK4A 
MIA PaCa-2 
Male 
age 65 
Primary Poor 
KRAS, 
TP53, 
INK4A 
PANC-1 
Male 
age 56 
Primary Poor 
KRAS, 
TP53, 
INK4A 
COLO 357 
Female 
age 77 
Lymph node 
metastasis 
Well 
KRAS, 
SMAD4 
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Appendix Figure 1.1 STR profile of AsPC-1 cells 
This confirmed the identity of the AsPC-1 cell line. 
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Appendix Figure 1.2 STR profile of MIA PaCa-2 cells 
This confirmed the identity of the MIA PaCa-2 cell line. 
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Appendix Figure 1.3 STR profile of PANC-1 cells 
This confirmed the identity of the PANC-1 cell line. 
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Appendix Figure 1.4 STR profile of COLO 357 cells 
This confirmed the identity of the COLO 357 cell line. 
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Appendix Figure 1.5 STR profile of PS1 cells 
This confirmed the identity of the PS1 cell line, it did not match any other cell 
lines in the published databases. 
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Appendix 2: Gemcitabine response 
Appendix 2.1 Cell viability 
MTS cell viability assays were used to determine the GI50 of all the PDAC cancer cells 
and the PS1 stellate cell line to gemcitabine treatment 
 
Appendix 2.1.1 Method 
MTS cell viability assays were carried out according to Section 2.2.1. Serial dilutions 
of gemcitabine were prepared to treat the cell cultures after 24 hours. In total, 17 drug 
solutions were added to the 96 well plates (10 µl per well) to give a final drug 
concentration ranging from 1.22 pM to 50 µM. 
 
Appendix 2.1.2 Results 
Cell viability was determined using standard MTS assays. The growth inhibition to 50 
% viability (GI50) of gemcitabine, for PS1, AsPC-1, MIA PaCa-2, COLO 357 and 
PANC-1 cell lines in 2D culture was calculated (Appendix Figure 2.1). 
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Appendix Figure 2.1 MTS assay dose response following gemcitabine treatment 
MTS cell viability assays gave a GI
50
 value of 90 nM (A), 121 nM (B), 7 nM (C), 17 nM 
(D) and 16 nM (E) for gemcitabine with the MIA PaCa-2, PANC-1, AsPC-1, COLO 357 
and PS1 cell lines respectively. These values provide a starting value to use for drug 
treatment moving into co-culture and 3D models. The graphs represent the mean cell 
viability from three technical repeats on each plate from at least three biological 
replicates. 
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Appendix 2.2 Cell proliferation 
Flow cytometry analysis was used to determine AsPC-1 and PS1 response to 
gemcitabine in both mono- and co-cultures. 
 
Appendix 2.2.1 Method 
Cell proliferation assays of PS1 and AsPC-1 proliferation in response to increasing 
concentrations of gemcitabine in mono- and co-culture conditions were carried out 
using CellTracker dyes and Flow Cytometry analysis. 
 
Appendix 2.2.2 Results 
Geometric mean was used to determine the change in proliferation of both cell lines 
in response to gemcitabine treatment. There was no difference in the response of 
either cell line to drug in mono- or co-culture in 2D (Appendix Figure 2.2). 
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Appendix Figure 2.2 Flow Cytometry analysis of gemcitabine dose response 
Flow Cytometry analysis assays showed that as the drug concentration increased, the 
proliferation of the cells decreased (measured by an increasing geometric mean 
indicating less cell division). The graph shows the change in cell proliferation of both 
cell lines in mono- or co-culture to gemcitabine treatment. The average geometric mean 
value from three biological replicates has been plotted. Two-way ANOVA analysis was 
carried out to analyse the data. There was no significant difference in response to 
gemcitabine treatment of each cell line in mono- or co-culture. 
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Appendix 3: Small interfering RNA (siRNA) transfection 
To determine the specificity of FGFR1 antibodies, siRNA-mediated knockdown was 
performed. 
 
Appendix 3.1 Method 
AsPC-1 and PS1 cells were seeded into 100 mm dishes at a density of 6 x 105 and 
2.5 x 105 cells per dish respectively. After 24 hours, siRNA was diluted in optiMEM 
(31985-062, Gibco) to give a final concentration of 10 nM. InterferIN (24µl) (409-10, 
Polyplus) was used as the transfection reagent and appropriate controls were 
included (Appendix Table 3.1). RNA extraction was carried out after 48 hours (Section 
2.5.5) and cell lysates were harvested after 72 hours (Section 2.4). Western blot 
analysis was performed with antibodies listed in Table 2.3 and Appendix Table 3.2. 
Primers used to analyse gene expression by qPCR are listed in Table 2.1 and 
Appendix Table 3.3. 
 
Appendix 3.2 Results 
Successful knockdown of FGFR1 was confirmed by Western blot (Section 2.4 and 
Appendix Figure 3.1) and qPCR (Section 2.5.5 and Appendix Figures 3.2). 
Fibronectin and pleckstrin homology-like domain family A member 1 (PHLDA1) 
knockdown were used as positive controls in PS1 and AsPC-1 cells respectively.  
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Appendix Table 3.1 siRNA knockdown conditions and controls 
Condition PS1 AsPC-1 
Negative control optiMEM only optiMEM only 
Non-targeting 
negative control 
nt siRNA pool 
(D-001810-10-20, 
Dharmacon) 
nt siRNA pool 
(D-001810-10-20, 
Dharmacon) 
Positive control 
Fibronectin siRNA pool 
(M-009853-01, Dharmacon) 
PHLDA1 siRNA pool 
(L-012389-00, Dharmacon) 
Targeted 
knockdown 
FGFR1 siRNA pool 
(L-003131-00, Dharmacon) 
FGFR1 siRNA pool 
(L-003131-00, Dharmacon) 
 
 
Appendix Table 3.2 Positive control antibodies for siRNA-mediated 
knockdown 
Antibody Species 
Incubation 
conditions 
Dilution for 
IF/IHC 
Dilution 
for WB 
Fibronectin 
(sc-73601, Santa Cruz) 
Mouse O/N 4oC  1:1000 
PHLDA1 
(HPA019000-100UL, 
Sigma-Aldrich) 
Rabbit O/N 4oC  1:1000 
 
 
Appendix Table 3.3 Positive control primers for siRNA-mediated knockdown 
Target Sequence – Forward Sequence – Reverse 
PHLDA1 
CAG-AGG-GCA-AGG-AGA-
TCG-AC 
GTG-GAT-TTG-ACC-GCC-
AGG-AT 
Fibronectin 
AAC-AAA-CAC-TAA-TGT-
TAA-TTG-CCC-A 
TCG-GGA-ATC-TTC-TCT-
GTC-AGC 
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Appendix Figure 3.1 Western blot analysis of siRNA-mediated knockdown 
Western blot analysis of protein levels following siRNA-mediated knockdown of 
FGFR1 in AsPC-1 (A) and PS1 (B) cells. Negative controls of OptiMEM only and non-
targeting (nt) siRNA were used, as well as a relevant positive control siRNA for each 
cell line (PHLDA1 for AsPC-1 cells and fibronectin for PS1 cells). 
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Appendix Figure 3.2 qPCR analysis of siRNA-mediated knockdown 
Gene expression analysis of RNA levels by qPCR following siRNA-mediated 
knockdown of FGFR1 in AsPC-1 (A) and PS1 (B) cells. All samples were normalised 
to the relevant housekeeping primer (B2M and HPRT-1) and then to the non-targeting 
(nt) siRNA negative control. The expression of both the FGFR1b and FGFR1c 
isoform was analysed, as well as a relevant positive control for each cell line 
(PHLDA1 for AsPC-1 cells and fibronectin (Fn) for PS1 cells). 
351 
 
Appendix 4: Western blots 
Appendix Figure 4.1, 4.2, 4.3, 4.4 and 4.5 show the full Western blot images for all 
antibodies from Figures 4.7, 5.6 and 5.9 and Appendix Figure 3.1 respectively. 
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Appendix Figure 4.1 FGFR1 shRNA knockdown Western blot 
Full Western blot images of the antibodies used in Figure 4.7 to confirm FGFR1 
knockdown following doxycycline (dox) induction of shRNA for 48 hours. FGFR1 
antibody (A) was blotted with HSC70 (B) as a loading control.  
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Appendix Figure 4.2 Inducible FGFR1-HT expression Western blot 
Full Western blot images of the antibodies used in Figure 5.6 to confirm FGFR1-HT 
expression following treatment with increasing concentrations of doxycycline (dox) 
for 48 hours. FGFR1 (A), HaloTag (B), p-ERK (C), t-ERK (D) antibodies were blotted 
with GAPDH (E) as a loading control.  
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Appendix Figure 4.3 Functionality of FGFR1-HT construct Western blot 
Full Western blot images of the antibodies used in Figure 5.9 to confirm FGFR1-HT 
functionality following treatment with doxycycline (dox) for 48 hours to induce FGFR1-
HT expression and then stimulation with 100 ng/ml FGF2 for 15 minutes. FGFR1 (A), 
HaloTag (B), p-ERK (C), t-ERK (D) antibodies were blotted with GAPDH (E) as a 
loading control.   
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Appendix Figure 4.4 AsPC-1 siRNA knockdown Western blot 
Full Western blot images of the antibodies used in Appendix Figure 3.1A to confirm 
siRNA-mediated knockdown of FGFR1. Negative controls of OptiMEM only and 
non-targeting (nt) siRNA were used, as well as PHLDA1 siRNA as a positive 
control. FGFR1 (A) and PHLDA1 (B) antibodies were blotted with HSC70 (C) as a 
loading control.   
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Appendix Figure 4.5 PS1 siRNA knockdown Western blot 
Full Western blot images of the antibodies used in Appendix Figure 3.1B to confirm 
siRNA-mediated knockdown of FGFR1. Negative controls of OptiMEM only and 
non-targeting (nt) siRNA were used, as well as Fibronectin siRNA as a positive 
control. Fibronectin (A) and FGFR1 (B) antibodies were blotted with HSC70 (C) as 
a loading control.   
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Appendix 5: ChIP 
Appendix 5.1 ChIP optimisation 
In early optimisation of cell number for ChIP, chromatin harvesting and sonication of 
PS1 cells was compared to the positive control MFE-296 (FGFR2 mutant endometrial 
cancer).  
 
Appendix 5.1.1 Method 
MFE-296 cells were grown in minimum essential medium (MEM) (M7278, Sigma) 
plus 10 % (v/v) FBS. Cells were harvested and sonicated according to the Millipore 
protocol (Section 2.7.3). One flask of MFE-296 cells was used (positive control) 
compared to 14 flasks of PS1 cells. 
 
Appendix 5.1.2 Results 
Input DNA of unsonicated and sonicated chromatin isolated from PS1 and MFE-296 
cells was run on an agarose gel. The sonication had fragmented the chromatin in both 
samples to a sufficient range of sizes (150-500 bp), however the MFE-296 range went 
up to 1,000 bp, indicating that more sonication may be required (Appendix Figure 
4.1). The amount of DNA extracted from PS1 cells was much lower than from MFE-
296 cells, despite having many more flasks of starting material. This indicated that a 
high cell number of cells (20 million) would be needed to have enough chromatin to 
analyse by ChIP-seq. 
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Appendix Figure 5.1 Chromatin harvesting optimisation 
Cell number required for efficient chromatin isolation and sonication for ChIP-seq 
was optimised using MFE-296 cells as a positive control. Fragmentation of both 
cells lines after 10 sonication cycles can be seen after sonication (son), however, 
the DNA band for MFE-296 cells is much brighter than PS1 cells. Also, further 
sonication would have been required to enrich the fragment size within the 100-
500 bp acceptable range. 
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Appendix 5.2 ChIP-PCR 
During the optimisation for ChIP-seq experiments, ChIP-PCR analysis was carried 
out to analyse the expression of some previous FGFR1-targeted hits shown in PSCs. 
 
Appendix 5.2.1 Method 
PS1 cells (20 million) were seeded in a series of 150 mm3 dishes. After 24 hours, 
cells were placed in serum free media overnight and FGF2 stimulation was carried 
out according to Section 2.1.3. Chromatin was harvested and fragmented from both 
FGF2 stimulated and unstimulated control cells according to Section 2.7.4.2. 
Immunoprecipitation with an FGFR1 and relevant IgG antibody (Table 2.3) and DNA 
extraction were performed according to Sections 2.7.4.3 and Section 2.7.4.4. 
Analysis of potential FGFR1 targets from previous work was performed by qPCR 
using relevant primers (Section 2.5.5, Table 2.1 and Appendix Table 4.1). 
 
Appendix 5.2.2 Results 
The levels of relevant FGFR1 targets in each sample were normalised to the IgG 
negative control. Cells stimulated with FGF2 had increased levels of these target 
genes, compared to unstimulated control samples, apart from JunB (Appendix Figure 
4.2). This indicates that when cells are stimulated with FGF2, there is increased 
nuclear localisation of FGFR1 and therefore more binding to relevant target genes. 
However, this experiment was only performed once as ChIP-seq analysis is more 
detailed and allowed new FGFR1 target genes to be identified. 
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Appendix Table 5.1 FGFR1 target gene primers 
Target Sequence – Forward Sequence – Reverse 
SP2 
GGC-CTC-ACC-CTA-AGG-
ACT-TC 
GGG-GAC-CGA-CAG-CAC-
TAT-TA 
ZN384 
GCC-CCT-CTT-TCT-CCA-
TTA-GC 
CTT-CTG-GAG-CGA-GAC-
AGA-CC 
ROCK1 
GCA-AGA-AGC-CTT-TTC-
GTC-GG 
CGT-AAA-TGG-GTT-CAA-
CGC-CG 
JUNB 
GCT-GAC-TAG-CGC-GGT-
ATA-AA 
GTG-CGC-AAA-AGC-CCT-
GTC 
CDK12 
TCG-CGT-TGT-TTG-ATA-
AGC-AG 
CTT-TCT-TGC-CTC-CGT-
TTC-AC 
GLI1 
ACA-GGG-AGA-CAC-CGA-
AGA-TG 
AAG-AGC-CTC-CAA-GGA-
AAT-GG 
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Appendix Figure 5.2 ChIP-PCR of potential FGFR1 target genes 
ChIP-PCR analysis was performed on chromatin isolated from PS1 cells stimulated 
with FGF2, compared to unstimulated controls. FGFR1 binding to potential target 
genes was analysed by qPCR and enrichment levels were plotted relative to the IgG 
control sample. Most of the target genes showed enriched FGFR1 binding upon 
FGF2 stimulation. 
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Appendix 6: Tables of hits 
Appendix 6.1 Total peptide changes 
Appendix Table 6.1 Most decreased peptides upon FGFR inhibition 
Log2 
(AZD/DMSO) 
total protein 
levels 
Protein names 
Gene 
names 
Function 
-4.89711 
MARCKS-related 
protein 
MARCKSL1 
Controls cell movement by regulating actin 
cytoskeleton homeostasis and filopodium 
and lamellipodium formation 
-4.32754 
Nuclear factor 1 X-
type;Nuclear factor 1 
NFIX 
These proteins are individually capable of 
activating transcription and replication 
-3.98183 
Sodium-dependent 
phosphate 
transporter 2 
SLC20A2 
Sodium-phosphate symporter which seems 
to play a fundamental housekeeping role in 
phosphate transport by absorbing phosphate 
from interstitial fluid for normal cellular 
functions such as cellular metabolism, signal 
transduction, and nucleic acid and lipid 
synthesis 
-3.91147 
FH1/FH2 domain-
containing protein 1 
FHOD1 
Required for the assembly of F-actin 
structures, such as stress fibers 
-3.56177 
Protein-tyrosine 
sulfotransferase 1 
TPST1 
Catalyzes the O-sulfation of tyrosine 
residues within acidic motifs of polypeptides, 
using 3'-phosphoadenylyl sulfate (PAPS) as 
cosubstrate 
-3.51652 
Cytochrome c 
oxidase assembly 
factor 7 
COA7 
Required for assembly of mitochondrial 
respiratory chain complex I and complex IV 
-3.30857 
Tetratricopeptide 
repeat protein 7A 
TTC7A 
Component of a complex required to localize 
phosphatidylinositol 4-kinase (PI4K) to the 
plasma membrane 
-3.00918 
Glutathione 
peroxidase 1 
GPX1 
May constitute a glutathione peroxidase-like 
protective system against oxidative stresses 
-2.93539 Intersectin-2 ITSN2 
Adapter protein that may provide indirect link 
between the endocytic membrane traffic and 
the actin assembly machinery 
-2.92123 
Replication factor C 
subunit 1 
RFC1 
Plays a role in DNA transcription regulation, 
DNA replication and repair 
-2.91835 
BUB3-interacting and 
GLEBS motif-
containing protein 
ZNF207 
ZNF207 
Kinetochore- and microtubule-binding 
protein that plays a key role in spindle 
assembly 
-2.54075 
Ras-related protein 
Rab-31 
RAB31 
Key regulator of intracellular membrane 
trafficking 
-2.35453 
Histone deacetylase 
complex subunit 
SAP130 
SAP130 Acts as a transcriptional repressor 
-2.25421 Selenoprotein S VIMP;SELS 
Involved in the degradation process of 
misfolded endoplasmic reticulum (ER) 
luminal proteins 
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Log2 
(AZD/DMSO) 
total protein 
levels 
Protein names 
Gene 
names 
Function 
-2.23287 
NADH 
dehydrogenase 
[ubiquinone] iron-
sulfur protein 8, 
mitochondrial 
NDUFS8 
Part of the mitochondrial membrane 
respiratory chain 
-2.1943 
Amyloid beta A4 
precursor protein-
binding family B 
member 2 
APBB2 
May modulate the internalization of amyloid-
beta precursor protein 
-2.18975 
Transmembrane 
protein 51 
TMEM51  
-2.15253 
Pre-rRNA-processing 
protein TSR1 
homolog 
TSR1 
Required during maturation of the 40S 
ribosomal subunit in the nucleolus 
-2.14636 
Volume-regulated 
anion channel 
subunit LRRC8E 
LRRC8E Component of the anion channel VRAC 
-2.13332 Sorting nexin-17 SNX17 Regulator of endosomal recycling 
-2.13287 
Calcium-independent 
phospholipase A2-
gamma 
PNPLA8 Cleaves membrane phospholipids 
-2.11054 
Inositol 1,4,5-
trisphosphate 
receptor type 2 
ITPR2 Mediates the release of intracellular calcium 
-2.10362 
Serine/threonine-
protein phosphatase 
2A regulatory subunit 
B subunit alpha 
PPP2R3A 
Phosphatase – B subunit determines target 
and activity 
-2.08795 
Sodium/hydrogen 
exchanger 6 
SLC9A6 
Electroneutral exchange of protons for 
Na+ and K+ across the early and recycling 
endosome membranes 
-2.04367 Titin TTN 
Connects microfilaments affecting the 
function of striated muscles 
-2.03418 
NADH 
dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 
1 
NDUFB1 
Part of the mitochondrial membrane 
respiratory chain 
-2.02466 
ER membrane 
protein complex 
subunit 2 
EMC2  
-2.00131 Thrombospondin-3 THBS3 
Adhesive glycoprotein that mediates cell-to-
cell and cell-to-matrix interactions. Can bind 
to fibrinogen, fibronectin, laminin and type V 
collagen. 
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Appendix Table 6.2 Most increased peptides upon FGFR inhibition 
Log2 
(AZD/DMSO) 
total protein 
levels 
Protein names 
Gene 
names 
Function 
2.07153 
Pre-mRNA-
processing factor 17 
CDC40 Involved in mRNA splicing 
2.1054 
Active breakpoint 
cluster region-related 
protein 
ABR 
GTPase-activating protein for RAC and 
CDC42 
2.11896 
DNA dC->dU-editing 
enzyme APOBEC-3C 
APOBEC3C 
DNA deaminase (cytidine deaminase) 
which acts as an inhibitor of retrovirus 
replication 
2.25082 
Absent in melanoma 
1 protein 
AIM1  
2.38664 
Dehydrogenase/redu
ctase SDR family 
member on 
chromosome X 
DHRSX 
Involved in the positive regulation of 
starvation-induced autophagy 
2.39439 
Centromere-
associated protein 
E;Kinesin-like protein 
CENPE 
Microtubule plus-end-directed kinetochore 
motor which plays an important role in 
chromosome congression, microtubule-
kinetochore conjugation and spindle 
assembly checkpoint activation 
2.47182 
ATP-binding cassette 
sub-family B member 
7, mitochondrial 
ABCB7 
Involved in transport of heme from the 
mitochondria to the cytosol 
2.5983 
Glycosylated 
lysosomal membrane 
protein 
GLMP Transcription factor 
2.66223 
UAP56-interacting 
factor 
FYTTD1 
Required for mRNA export from the 
nucleus to the cytoplasm 
2.72045 
Deoxyribonuclease-1-
like 1 
DNASE1L1 deoxyribonuclease 
2.724 
Zinc finger protein 
808 
ZNF808 Involved in transcriptional regulation 
2.8061 
Death domain-
associated protein 6 
DAXX Transcriptional repressor 
2.80693 
Core histone macro-
H2A.2 
H2AFY2 Transcriptional repressor 
2.82514 
Ubiquitin carboxyl-
terminal 
hydrolase;Ubiquitin 
carboxyl-terminal 
hydrolase 30 
USP30 
Deubiquitinating enzyme tethered to the 
mitochondrial outer membrane that acts as 
a key inhibitor of mitophagy by 
counteracting the action of parkin (PRKN) 
2.93415 Sorting nexin-13 SNX13 Involved in intracellular trafficking 
2.94608 
Lysozyme; 
Lysozyme C 
LYZ 
Lysozyme C is capable of both hydrolysis 
and transglycosylation; it shows also a 
slight esterase activity. Bacteriolytic 
function 
3.25699 
39S ribosomal protein 
L10, mitochondrial 
MRPL10 RNA binding 
3.64192 
BCL2/adenovirus 
E1B 19 kDa protein-
interacting protein 3 
BNIP3 Induces apoptosis 
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Log2 
(AZD/DMSO) 
total protein 
levels 
Protein names 
Gene 
names 
Function 
4.91431 
Zinc finger C3H1 
domain-containing 
protein 
ZFC3H1 
Subunit of the trimeric poly(A) tail 
exosome targeting (PAXT) complex, a 
complex that directs a subset of long and 
polyadenylated poly(A) RNAs for 
exosomal degradation 
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Appendix 6.2 Nuclear peptide changes 
Appendix Table 6.3 Most decreased nuclear peptides upon FGFR inhibition 
Percentage 
change 
Protein names 
Significant 
in another 
fraction? 
Which 
Direction 
Peptides 
Gene 
names 
-45.8485 
Histone-lysine N-
methyltransferase 
NSD2 
Plasma 
Membrane 
(33 %) 
Opposite - 
increase in 
PM with 
AZD 
6 WHSC1 
-43.1173 
WD repeat-
containing protein 43 
IM 
(22 %) 
Opposite - 
increase in 
IM with 
AZD 
5 WDR43 
-40.9542 
Zinc finger protein 
318 
Cytoplasm 
(45 %) 
Opposite - 
increase in 
Cyt with 
AZD 
3 ZNF318 
-40.2951 Protein SON 
Plasma 
Membrane 
(55 %) 
Opposite - 
increase in 
PM with 
AZD 
14 SON 
-39.5653 
Heterogeneous 
nuclear 
ribonucleoprotein U 
Cytoplasm 
(36 %) 
Opposite - 
increase in 
Cyt with 
AZD 
38 HNRNPU 
-38.4907 
Zinc finger C3H1 
domain-containing 
protein 
Plasma 
Membrane 
(20 %) 
Opposite - 
increase in 
PM with 
AZD 
3 ZFC3H1 
-37.8679 
Regulation of nuclear 
pre-mRNA domain-
containing protein 2 
  
6 RPRD2 
-37.5041 
Histone-lysine N-
methyltransferase 
2D 
Cytoplasm 
(28 %) 
Opposite - 
increase in 
Cyt with 
AZD 
2 KMT2D 
-33.763 
Ribosome 
biogenesis 
regulatory protein 
homolog 
Cytoplasm 
(23 %) 
Opposite - 
increase in 
Cyt with 
AZD 
10 RRS1 
-31.2712 
Hepatocyte growth 
factor receptor 
IM 
(20 %) 
Opposite - 
increase in 
IM with 
AZD 
2 MET 
-30.741 
Eukaryotic 
translation initiation 
factor 6 
Plasma 
Membrane 
(23 %) 
Opposite - 
increase in 
PM with 
AZD 
6 EIF6 
-30.7352 
Zinc finger MYM-
type protein 4 
  4 ZMYM4 
-30.2354 Protein DEK   10 DEK 
-29.7403 Protein ENL 
Cytoplasm 
(26 %) 
Opposite - 
increase in 
Cyt with 
AZD 
3 MLLT1 
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Percentage 
change 
Protein names 
Significant 
in another 
fraction? 
Which 
Direction 
Peptides 
Gene 
names 
-29.4794 
PHD finger-like 
domain-containing 
protein 5A 
 
 
2 PHF5A 
-28.6006 
pre-rRNA processing 
protein FTSJ3 
Cytoplasm 
(29 %) 
Opposite - 
increase in 
Cyt with 
AZD 
10 FTSJ3 
-27.6277 DNA ligase 3 
  
3 LIG3 
-27.3851 
Integrator complex 
subunit 3 
  
5 INTS3 
-27.1325 Fos-related antigen 1 
  
4 FOSL1 
-26.827 
Barrier-to-
autointegration 
factor;Barrier-to-
autointegration 
factor, N-terminally 
processed 
IM 
(19 %) 
Opposite - 
increase in 
IM with 
AZD 
2 BANF1 
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Appendix Table 6.4 Most increased nuclear peptides upon FGFR inhibition 
Percentage 
change 
Protein names 
Significant 
in another 
fraction? 
Which 
Direction 
Peptides 
Gene 
names 
20.0689 
Cleavage and 
polyadenylation 
specificity factor 
subunit 4 
  1 CPSF4 
20.1101 
FH1/FH2 domain-
containing protein 1 
  2 FHOD1 
20.3297 
Ubiquitin-like protein 
ISG15 
  3 ISG15 
20.4251 
Centromere-
associated protein 
E;Kinesin-like protein 
Cytoplasm 
(40 %) 
Opposite - 
decrease in 
Cyt with 
AZD 
2 CENPE 
21.26094 
Ras-related GTP-
binding protein A 
Cytoplasm 
(27 %) 
Opposite - 
decrease in 
Cyt with 
AZD 
2 
RRAGA; 
RRAGB 
21.2845 
NHL repeat-containing 
protein 3 
Cytoplasm 
(25 %) 
Opposite - 
decrease in 
Cyt with 
AZD 
2 NHLRC3 
21.3897 
Phosphatidylinositol 5-
phosphate 4-kinase 
type-2 beta 
 
 
3 PIP4K2B 
21.5724 
HD domain-containing 
protein 2 
Cytoplasm 
(25 %) 
Opposite - 
decrease in 
Cyt with 
AZD 
2 HDDC2 
21.7991 
Activator of 90 kDa 
heat shock protein 
ATPase homolog 1 
  5 AHSA1 
22.6076 
Protein cornichon 
homolog 4 
  1 CNIH4 
23.1148 
A-kinase anchor 
protein 2 
Cytoplasm 
(25 %) 
Opposite - 
decrease in 
Cyt with 
AZD 
20 AKAP2 
23.1816 
Protein SCO1 
homolog, 
mitochondrial 
Cytoplasm 
(35 %) 
Opposite - 
decrease in 
Cyt with 
AZD 
2 SCO1 
23.2109 
Fibronectin;Anastellin;
Ugl-Y1;Ugl-Y2;Ugl-Y3 
IM 
(20 %) 
Opposite - 
decrease in 
IM with 
AZD 
94 FN1 
23.3054 
Lysosomal-associated 
transmembrane 
protein 4A 
  2 
LAPTM4
A 
23.3125 Ankyrin-2  
 
3 ANK2 
23.6622 
Probable Xaa-Pro 
aminopeptidase 3 
IM 
(19 %) 
Opposite - 
decrease in 
IM with 
AZD 
2 
XPNPEP
3 
369 
 
Percentage 
change 
Protein names 
Significant 
in another 
fraction? 
Which 
Direction 
Peptides 
Gene 
names 
26.1964 
Suppressor of SWI4 1 
homolog 
 
 
3 PPAN 
27.8245 Latrophilin-2  
 
3 
ADGRL2; 
LPHN2 
30.8725 
Tropomyosin alpha-3 
chain 
Cytoplasm 
(35 %) 
Opposite - 
decrease in 
Cyt with 
AZD 
18 TPM3 
43.4746 
Kinesin-like protein 
KIF3B;Kinesin-like 
protein KIF3B, N-
terminally 
processed;Kinesin-like 
protein;Kinesin-like 
protein KIF3A 
 
 
2 
KIF3B; 
KIF3A 
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Appendix 6.3 ChIP-seq peak enrichment 
Appendix Table 6.5 ChIP-seq enriched peaks across shRNA2 and shRNA3 
Symbol Gene Name 
CAPN15 calpain 15 
SH2B3 SH2B adaptor protein 3 
NTN3 netrin 3 
MC5R melanocortin 5 receptor 
CHPF chondroitin polymerizing factor 
TUB TUB bipartite transcription factor 
RNF4 ring finger protein 4 
ZFYVE9 zinc finger FYVE-type containing 9 
BAIAP2L2 BAI1 associated protein 2 like 2 
CYP2D7 cytochrome P450 family 2 subfamily D member 7 (gene/pseudogene) 
EPPK1 epiplakin 1 
LATS2 large tumor suppressor kinase 2 
ADORA2A adenosine A2a receptor 
SPECC1 sperm antigen with calponin homology and coiled-coil domains 1 
RAP2B RAP2B, member of RAS oncogene family 
DPRXP4 divergent-paired related homeobox pseudogene 4 
DLX3 distal-less homeobox 3 
TTLL11 tubulin tyrosine ligase like 11 
ZYG11A zyg-11 family member A, cell cycle regulator 
RREB1 ras responsive element binding protein 1 
ARHGAP27 Rho GTPase activating protein 27 
RUNX2 RUNX family transcription factor 2 
SIM2 SIM bHLH transcription factor 2 
PML promyelocytic leukemia 
SHANK2 SH3 and multiple ankyrin repeat domains 2 
CCDC68 coiled-coil domain containing 68 
LINC01140 long intergenic non-protein coding RNA 1140 
ERG ETS transcription factor ERG 
KCNJ9 potassium voltage-gated channel subfamily J member 9 
ERICH5 glutamate rich 5 
ADARB1 adenosine deaminase RNA specific B1 
BTBD6 BTB domain containing 6 
ISM2 isthmin 2 
TSPAN9 tetraspanin 9 
FBXL14 F-box and leucine rich repeat protein 14 
DNAAF5 dynein axonemal assembly factor 5 
SIVA1 SIVA1 apoptosis inducing factor 
PANX2 pannexin 2 
EPS8L2 EPS8 like 2 
CD248 CD248 molecule 
FAM110A family with sequence similarity 110 member A 
SCRIB scribble planar cell polarity protein 
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Symbol Gene Name 
MYO15A myosin XVA 
PLXND1 plexin D1 
RNF223 ring finger protein 223 
PAX8-AS1 PAX8 antisense RNA 1 
RYR2 ryanodine receptor 2 
EML5 EMAP like 5 
RASA3 RAS p21 protein activator 3 
PJA2 praja ring finger ubiquitin ligase 2 
CYP2W1 cytochrome P450 family 2 subfamily W member 1 
SYNGR3 synaptogyrin 3 
NFIL3 nuclear factor, interleukin 3 regulated 
LINC00235 long intergenic non-protein coding RNA 235 
FAM83H family with sequence similarity 83 member H 
BMS1P17 BMS1 pseudogene 17 
DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 
BMP8A bone morphogenetic protein 8a 
DHH desert hedgehog signaling molecule 
SLC25A37 solute carrier family 25 member 37 
SEPT5-
GP1BB 
SEPT5-GP1BB readthrough 
HAGLR HOXD antisense growth-associated long non-coding RNA 
HTRA4 HtrA serine peptidase 4 
PTPN23 protein tyrosine phosphatase non-receptor type 23 
SARM1 sterile alpha and TIR motif containing 1 
MATN4 matrilin 4 
HID1 HID1 domain containing 
MRPL38 mitochondrial ribosomal protein L38 
FAM162B family with sequence similarity 162 member B 
TRIML2 tripartite motif family like 2 
KRTCAP3 keratinocyte associated protein 3 
SCIN scinderin 
LMF1 lipase maturation factor 1 
TBCD tubulin folding cofactor D 
NPNT nephronectin 
ZAR1 zygote arrest 1 
HBQ1 hemoglobin subunit theta 1 
ZMIZ1 zinc finger MIZ-type containing 1 
A4GALT alpha 1,4-galactosyltransferase (P blood group) 
UTP6 UTP6 small subunit processome component 
LYPD6 LY6/PLAUR domain containing 6 
TMEM249 transmembrane protein 249 
ANKRD30B ankyrin repeat domain 30B 
BEGAIN brain enriched guanylate kinase associated 
KIF16B kinesin family member 16B 
CBY3 chibby family member 3 
STRN4 striatin 4 
372 
 
Symbol Gene Name 
INPP5F inositol polyphosphate-5-phosphatase F 
HAGLR HOXD antisense growth-associated long non-coding RNA 
IMPA2 inositol monophosphatase 2 
MUC2 mucin 2, oligomeric mucus/gel-forming 
SIVA1 SIVA1 apoptosis inducing factor 
C5orf66 chromosome 5 open reading frame 66 
ST13P4 ST13, Hsp70 interacting protein pseudogene 4 
CEP131 centrosomal protein 131 
MIR638 microRNA 638 
KCTD17 potassium channel tetramerization domain containing 17 
KCNH3 potassium voltage-gated channel subfamily H member 3 
SLC25A12 solute carrier family 25 member 12 
ELFN2 
extracellular leucine rich repeat and fibronectin type III domain containing 
2 
ZMYND19 zinc finger MYND-type containing 19 
RASIP1 Ras interacting protein 1 
MIR939 microRNA 939 
ADPRHL1 ADP-ribosylhydrolase like 1 
GPR62 G protein-coupled receptor 62 
TUBBP5 tubulin beta pseudogene 5 
ZNF737 zinc finger protein 737 
LOC154449 uncharacterized LOC154449 
RNH1 ribonuclease/angiogenin inhibitor 1 
PCDHB15 protocadherin beta 15 
ZNF414 zinc finger protein 414 
TRIM11 tripartite motif containing 11 
ADAMTS10 ADAM metallopeptidase with thrombospondin type 1 motif 10 
NABP1 nucleic acid binding protein 1 
GABBR2 gamma-aminobutyric acid type B receptor subunit 2 
 
 
 
 
 
 
 
 
